<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004252" GROUP_ID="BACK" ID="599480011918282642" MERGED_FROM="" MODIFIED="2017-03-27 21:51:49 +0100" MODIFIED_BY="Shireen Harbin" REVIEW_NO="" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2017-03-27 16:15:53 -0400" MODIFIED_BY="[Empty name]">
<TITLE>Muscle relaxants for non-specific low-back pain</TITLE>
<CONTACT>
<PERSON ID="5654" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Maurits</FIRST_NAME>
<MIDDLE_INITIALS>W</MIDDLE_INITIALS>
<LAST_NAME>van Tulder</LAST_NAME>
<SUFFIX>PhD</SUFFIX>
<POSITION/>
<EMAIL_1>maurits.van.tulder@vu.nl</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Health Sciences, Faculty of Earth and Life Sciences</DEPARTMENT>
<ORGANISATION>VU University Amsterdam</ORGANISATION>
<ADDRESS_1>PO Box 7057</ADDRESS_1>
<ADDRESS_2>Room U454</ADDRESS_2>
<CITY>Amsterdam</CITY>
<ZIP>1007 MB</ZIP>
<REGION/>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<PHONE_1>+31 20 598 6587</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2017-03-27 16:15:02 -0400" MODIFIED_BY="Shireen Harbin">
<PERSON ID="5654" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Maurits</FIRST_NAME>
<MIDDLE_INITIALS>W</MIDDLE_INITIALS>
<LAST_NAME>van Tulder</LAST_NAME>
<SUFFIX>PhD</SUFFIX>
<POSITION/>
<EMAIL_1>maurits.van.tulder@vu.nl</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Health Sciences, Faculty of Earth and Life Sciences</DEPARTMENT>
<ORGANISATION>VU University Amsterdam</ORGANISATION>
<ADDRESS_1>PO Box 7057</ADDRESS_1>
<ADDRESS_2>Room U454</ADDRESS_2>
<CITY>Amsterdam</CITY>
<ZIP>1007 MB</ZIP>
<REGION/>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<PHONE_1>+31 20 598 6587</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12729" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Tony</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Touray</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>EMGO Institute for Health and Care Research</DEPARTMENT>
<ORGANISATION>VU University Medical Center</ORGANISATION>
<ADDRESS_1>PO Box 7057</ADDRESS_1>
<ADDRESS_2/>
<CITY>Amsterdam</CITY>
<ZIP>1007 MB</ZIP>
<REGION/>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<PHONE_1>+ 31 20 444 8178</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8619" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Andrea</FIRST_NAME>
<MIDDLE_INITIALS>D</MIDDLE_INITIALS>
<LAST_NAME>Furlan</LAST_NAME>
<SUFFIX>MD PhD</SUFFIX>
<POSITION>Scientist</POSITION>
<EMAIL_1>afurlan@iwh.on.ca</EMAIL_1>
<EMAIL_2/>
<URL>http://www.iwh.on.ca/researchers/andrea-furlan</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Institute for Work &amp; Health</ORGANISATION>
<ADDRESS_1>481 University Avenue, Suite 800</ADDRESS_1>
<ADDRESS_2/>
<CITY>Toronto</CITY>
<ZIP>M5G 2E9</ZIP>
<REGION>ON</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 416 927-2027 ext: 2171</PHONE_1>
<PHONE_2/>
<FAX_1>+1 416 927-4167</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12725" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Sherra</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Solway</LAST_NAME>
<SUFFIX/>
<POSITION>Quality lead</POSITION>
<EMAIL_1>solways@smh.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>St Michael's Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Toronto</CITY>
<ZIP/>
<REGION>ON</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="D28FC80C82E26AA20080535FB1EA31C4" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Lex</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Bouter</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Epidemiology</POSITION>
<EMAIL_1>lm.bouter@vu.nl</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>VU University</ORGANISATION>
<ADDRESS_1>De Boelelaan 1105</ADDRESS_1>
<ADDRESS_2/>
<CITY>Amsterdam</CITY>
<ZIP>1081 HV</ZIP>
<REGION/>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<PHONE_1>+31 20 5989898</PHONE_1>
<PHONE_2/>
<FAX_1>+31 20 598 5300</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-07-07 10:16:39 -0400" MODIFIED_BY="Marie-Andree Nowlan">
<UP_TO_DATE>
<DATE DAY="31" MONTH="10" YEAR="2002"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="10" YEAR="2002"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="12" YEAR="2004"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2003"/>
</DATES>
<WHATS_NEW MODIFIED="2017-03-27 16:15:53 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2017-03-27 16:15:53 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="3" YEAR="2017"/>
<DESCRIPTION>
<P>Feedback received February 2017. Response added March 2017. See Feedback section.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-03-20 15:12:43 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-03-20 15:12:43 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-06-23 09:19:47 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="4" YEAR="2005"/>
<DESCRIPTION>
<P>Issue 3, 2005: extra precautions about the potential for dependency were added to the discussion section and to the Reviewers' conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2008-06-23 09:18:43 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="11" YEAR="2004"/>
<DESCRIPTION>
<P>Feedback added: 28 September 2004<BR/>Response to feedback added: 1 November 2004<BR/>See Feedback section.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Institute for Research in Extramural Medicine</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Institute for Work &amp; Health</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Health Insurance Board</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-06-23 15:30:11 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-06-20 15:32:15 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-06-20 15:32:15 -0400" MODIFIED_BY="[Empty name]">Muscle relaxants for non-specific low-back pain</TITLE>
<SUMMARY_BODY>
<P>Muscle relaxants are effective for short-term symptomatic relief in patients with acute and chronic low back pain. However, the incidence of drowsiness, dizziness and other side effects is high. Muscle relaxants must be used with caution and it must be left to the discretion of the physician to weigh the pros and cons and to determine whether or not a specific patient is a suitable candidate for a course of muscle relaxants. Large high quality trials are needed that directly compare muscle relaxants to analgesics or NSAIDs and future studies should focus on reducing the incidence and severity of side effects.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>The use of muscle relaxants in the management of non-specific low back pain is controversial. It is not clear if they are effective, and concerns have been raised about the potential adverse effects involved.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The aim of this review was to determine if muscle relaxants are effective in the treatment of non-specific low back pain.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>A computer-assisted search of the Cochrane Library (Issue 3, 2002), MEDLINE (1966 up to October 2002) and EMBASE (1988 up to October 2002) was carried out. These databases were searched using the algorithm recommended by the Cochrane Back Review Group. References cited in the identified articles and other relevant literature were screened.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised and/or double-blinded controlled trials, involving patients diagnosed with non-specific low back pain, treated with muscle relaxants as monotherapy or in combination with other therapeutic modalities, were included for review.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two authors independently carried out the methodological quality assessment and data extraction of the trials. The analysis comprised not only a quantitative analysis (statistical pooling) but also a qualitative analysis ("best evidence synthesis"). This involved the appraisal of the strength of evidence for various conclusions using a rating system based on the quality and outcomes of the studies included. Evidence was classified as "strong", "moderate", "limited", "conflicting" or "no" evidence.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Thirty trials met the inclusion criteria. Twenty-three trials (77%) were of high quality, 24 trials (80%) were on acute low back pain. Four trials studied benzodiazepines, 11 non-benzodiazepines and two antispasticity muscle relaxants in comparison with placebo. Results showed that there is strong evidence that any of these muscle relaxants are more effective than placebo for patients with acute LBP on short-term pain relief. The pooled RR for non-benzodiazepines versus placebo after two to four days was 0.80 [95% CI; 0.71 to 0.89] for pain relief and 0.49 [95% CI; 0.25 to 0.95] for global efficacy. Adverse events, however, with a relative risk of 1.50 [95% CI; 1.14 to 1.98] were significantly more prevalent in patients receiving muscle relaxants and especially the central nervous system adverse effects (RR 2.04; 95% CI; 1.23 to 3.37). The various muscle relaxants were found to be similar in performance.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Muscle relaxants are effective in the management of non-specific low back pain, but the adverse effects require that they be used with caution. Trials are needed that evaluate if muscle relaxants are more effective than analgesics or non-steroidal anti-inflammatory drugs.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-06-23 15:30:11 -0400" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-06-23 09:25:41 -0400" MODIFIED_BY="[Empty name]">
<P>Muscle relaxants are one of the many treatments currently employed in the management of non-specific low back pain. Thirty-five percent of patients visiting a primary care physician for low back pain are prescribed muscle relaxants (<LINK REF="REF-Cherkin-1998" TYPE="REFERENCE">Cherkin 1998</LINK>). The term "muscle relaxants" is very broad and includes a wide range of drugs with different indications and mechanisms of action. Muscle relaxants can be divided into two main categories: antispasmodic and antispasticity medications. </P>
<P>Antispasmodics are used to decrease muscle spasm associated with painful conditions such as low back pain. Antispasmodics can be subclassified into benzodiazepines and non-benzodiazepines. </P>
<P>Benzodiazepines (e.g., diazepam, tetrazepam) are used as anxiolytics, sedatives, hypnotics, anticonvulsants, and/or skeletal muscle relaxants (<LINK REF="REF-Jackson-1993" TYPE="REFERENCE">Jackson 1993</LINK>). In general, there is no evidence that any one benzodiazepine is more effective than another if adequate dosage is given; however, pharmacokinetic differences between the drugs may be important considerations in prescription choice. </P>
<P>Non-benzodiazepines include a variety of drugs that can act at the brain stem or spinal cord level (<LINK REF="REF-Jackson-1993" TYPE="REFERENCE">Jackson 1993</LINK>). The mechanisms of action with the central nervous system are still not completely understood. Cyclobenzaprine is structurally similar to the tricyclic antidepressants; however, it has strong side effects such as sedation (<LINK REF="REF-Lofland-2001" TYPE="REFERENCE">Lofland 2001</LINK>). It is currently believed that cyclobenzaprine acts in the brain stem rather than at the spinal cord level. Carisoprodol and metaxalone have moderate antispasmodic effects and are mildly sedative. Carisoprodol blocks interneuronal activity in the descending reticular formation and spinal cord. Carisoprodol is metabolized to meprobamate. Meprobamate was introduced as an anti-anxiety agent in 1955 and is prescribed primarily to treat anxiety, tension, and associated muscle spasms. Its onset and duration of action are similar to the intermediate-acting barbiturates; however, therapeutic doses of meprobamate produce less sedation and toxicity than barbiturates. Excessive use can result in psychological and physical dependence. Chlorzoxazone acts at the spinal cord and subcortical levels, inhibiting multisynaptic reflex arcs. The mechanism of action of methocarbamol in humans has not been established, but may be due to central nervous system depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber. Cyclobenzaprine and orphenadrine have anticholinergic activity (which is responsible for some side effects such as dry mouth). Tolperisone has a lidocaine-like-activity and stabilizes nerve membranes. It blocks in a dose-dependent manner mono- and polysynaptic reflexes at the spinal level. Tolperisone is supposed to mediate muscle relaxation without concomitant sedation or withdrawal phenomena (<LINK REF="STD-Pratzel-1996" TYPE="STUDY">Pratzel 1996</LINK>). Some antispasmodic drugs (e.g. Tizanidine) have showed in animal studies that in addition to muscle relaxant and antinociceptive effect they have also gastroprotective effects which may favour the combination of antispasmodics with non-steroidal anti-inflammatory drugs (NSAIDs) (<LINK REF="STD-Sirdalud-1998" TYPE="STUDY">Sirdalud 1998</LINK>).</P>
<P>Antispasticity medications are used to reduce spasticity that interferes with therapy or function, such as in cerebral palsy, multiple sclerosis and spinal cord injuries (<LINK REF="REF-Rosche-2002" TYPE="REFERENCE">Rosche 2002</LINK>). The mechanism of action of the antispasticity drugs with the peripheral nervous system (e.g., dantrolene sodium) is the blockade of the sarcoplasmic reticulum calcium channel. This reduces calcium concentration and diminishes actin-myosin interaction. Baclofen is a gama-aminobutyric acid (GABA) derivative with central nervous system action. It inhibits transmission at spinal level and also depresses the central nervous system (<LINK REF="REF-Abbruzzese-2002" TYPE="REFERENCE">Abbruzzese 2002</LINK>). </P>
<P>The use of muscle relaxants for low back pain continues to be a source of controversy amongst physicians, mainly because of their side effects. In addition to sedation, potential adverse effects include drowsiness, headache, blurred vision, nausea and vomiting. Potential for abuse and dependency has also been reported (<LINK REF="REF-Elder-1991" TYPE="REFERENCE">Elder 1991</LINK>). The controversy is evident in the recommendations found in national clinical guidelines for the management of low back pain in primary care. Some guidelines recommend muscle relaxants alone or in combination with NSAIDs as optional, others clearly do not recommended using them (<LINK REF="REF-Koes-2001" TYPE="REFERENCE">Koes 2001</LINK>). Despite this, 91 per cent of physicians report using muscle relaxants even if they are conditionally discouraged by guidelines (<LINK REF="REF-Di-Iorio-2000" TYPE="REFERENCE">Di Iorio 2000</LINK>). </P>
<P>The role of muscle spasm in the pathophysiology of low back pain is also controversial. Low back pain is generally considered to be the result of a self-perpetuating cycle of pain and spasm. Some physicians have questioned this model and thus, the efficacy of muscle relaxants (<LINK REF="REF-Johnson-1989" TYPE="REFERENCE">Johnson 1989</LINK>). Others view muscle spasm as a protective physiologic response that should not be inhibited by muscle relaxants (<LINK REF="REF-Littrell-1993" TYPE="REFERENCE">Littrell 1993</LINK>). Muscle spasm secondary to a pathological lesion in the lumbosacral region (e.g. facet joints, discs, muscles or ligaments) will immobilize the back and therefore contribute to the healing process. </P>
<P>Controversies surrounding muscle relaxants have resulted in some resistance to their use in patient care. Studies have been published which suggest a potential role for muscle relaxants in clinical practice (<LINK REF="REF-Browning-2001" TYPE="REFERENCE">Browning 2001</LINK>); however, there is a lack of good quality research on the clinical application of these drugs (<LINK REF="REF-Van-Tulder-1997a" TYPE="REFERENCE">Van Tulder 1997a</LINK>). This review aims to provide evidence on the efficacy and effectiveness of muscle relaxants in the management of non-specific low back pain.</P>
</BACKGROUND>
<OBJECTIVES>
<P>The aim of this systematic review was to determine if muscle relaxants are effective in the treatment of non-specific low back pain. The following comparisons were investigated: </P>
<P>1) Muscle relaxants vs. Placebo<BR/>2) Muscle relaxants vs. Paracetamol/Acetaminophen<BR/>3) Muscle relaxants vs. NSAIDs<BR/>4) Muscle relaxants vs. Muscle relaxants<BR/>5) Muscle relaxants + Analgesics/NSAIDs vs. Placebo + Analgesics/NSAIDs</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-06-23 09:25:49 -0400" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Only randomised controlled trials (RCTs) and double-blind controlled clinical trials (CCTs) were included.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Only trials involving patients diagnosed with "non-specific low back pain" were included. Non-specific low back pain was defined as pain localised between the scapulae and inferior gluteal folds which may or may not radiate down towards the knees, for which specific etiologies such as infections, neoplasms, metastases, osteoporosis, fractures, rheumatological disorders, neurological disorders and other relevant pathological entities have been ruled out clinically.</P>
<P>Trials involving patients with various musculoskeletal disorders were included if results were presented separately for the subgroup of low back pain patients or if more than 50 per cent of the study population consisted of low back pain patients.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>The use of muscle relaxants as monotherapy or in combination with other therapeutic modalities were included. The muscle relaxants that are included in this review are: benzodizepines (diazepam and tetrazepam), non-benzodiazepines antispasmodics (cyclobenzaprine, carisoprodol, chlorzoxazone, mepobramate, methocarbamol, metaxalone, orphenadrine, tizanidine and flupirtine), and antispasticity drugs (baclofen and dantrolene sodium). We excluded the muscle relaxant chlormezanone (Trancopal) from this review because this drug was discontinued worldwide in 1996 by its manufacturer, due to confirmed serious and rare cutaneous reactions (toxic epidermal necrolysis) associated with this drug (<LINK REF="REF-Roujeau-1995" TYPE="REFERENCE">Roujeau 1995</LINK>). We also excluded botulinum toxin, because it is not usually classified as a muscle relaxant.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Trials using one or more of the following outcome measures were included:<BR/>
</P>
<UL>
<LI>Pain intensity (e.g., visual analogue scale (VAS) or numerical rating scale (NRS)) at rest or during the day.</LI>
<LI>Global measure (overall improvement, proportion of patients recovered) assessed by the patient</LI>
<LI>Back pain specific functional status (e.g., Roland Disability Questionnaire, Oswestry Scale)</LI>
<LI>Return to work (return to work status, number of days off work)</LI>
<LI>Physiological outcomes (e.g., muscle spasm, range of motion, spinal flexibility, Lasegue test or muscle strength) </LI>
<LI>Generic functional status (e.g., SF-36, Nottingham Health Profile, Sickness Impact Profile)</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-06-23 09:25:41 -0400" MODIFIED_BY="[Empty name]">
<P>A computer-assisted search of the Cochrane Library (Issue 3, 2002), MEDLINE (up to October 2002) and EMBASE (up to October 2002) was carried out. These databases were searched using the algorithm recommended in the Cochrane Collaboration Handbook (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>) and the Back Review Group. Pertinent references cited in the identified articles were also screened as well as references of other systematic reviews (<LINK REF="REF-Bigos-1994" TYPE="REFERENCE">Bigos 1994</LINK>; <LINK REF="REF-Van-Tulder-1997a" TYPE="REFERENCE">Van Tulder 1997a</LINK>; <LINK REF="REF-Browning-2001" TYPE="REFERENCE">Browning 2001</LINK>). A language restriction excluding studies not published in English, Dutch, German, Spanish or Portuguese was applied to the selection process, because the authors were not able to read and understand any other languages. If possible, studies published in other languages will be included in a future update of this review. See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> and <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-06-23 09:25:49 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">General procedure of the review</HEADING>
<P>The review started with a literature search. Studies meeting the inclusion criteria were screened and analysed for methodological quality. This was followed by the extraction and analysis of the relevant data. The selection of studies, methodological quality assessment and data extraction were carried out by two independent authors. Twenty studies that were originally identified in MEDLINE, EMBASE and the Cochrane Library were independently assessed by one pair of authors (TT and MvT). Ten studies (<LINK REF="STD-Baptista-1988" TYPE="STUDY">Baptista 1988</LINK>; <LINK REF="STD-Bianchi-1978" TYPE="STUDY">Bianchi 1978</LINK>; <LINK REF="STD-Bragstad-1979" TYPE="STUDY">Bragstad 1979</LINK>; <LINK REF="STD-Corts-Giner-1989" TYPE="STUDY">Corts Giner 1989</LINK>; <LINK REF="STD-Lepisto-1979" TYPE="STUDY">Lepisto 1979</LINK>; <LINK REF="STD-Pipino-1991" TYPE="STUDY">Pipino 1991</LINK>; <LINK REF="STD-Pratzel-1996" TYPE="STUDY">Pratzel 1996</LINK>; <LINK REF="STD-Salzmann-1992" TYPE="STUDY">Salzmann 1992</LINK>; <LINK REF="STD-Sirdalud-1998" TYPE="STUDY">Sirdalud 1998</LINK>; <LINK REF="STD-Weber-1980" TYPE="STUDY">Weber 1980</LINK>) were included at a later stage and were<BR/>independently assessed by another pair of reviewers (MvT and SS; AF and SS). Results at each stage were compared and discrepancies were resolved in a consensus meeting.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Methodological quality assessment</HEADING>
<P>The methodological quality of each RCT was assessed using the criteria recommended by the Cochrane Back Review Group (<LINK REF="REF-Van-Tulder-1997b" TYPE="REFERENCE">Van Tulder 1997b</LINK>). The studies were not blinded for authors, institutions or the journals in which the studies were published. A pilot test was conducted using a trial on NSAIDs for back pain that is not included in the present systematic review. Only the criteria pertaining to internal validity were applied:</P>
<P>1) Adequate allocation concealment,<BR/>2) Adequate method of randomisation,<BR/>3) Similarity of baseline characteristics,<BR/>4) Blinding of patients,<BR/>5) Blinding of care provider,<BR/>6) Equal co-interventions,<BR/>7) Adequate compliance,<BR/>8) Identical timing of outcome assessment,<BR/>9) Blinded outcome assessment,<BR/>10) Withdrawals and drop outs adequate,<BR/>11) Intention-to-treat analysis.</P>
<P>All items were scored as positive (+), negative (-) or unclear (?). High quality was defined as fulfilling six or more of the 11 quality criteria. A sensitivity analysis in which the effect of variations in the cut-off point distinguishing studies of high and low methodological quality was conducted. We did not contact the authors for additional information because most studies had been published many years ago with only seven studies published in or after 1990.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>The data extraction was carried out by the same authors who performed the quality assessment using a standardised data extraction sheet. The studies were not blinded for authors, institutions or journals in which the studies were published. A pilot test was conducted using a trial on NSAIDs for back pain that is not included in the present systematic review.</P>
<P>The following data were extracted from the studies:<BR/>1) <B>Characteristics of the studies<BR/>
</B>The sponsors of the study and their contributions as well as authors affiliations.</P>
<P>2) <B>Characteristics of study population<BR/>
</B>Data pertaining to the sample sizes, and gender and age of the patients in the samples. The diagnosis of the patients was also noted. A distinction was made between acute/subacute low back pain (duration of symptoms less than 12 weeks) and chronic low back pain (duration of symptoms 12 weeks or more). The presence or absence of sciatica and muscle spasms was also recorded.</P>
<P>3) <B>Characteristics of interventions<BR/>
</B>The muscle relaxants investigated and the reference treatments to which they were compared were noted. Specifically, the type of muscle relaxant (benzodiazepine, non-benzodiazepine antispasmodics or antispasticity drug), the doses administered and the frequency and duration of the administration of the treatments was registered.</P>
<P>4) <B>Characteristics of outcomes<BR/>
</B>The outcome parameters used in the various trials and the performance of the treatments as recorded on these parameters was extracted. The performance of the treatments were regarded positive (in favour of intervention) if the difference from the control group was statistically significant (p &lt; 0.05). For pain outcomes, we considered pain at rest (first) and pain during the day (second). With regard to global improvement, if the authors reported both physician's and patient's opinion, we extracted only the patient's opinion. If they reported only the physician's assessment, then we used this data. We also assessed whether there was a clinically important difference of pain outcomes. (<LINK REF="REF-Farrar-2000" TYPE="REFERENCE">Farrar 2000</LINK>; <LINK REF="REF-Farrar-2001" TYPE="REFERENCE">Farrar 2001</LINK>) We considered a clinically important difference in VAS to be &gt;16mm or &gt;30% decrease. For a 11-points NRS this was 2 points or more.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data analysis</HEADING>
<P>A qualitative analysis ("best evidence synthesis") was conducted using a rating system consisting of the following levels of evidence:<BR/>Level 1 - strong evidence: generally consistent findings in multiple high quality trials<BR/>Level 2 - moderate evidence: generally consistent findings in multiple low quality trials and/or one high quality trial<BR/>Level 3a - limited evidence: only one low quality trial<BR/>Level 3b - conflicting evidence: inconsistent findings in multiple trials<BR/>Level 4 - no evidence: no RCTs and no double-blind trials</P>
<P>A quantitative or meta-analysis was conducted if studies provided sufficient data. The results were tabulated and formally tested for homogeneity. If data were statistically heterogeneous, reasons for heterogeneity were explored. Data were pooled using the random effects model. The results were plotted as relative risks (RR) with corresponding 95% confidence intervals (95% CI). All RRs were calculated so that a RR smaller than 1 indicated a positive effect of muscle relaxants. For example, a RR of 0.74 (95%CI 0.55 to 0.98) means that the chance of "not getting pain relief" is 26% less in the muscle relaxants group compared to the placebo group, with a confidence interval of 2% to 45%. The data entered in the meta-analyses were adversive outcomes, that is: number of patients with "no pain relief", "no global improvement", "no improvement in muscle spasms", etc. The analyses were performed separately for drug types (benzodiazepines, non-benzodiazepines and antispasticity drugs), for various outcome measures and for various follow-up moments.</P>
<P>Subgroup analyses were planned for the following combinations:<BR/>a) Low back pain with and without sciatica or muscle spasms<BR/>b) Different doses of muscle relaxants<BR/>c) Ambulant versus bed rest patients<BR/>d) Injection versus oral therapy</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-06-23 15:30:11 -0400" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-06-23 09:08:14 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Results of the literature search and selection</HEADING>
<P>The computer-assisted literature search produced a yield of seven references in the Cochrane Library, 25 in Medline and 25 in Embase. Taking into account 11 articles that were cross-referenced in the three databases, a net total of 46 articles were found to be potentially eligible. Further assessment of the articles and application of the in- and exclusion criteria resulted in 22 articles. Eight additional studies were identified through reference checking (<LINK REF="STD-Baptista-1988" TYPE="STUDY">Baptista 1988</LINK>; <LINK REF="STD-Bianchi-1978" TYPE="STUDY">Bianchi 1978</LINK>; <LINK REF="STD-Bragstad-1979" TYPE="STUDY">Bragstad 1979</LINK>; <LINK REF="STD-Corts-Giner-1989" TYPE="STUDY">Corts Giner 1989</LINK>; <LINK REF="STD-Lepisto-1979" TYPE="STUDY">Lepisto 1979</LINK>; <LINK REF="STD-Pipino-1991" TYPE="STUDY">Pipino 1991</LINK>; <LINK REF="STD-Salzmann-1992" TYPE="STUDY">Salzmann 1992</LINK>; <LINK REF="STD-Sirdalud-1998" TYPE="STUDY">Sirdalud 1998</LINK>), resulting in a total of 30 studies.</P>
<P>Not all studies included in the systematic review of cyclobenzaprine for back pain (<LINK REF="REF-Browning-2001" TYPE="REFERENCE">Browning 2001</LINK>) were included in the present review, because some of them had included a mixed population of patients with various musculoskeletal disorders. We only included studies if results were presented separately for low back pain patients or if more than 50% of the study population consisted of low back pain patients (see Table "Characteristics of excluded studies").</P>
<P>The following studies were identified in the comparisons investigated (some studies included more than one comparison, so the total is more than 30):<BR/>1) <B>Muscle relaxants vs. placebo</B>
<BR/>1a) Benzodiazepines vs. placebo (4 studies: <LINK REF="STD-Arbus-1990" TYPE="STUDY">Arbus 1990</LINK>; <LINK REF="STD-Basmajian-1978" TYPE="STUDY">Basmajian 1978</LINK>; <LINK REF="STD-Moll-1973" TYPE="STUDY">Moll 1973</LINK>; <LINK REF="STD-Salzmann-1992" TYPE="STUDY">Salzmann 1992</LINK>)<BR/>1b) Non-benzodiazepines vs. placebo (11 studies: <LINK REF="STD-Baptista-1988" TYPE="STUDY">Baptista 1988</LINK>; <LINK REF="STD-Barrata-1982" TYPE="STUDY">Barrata 1982</LINK>; <LINK REF="STD-Basmajian-1978" TYPE="STUDY">Basmajian 1978</LINK>; <LINK REF="STD-Berry-1988a" TYPE="STUDY">Berry 1988a</LINK>; <LINK REF="STD-Bianchi-1978" TYPE="STUDY">Bianchi 1978</LINK>; <LINK REF="STD-Gold-1978" TYPE="STUDY">Gold 1978</LINK>; <LINK REF="STD-Hindle-1972" TYPE="STUDY">Hindle 1972</LINK>; <LINK REF="STD-Klinger-1988" TYPE="STUDY">Klinger 1988</LINK>; <LINK REF="STD-Lepisto-1979" TYPE="STUDY">Lepisto 1979</LINK>; <LINK REF="STD-Pratzel-1996" TYPE="STUDY">Pratzel 1996</LINK>; <LINK REF="STD-Worz-1996" TYPE="STUDY">Worz 1996</LINK>)<BR/>1c) Antispasticity vs. placebo (2 studies: <LINK REF="STD-Casale-1988" TYPE="STUDY">Casale 1988</LINK>; <LINK REF="STD-Dapas-1983" TYPE="STUDY">Dapas 1983</LINK>)<BR/>2) <B>Muscle relaxants vs. paracetamol/Acetaminophen</B> (no studies)<BR/>3) <B>Muscle relaxants vs. NSAIDs</B> (no studies)<BR/>4) <B>Muscle relaxants vs. muscle relaxants</B> (8 studies: <LINK REF="STD-Baptista-1988" TYPE="STUDY">Baptista 1988</LINK>; <LINK REF="STD-Basmajian-1978" TYPE="STUDY">Basmajian 1978</LINK>; <LINK REF="STD-Boyles-1983" TYPE="STUDY">Boyles 1983</LINK>; <LINK REF="STD-Bragstad-1979" TYPE="STUDY">Bragstad 1979</LINK>; <LINK REF="STD-Hennies-1981" TYPE="STUDY">Hennies 1981</LINK>; <LINK REF="STD-Hindle-1972" TYPE="STUDY">Hindle 1972</LINK>; <LINK REF="STD-Pipino-1991" TYPE="STUDY">Pipino 1991</LINK>; <LINK REF="STD-Rollings-1983" TYPE="STUDY">Rollings 1983</LINK>)<BR/>5) <B>Muscle relaxants + analgesics/NSAIDs vs. placebo + analgesics/NSAIDs</B> (6 studies: <LINK REF="STD-Berry-1988b" TYPE="STUDY">Berry 1988b</LINK>; <LINK REF="STD-Borenstein-1990" TYPE="STUDY">Borenstein 1990</LINK>; <LINK REF="STD-Corts-Giner-1989" TYPE="STUDY">Corts Giner 1989</LINK>; <LINK REF="STD-Hingorani-1966" TYPE="STUDY">Hingorani 1966</LINK>; <LINK REF="STD-Sirdalud-1998" TYPE="STUDY">Sirdalud 1998</LINK>; <LINK REF="STD-Tervo-1976" TYPE="STUDY">Tervo 1976</LINK>)</P>
<P>
<B>Other comparisons<BR/>
</B>Other studies compared ethoheptazine plus meprobamate plus aspirin vs. NSAID (mefenamic acid) (<LINK REF="STD-Sweetman-1987" TYPE="STUDY">Sweetman 1987</LINK>), orphenadrine vs. phenobarbital (<LINK REF="STD-Gold-1978" TYPE="STUDY">Gold 1978</LINK>), orphenadrine plus paracetamol vs. aspirin (<LINK REF="STD-Hingorani-1971" TYPE="STUDY">Hingorani 1971</LINK>), and diazepam plus paracetamol - codeine vs. levomepromazine plus paracetamol - codeine (<LINK REF="STD-Weber-1980" TYPE="STUDY">Weber 1980</LINK>). These studies are summarized in the table with "characteristics of included studies", but not included in the results section because they could not be classified in one of the predefined comparisons.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Study characteristics</HEADING>
<P>Twenty-two studies declared at least one relationship with the pharmaceutical industry. These relationships varied from authors affiliated with the pharmaceutical industry, drugs supplied by the industry, support received (in terms of statistical evaluations, medical, scientific and editorial assistance) and explicitly declaration that the study was conducted with grants from the pharmaceutical industry or was directly conducted by them. In eight studies there was nothing declared with regards to any relationship with the pharmaceutical industry, but in some studies they used the pre-commercial name of the muscle relaxant drug, such as DS 103 - 282 for tizanidine.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sample characteristics</HEADING>
<P>Data on sample size, age and gender, type and duration of symptoms, and setting are summarized in the table with "characteristics of included studies". Twenty-four studies included patients with acute LBP and six studies chronic LBP (<LINK REF="STD-Arbus-1990" TYPE="STUDY">Arbus 1990</LINK>; <LINK REF="STD-Basmajian-1978" TYPE="STUDY">Basmajian 1978</LINK>; <LINK REF="STD-Pipino-1991" TYPE="STUDY">Pipino 1991</LINK>; <LINK REF="STD-Pratzel-1996" TYPE="STUDY">Pratzel 1996</LINK>; <LINK REF="STD-Salzmann-1992" TYPE="STUDY">Salzmann 1992</LINK>; <LINK REF="STD-Worz-1996" TYPE="STUDY">Worz 1996</LINK>). No studies specifically reported on patients with sciatica. Fourteen studies explicitly stated that the population to be treated had to be diagnosed with muscle spasms. However, the accuracy of this diagnosis was not discussed in any of these studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interventions</HEADING>
<P>Eight studies were identified which included benzodiazepines (<LINK REF="STD-Arbus-1990" TYPE="STUDY">Arbus 1990</LINK>; <LINK REF="STD-Basmajian-1978" TYPE="STUDY">Basmajian 1978</LINK>; <LINK REF="STD-Boyles-1983" TYPE="STUDY">Boyles 1983</LINK>; <LINK REF="STD-Hennies-1981" TYPE="STUDY">Hennies 1981</LINK>; <LINK REF="STD-Hingorani-1966" TYPE="STUDY">Hingorani 1966</LINK>; <LINK REF="STD-Moll-1973" TYPE="STUDY">Moll 1973</LINK>; <LINK REF="STD-Salzmann-1992" TYPE="STUDY">Salzmann 1992</LINK>; <LINK REF="STD-Weber-1980" TYPE="STUDY">Weber 1980</LINK>); 23 studies non-benzodiazepines (<LINK REF="STD-Baptista-1988" TYPE="STUDY">Baptista 1988</LINK>; <LINK REF="STD-Barrata-1982" TYPE="STUDY">Barrata 1982</LINK>; <LINK REF="STD-Basmajian-1978" TYPE="STUDY">Basmajian 1978</LINK>; <LINK REF="STD-Berry-1988a" TYPE="STUDY">Berry 1988a</LINK>; <LINK REF="STD-Berry-1988b" TYPE="STUDY">Berry 1988b</LINK>; <LINK REF="STD-Bianchi-1978" TYPE="STUDY">Bianchi 1978</LINK>; <LINK REF="STD-Borenstein-1990" TYPE="STUDY">Borenstein 1990</LINK>; <LINK REF="STD-Boyles-1983" TYPE="STUDY">Boyles 1983</LINK>; <LINK REF="STD-Bragstad-1979" TYPE="STUDY">Bragstad 1979</LINK>; <LINK REF="STD-Corts-Giner-1989" TYPE="STUDY">Corts Giner 1989</LINK>; <LINK REF="STD-Gold-1978" TYPE="STUDY">Gold 1978</LINK>; <LINK REF="STD-Hennies-1981" TYPE="STUDY">Hennies 1981</LINK>; <LINK REF="STD-Hindle-1972" TYPE="STUDY">Hindle 1972</LINK>; <LINK REF="STD-Hingorani-1971" TYPE="STUDY">Hingorani 1971</LINK>; <LINK REF="STD-Klinger-1988" TYPE="STUDY">Klinger 1988</LINK>; <LINK REF="STD-Lepisto-1979" TYPE="STUDY">Lepisto 1979</LINK>; <LINK REF="STD-Pipino-1991" TYPE="STUDY">Pipino 1991</LINK>; <LINK REF="STD-Pratzel-1996" TYPE="STUDY">Pratzel 1996</LINK>; <LINK REF="STD-Rollings-1983" TYPE="STUDY">Rollings 1983</LINK>; <LINK REF="STD-Sirdalud-1998" TYPE="STUDY">Sirdalud 1998</LINK>; <LINK REF="STD-Sweetman-1987" TYPE="STUDY">Sweetman 1987</LINK>; <LINK REF="STD-Tervo-1976" TYPE="STUDY">Tervo 1976</LINK>; <LINK REF="STD-Worz-1996" TYPE="STUDY">Worz 1996</LINK>); and 2 studies antispasticity drugs (<LINK REF="STD-Casale-1988" TYPE="STUDY">Casale 1988</LINK>; <LINK REF="STD-Dapas-1983" TYPE="STUDY">Dapas 1983</LINK>).</P>
<P>Five studies made use of injection therapy. In one of these studies the efficacy of a single intravenous injection was evaluated (<LINK REF="STD-Klinger-1988" TYPE="STUDY">Klinger 1988</LINK>), while in the other four studies an intramuscular injection was followed by oral medication (<LINK REF="STD-Hingorani-1966" TYPE="STUDY">Hingorani 1966</LINK>; <LINK REF="STD-Moll-1973" TYPE="STUDY">Moll 1973</LINK>; <LINK REF="STD-Pipino-1991" TYPE="STUDY">Pipino 1991</LINK>; <LINK REF="STD-Tervo-1976" TYPE="STUDY">Tervo 1976</LINK>).</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-06-23 15:30:11 -0400" MODIFIED_BY="[Empty name]">
<P>The median score for methodological quality of all the included studies was 6 with a range of 3-9. Using a cut-off point of 6 out of 11 criteria, 23 of the 30 studies (77%) were of high quality (<LINK REF="STD-Arbus-1990" TYPE="STUDY">Arbus 1990</LINK>; <LINK REF="STD-Baptista-1988" TYPE="STUDY">Baptista 1988</LINK>; <LINK REF="STD-Barrata-1982" TYPE="STUDY">Barrata 1982</LINK>; <LINK REF="STD-Berry-1988a" TYPE="STUDY">Berry 1988a</LINK>; <LINK REF="STD-Berry-1988b" TYPE="STUDY">Berry 1988b</LINK>; <LINK REF="STD-Bianchi-1978" TYPE="STUDY">Bianchi 1978</LINK>; <LINK REF="STD-Boyles-1983" TYPE="STUDY">Boyles 1983</LINK>; <LINK REF="STD-Bragstad-1979" TYPE="STUDY">Bragstad 1979</LINK>; <LINK REF="STD-Casale-1988" TYPE="STUDY">Casale 1988</LINK>; <LINK REF="STD-Corts-Giner-1989" TYPE="STUDY">Corts Giner 1989</LINK>; <LINK REF="STD-Dapas-1983" TYPE="STUDY">Dapas 1983</LINK>; <LINK REF="STD-Hennies-1981" TYPE="STUDY">Hennies 1981</LINK>; <LINK REF="STD-Hindle-1972" TYPE="STUDY">Hindle 1972</LINK>; <LINK REF="STD-Hingorani-1966" TYPE="STUDY">Hingorani 1966</LINK>; <LINK REF="STD-Hingorani-1971" TYPE="STUDY">Hingorani 1971</LINK>; <LINK REF="STD-Klinger-1988" TYPE="STUDY">Klinger 1988</LINK>; <LINK REF="STD-Lepisto-1979" TYPE="STUDY">Lepisto 1979</LINK>; <LINK REF="STD-Pratzel-1996" TYPE="STUDY">Pratzel 1996</LINK>; <LINK REF="STD-Rollings-1983" TYPE="STUDY">Rollings 1983</LINK>; <LINK REF="STD-Salzmann-1992" TYPE="STUDY">Salzmann 1992</LINK>; <LINK REF="STD-Sirdalud-1998" TYPE="STUDY">Sirdalud 1998</LINK>; <LINK REF="STD-Tervo-1976" TYPE="STUDY">Tervo 1976</LINK>; <LINK REF="STD-Worz-1996" TYPE="STUDY">Worz 1996</LINK>). See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<P>The most common methodological shortcomings in the studies involved (in order of frequency):<BR/>
</P>
<UL>
<LI>Inadequate concealment of the drug allocation procedures (93% scored 'negative' or 'unclear')</LI>
<LI>Failing to evaluate compliance (83% scored 'negative' or 'unclear')</LI>
<LI>Inadequate method of randomisation (80% scored 'negative' or 'unclear')</LI>
<LI>Non-equivalent co-interventions (60% scored 'negative' or 'unclear')</LI>
<LI>Failing to apply intention-to-treat analysis (60% scored 'negative' or 'unclear')</LI>
<LI>Dissimilarity of the baseline characteristics (47% scored 'negative' or 'unclear')</LI>
<LI>Inadequate dropouts (33% scored 'negative' or 'unclear')</LI>
</UL>
<P>Almost all studies had identical timing of outcome measures (90%) and had adequately blinded patients (93%), outcome assessments (93%) and care provider (93%).</P>
<P>Comparison of the scores by the authors for each study demonstrated a author concurrence rate of 73%. The disagreement in 27% of the scores could be attributed to subtle differences in interpretation of the criteria. This was reflected in the systematic nature of the discrepancies in scoring. Random errors in reading of the articles and recording of the assessments, as well as ambiguities in the presentation of information in the articles also played a role. All disagreements were resolved in a consensus meeting.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-06-23 09:08:14 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1a) Benzodiazepines vs. placebo</HEADING>
<P>Four studies were identified, one on acute LBP (<LINK REF="STD-Moll-1973" TYPE="STUDY">Moll 1973</LINK>) and three on chronic LBP (<LINK REF="STD-Arbus-1990" TYPE="STUDY">Arbus 1990</LINK>; <LINK REF="STD-Basmajian-1978" TYPE="STUDY">Basmajian 1978</LINK>; <LINK REF="STD-Salzmann-1992" TYPE="STUDY">Salzmann 1992</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Acute LBP</HEADING>
<P>The one low quality trial on acute LBP showed that there is limited evidence (1 trial; 50 people) that an intramuscular injection of diazepam followed by oral diazepam for 5 days is more effective than placebo for patients with acute LBP on short-term pain relief and better overall improvement, but is associated with substantially more central nervous system side effects (<LINK REF="STD-Moll-1973" TYPE="STUDY">Moll 1973</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Chronic LBP</HEADING>
<P>The two high quality trials on chronic LBP (<LINK REF="STD-Arbus-1990" TYPE="STUDY">Arbus 1990</LINK>; <LINK REF="STD-Salzmann-1992" TYPE="STUDY">Salzmann 1992</LINK>) showed that there is strong evidence (2 trials; 222 people) that tetrazepam 50 mg t.i.d. is more effective than placebo for patients with chronic LBP on short-term pain relief and overall improvement. The pooled RRs and 95% CIs for pain intensity were 0.82 (0.72 to 0.94) after 5-7 days follow-up and 0.71 (0.54 to 0.93) after 10-14 days. The pooled RR and 95% CI for overall improvement was 0.63 (0.42 to 0.97) after 10-14 days follow-up. One high quality trial (<LINK REF="STD-Arbus-1990" TYPE="STUDY">Arbus 1990</LINK>) showed that there is moderate evidence (1 trial; 50 people) that tetrazepam is more effective than placebo on short-term decrease of muscle spasm. One low quality trial showed that there is limited evidence (1 trial; 76 people) that there is no difference between diazepam and placebo on short-term decrease of muscle spasm (<LINK REF="STD-Basmajian-1978" TYPE="STUDY">Basmajian 1978</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">1b) Non-benzodiazepines vs. placebo</HEADING>
<P>Eleven studies were identified, eight on acute LBP (<LINK REF="STD-Baptista-1988" TYPE="STUDY">Baptista 1988</LINK>; <LINK REF="STD-Barrata-1982" TYPE="STUDY">Barrata 1982</LINK>; <LINK REF="STD-Berry-1988a" TYPE="STUDY">Berry 1988a</LINK>; <LINK REF="STD-Bianchi-1978" TYPE="STUDY">Bianchi 1978</LINK>; <LINK REF="STD-Gold-1978" TYPE="STUDY">Gold 1978</LINK>; <LINK REF="STD-Hindle-1972" TYPE="STUDY">Hindle 1972</LINK>; <LINK REF="STD-Klinger-1988" TYPE="STUDY">Klinger 1988</LINK>; <LINK REF="STD-Lepisto-1979" TYPE="STUDY">Lepisto 1979</LINK>) and three on chronic LBP (<LINK REF="STD-Basmajian-1978" TYPE="STUDY">Basmajian 1978</LINK>; <LINK REF="STD-Pratzel-1996" TYPE="STUDY">Pratzel 1996</LINK>; <LINK REF="STD-Worz-1996" TYPE="STUDY">Worz 1996</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Acute LBP</HEADING>
<P>One high quality study on acute LBP (<LINK REF="STD-Klinger-1988" TYPE="STUDY">Klinger 1988</LINK>) showed that there is moderate evidence (1 trial; 80 people) that a single intravenous injection of 60 mg orphenadrine is more effective than placebo in immediate relief of pain and muscle spasm for patients with acute LBP.</P>
<P>Three high quality (<LINK REF="STD-Barrata-1982" TYPE="STUDY">Barrata 1982</LINK>; <LINK REF="STD-Berry-1988a" TYPE="STUDY">Berry 1988a</LINK>; <LINK REF="STD-Lepisto-1979" TYPE="STUDY">Lepisto 1979</LINK>) and one low quality trial (<LINK REF="STD-Gold-1978" TYPE="STUDY">Gold 1978</LINK>) showed that there is strong evidence (4 trials; 294 people) that oral non-benzodiazepines are more effective than placebo for patients with acute LBP on short-term pain relief, global efficacy and improvement of physical outcomes. The pooled RR and 95% CIs for pain intensity was 0.80 (0.71 to 0.89) after 2-4 days (4 trials; 294 people) and 0.58 (0.45 to 0.76) after 5-7 days follow-up (3 trials; 244 people). The pooled RR and 95% CIs for global efficacy was 0.49 (0.25 to 0.95) after 2-4 days (4 trials; 222 people) and 0.68 (0.41 to 1.13) after 5-7 days follow-up (4 trials; 323 people). The pooled RR and 95% CIs for physical outcomes was 0.76 (0.66 to 0.88) after 2-4 days (3 trials; 252 people) and 0.55 (0.40 to 0.77) after 5-7 days follow-up (3 trials; 251 people).</P>
<P>Of the three high quality trials (<LINK REF="STD-Baptista-1988" TYPE="STUDY">Baptista 1988</LINK>; <LINK REF="STD-Bianchi-1978" TYPE="STUDY">Bianchi 1978</LINK>; <LINK REF="STD-Hindle-1972" TYPE="STUDY">Hindle 1972</LINK>) that could not be included in the statistical pooling due to insufficient data, one large trial (267 people) reported no differences after 3 and 7 days in pain relief and global efficacy between tizanidine and placebo (<LINK REF="STD-Baptista-1988" TYPE="STUDY">Baptista 1988</LINK>). Two small trials (48 people each) reported that oral non-benzodiazepines are more effective than placebo regarding pain intensity, global efficacy and muscle spasm after 7 and 14 days (<LINK REF="STD-Bianchi-1978" TYPE="STUDY">Bianchi 1978</LINK>) and on pain intensity after 4 days (<LINK REF="STD-Hindle-1972" TYPE="STUDY">Hindle 1972</LINK>). However, in the last trial groups were not similar at baseline which may have biased the results.</P>
<P>Strong evidence from all eight trials on acute LBP (724 people) showed that muscle relaxants are associated with more total adverse effects and central nervous system adverse effects than placebo, but not with more gastrointestinal adverse effects; RRs and 95% CIs were 1.50 (1.14 to 1.98), 2.04 (1.23 to 3.37) and 0.95 (0.29 to 3.19), respectively. The most commonly and consistently reported adverse events involving the central nervous system were drowsiness and dizziness. For the gastrointestinal tract this was nausea. The incidence of other adverse events associated with muscle relaxants was negligible.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Chronic LBP</HEADING>
<P>One high quality trial (<LINK REF="STD-Worz-1996" TYPE="STUDY">Worz 1996</LINK>) showed that there is moderate evidence (1 trial; 107 people) that flupirtin is more effective than placebo for patients with chronic LBP on short-term pain relief and overall improvement after 7 days, but not on reduction of muscle spasm. One high quality trial (<LINK REF="STD-Pratzel-1996" TYPE="STUDY">Pratzel 1996</LINK>) showed that there is moderate evidence (1 trial; 112 people) that tolperisone is more effective than placebo for patients with chronic LBP on short-term overall improvement after 21 days, but not on pain relief and reduction of muscle spasm. The low quality trial (<LINK REF="STD-Basmajian-1978" TYPE="STUDY">Basmajian 1978</LINK>) showed that there is limited evidence (1 trial; 76 people) that there is no difference on short-term reduction of muscle spasm after 18 days between cyclobenzaprine and placebo for patients with chronic LBP. The two high quality trials did not show a difference in side effects.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">1c) Antispasticity drugs vs. placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Acute LBP</HEADING>
<P>Two high quality trials (<LINK REF="STD-Casale-1988" TYPE="STUDY">Casale 1988</LINK>; <LINK REF="STD-Dapas-1983" TYPE="STUDY">Dapas 1983</LINK>) showed that there is strong evidence (2 trials; 220 people) that antispasticity muscle relaxants are more effective than placebo for patients with acute LBP on short-term pain relief and reduction of muscle spasm after 4 days. One high quality trial (<LINK REF="STD-Dapas-1983" TYPE="STUDY">Dapas 1983</LINK>) also showed that there is moderate evidence that antispasticity muscle relaxants are more effective than placebo for patients with acute LBP on short-term pain relief, reduction of muscle spasm, and overall improvement after 10 days.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2) Muscle relaxants vs. paracetamol/acetaminophen</HEADING>
<P>No RCTs or double-blind trials were identified.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3) Muscle relaxants vs. NSAIDs</HEADING>
<P>No RCTs or double-blind trials were identified.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4) Muscle relaxants vs. muscle relaxants</HEADING>
<P>Eight studies were identified, 5 high quality (<LINK REF="STD-Boyles-1983" TYPE="STUDY">Boyles 1983</LINK>; <LINK REF="STD-Bragstad-1979" TYPE="STUDY">Bragstad 1979</LINK>; <LINK REF="STD-Hennies-1981" TYPE="STUDY">Hennies 1981</LINK>; <LINK REF="STD-Hindle-1972" TYPE="STUDY">Hindle 1972</LINK>; <LINK REF="STD-Rollings-1983" TYPE="STUDY">Rollings 1983</LINK>) and three low quality trials (<LINK REF="STD-Baptista-1988" TYPE="STUDY">Baptista 1988</LINK>; <LINK REF="STD-Basmajian-1978" TYPE="STUDY">Basmajian 1978</LINK>; <LINK REF="STD-Pipino-1991" TYPE="STUDY">Pipino 1991</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Carisoprodol</HEADING>
<P>This muscle relaxant was investigated in two high quality studies on acute low back pain. The first study compared carisoprodol with diazepam (<LINK REF="STD-Boyles-1983" TYPE="STUDY">Boyles 1983</LINK>). Carisoprodol was superior in performance on all the outcome parameters measured. Comparison of carisoprodol with cyclobenzaprine-hydrochloride in the second study revealed no statistically significant differences between the two treatments (<LINK REF="STD-Rollings-1983" TYPE="STUDY">Rollings 1983</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Chlorzoxazone</HEADING>
<P>This muscle relaxant was compared with tizanidine in one high quality study in a very small sample of patients (27 people) with degenerative lumbar disc disease (<LINK REF="STD-Bragstad-1979" TYPE="STUDY">Bragstad 1979</LINK>). No differences were found between the treatments.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cyclobenzaprine-hydrochloride</HEADING>
<P>Cyclobenzaprine was compared with diazepam in a low quality trial on chronic low back pain, but no significant differences between the treatments were identified (<LINK REF="STD-Basmajian-1978" TYPE="STUDY">Basmajian 1978</LINK>). There was also no significant difference between cyclobenzaprine and carisoprodol in one high quality study on acute low back pain (<LINK REF="STD-Rollings-1983" TYPE="STUDY">Rollings 1983</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Diazepam</HEADING>
<P>In comparison with carisoprodol, diazepam was found to be inferior in performance on muscle spasm, global efficacy and functional status in a high quality trial on acute low back pain (<LINK REF="STD-Boyles-1983" TYPE="STUDY">Boyles 1983</LINK>). In a very small high quality trial (30 people) comparing diazepam with tizanidine there were no differences in pain, functional status and muscle spasm after seven days (<LINK REF="STD-Hennies-1981" TYPE="STUDY">Hennies 1981</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tizanidine</HEADING>
<P>This muscle relaxant was compared with chlorzoxazone and diazepam in two very small high quality trials (<LINK REF="STD-Bragstad-1979" TYPE="STUDY">Bragstad 1979</LINK>; <LINK REF="STD-Hennies-1981" TYPE="STUDY">Hennies 1981</LINK>). Both trials did not find any differences in pain, functional status and muscle spasm after 7 days.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Pridinol mesilate</HEADING>
<P>One low quality trial showed no differences between this muscle relaxant and thiocolchicoside on pain relief and global efficacy (<LINK REF="STD-Pipino-1991" TYPE="STUDY">Pipino 1991</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5) Muscle relaxants + analgesics/NSAIDs vs. placebo + analgesics/NSAIDs</HEADING>
<P>Six studies were identified on acute LBP, five high quality (<LINK REF="STD-Berry-1988b" TYPE="STUDY">Berry 1988b</LINK>; <LINK REF="STD-Corts-Giner-1989" TYPE="STUDY">Corts Giner 1989</LINK>; <LINK REF="STD-Hingorani-1966" TYPE="STUDY">Hingorani 1966</LINK>; <LINK REF="STD-Sirdalud-1998" TYPE="STUDY">Sirdalud 1998</LINK>; <LINK REF="STD-Tervo-1976" TYPE="STUDY">Tervo 1976</LINK>) and one low quality trial (<LINK REF="STD-Borenstein-1990" TYPE="STUDY">Borenstein 1990</LINK>). Five trials evaluated non-benzodiazepines and only one trial benzodiazepines (<LINK REF="STD-Hingorani-1966" TYPE="STUDY">Hingorani 1966</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Acute LBP</HEADING>
<P>Three high quality trials showed that there is strong evidence (3 trials; 560 people) that tizanidine plus analgesics (<LINK REF="STD-Corts-Giner-1989" TYPE="STUDY">Corts Giner 1989</LINK>) or NSAIDs (<LINK REF="STD-Berry-1988b" TYPE="STUDY">Berry 1988b</LINK>; <LINK REF="STD-Sirdalud-1998" TYPE="STUDY">Sirdalud 1998</LINK>) is more effective than placebo plus analgesics or NSAIDs for patients with acute LBP on short-term pain relief and decrease of muscle spasm after 3-4 and 7-8 days. The other high quality trial showed no difference on global efficacy, but the orphenadrine plus paracetamol group had statistically significantly fewer disability days than the placebo plus paracetamol group (<LINK REF="STD-Tervo-1976" TYPE="STUDY">Tervo 1976</LINK>). The low quality trial showed statistically significantly greater decrease of muscle spasm for cyclobezaprine plus NSAIDs after 14 days, but no differences on pain intensity and global efficacy (<LINK REF="STD-Borenstein-1990" TYPE="STUDY">Borenstein 1990</LINK>). Data on adverse events from four studies (556 people) were pooled (<LINK REF="STD-Berry-1988b" TYPE="STUDY">Berry 1988b</LINK>; <LINK REF="STD-Borenstein-1990" TYPE="STUDY">Borenstein 1990</LINK>; <LINK REF="STD-Sirdalud-1998" TYPE="STUDY">Sirdalud 1998</LINK>; <LINK REF="STD-Tervo-1976" TYPE="STUDY">Tervo 1976</LINK>). Using the random effects model the RR and 95% CI was 1.34 [95%CI 0.67 to 2.67] indicating that there was no statistically significant difference in total adverse effects. However, the RRs and 95% CIs for central nervous system and gastrointestinal adverse effects were 2.44 (1.05 to 5.63) and 0.54 (0.26 to 1.14), respectively, showing that combination therapy was responsible for significantly more central nervous system adverse effects.</P>
<P>One high quality trial showed no differences on subjective and objective outcomes between a benzodiazepine (diazepam) plus calcium aspirin versus placebo plus calcium aspirin (<LINK REF="STD-Hingorani-1966" TYPE="STUDY">Hingorani 1966</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pre-planned subgroup analyses</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">a) Low back pain with and without sciatica and muscle spasms</HEADING>
<P>No trials specifically addressed sciatica. We could not perform a sub-group analysis of the studies in which muscle spasms were identified because the accuracy of these measurements is not described and because we cannot assume that the trials that didn't mention muscle spasm reflect in reality patients without muscle spasm.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">b) Different doses of muscle relaxants</HEADING>
<P>Various muscle relaxants were investigated in multiple studies, but the studies either included the same doses (for example, all studies evaluating cyclobenzaprine used a dose of 10 mg t.i.d.) or were found to be too heterogeneous in terms of control interventions and outcome parameters to be able to make any comparisons.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">c) Ambulant patients versus bed rest patients</HEADING>
<P>Two high quality studies involved patients prescribed bed rest. One study compared an antispasticity muscle relaxant (baclofen) with placebo and incorporated bed rest in the therapeutic regimen (<LINK REF="STD-Dapas-1983" TYPE="STUDY">Dapas 1983</LINK>). In comparison with placebo there was significant relief of pain and improvement in terms of global efficacy. Relief of spasm did not reach statistical significance. The second study investigated a benzodiazepine (diazepam) plus calcium aspirin versus placebo plus calcium aspirin and involved patients treated with complete bed rest (<LINK REF="STD-Hingorani-1966" TYPE="STUDY">Hingorani 1966</LINK>). No difference was found between the two treatments in this trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">d) Injection therapy</HEADING>
<P>Five studies made use of injection therapy, of which four evaluated an intramuscular injection followed by oral medication compared with placebo or another muscle relaxant. No trial compared injection with oral medication.</P>
<P>The first high quality study made use of an initial course of diazepam therapy administered intramuscularly at a dose of 10mg every six hours for 24 hours (<LINK REF="STD-Hingorani-1966" TYPE="STUDY">Hingorani 1966</LINK>). This was followed by a course of oral therapy plus calcium aspirin. No differences were found between the diazepam and placebo groups at the end of the trial, and the effect of the injection therapy was not clear.</P>
<P>The second high quality study found shorter duration of disability with 60mg of orphenadrine administered intramuscularly followed by oral tablets plus paracetamol compared with placebo. There was no difference in global efficacy. Drop-out rate in this trial was high (<LINK REF="STD-Tervo-1976" TYPE="STUDY">Tervo 1976</LINK>).</P>
<P>One high quality study using 60mg of orphenadrine administered intravenously compared to placebo found significant relief of pain and spasm 45 minutes after one single injection (<LINK REF="STD-Klinger-1988" TYPE="STUDY">Klinger 1988</LINK>).</P>
<P>One low quality trial showed a better therapeutic effect with intramuscular diazepam followed by oral tablets compared with placebo, but groups were different at baseline (<LINK REF="STD-Moll-1973" TYPE="STUDY">Moll 1973</LINK>).</P>
<P>The other low quality trial showed no differences between pridinol mesilate and thiocolchicoside intramuscular followed by oral tablets (<LINK REF="STD-Pipino-1991" TYPE="STUDY">Pipino 1991</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>A best case analysis was carried out in which internal validity criteria that were scored as unclear ("?") were scored as positive. This obviously increased the number of high quality studies and resulted in only two studies still being considered low quality (<LINK REF="STD-Basmajian-1978" TYPE="STUDY">Basmajian 1978</LINK>; <LINK REF="STD-Gold-1978" TYPE="STUDY">Gold 1978</LINK>). This procedure changed the results of benzodiazepines versus placebo for acute LBP from limited to moderate evidence, but had no consequences for any of the other results.</P>
<P>Lowering the threshold distinguishing higher and lower quality studies from 6 out of 11 criteria to 5 out of 11 criteria changed three studies from low to high quality (<LINK REF="STD-Moll-1973" TYPE="STUDY">Moll 1973</LINK>; <LINK REF="STD-Pipino-1991" TYPE="STUDY">Pipino 1991</LINK>; <LINK REF="STD-Sweetman-1987" TYPE="STUDY">Sweetman 1987</LINK>). This produced the same consequences described in the paragraph above, changing the results of benzodiazepines versus placebo for acute LBP from limited to moderate evidence.</P>
<P>Raising the threshold from 6 out of 11 to 7 out of 11 criteria consequently decreased the number of high quality studies; 10 trials with quality score of 6 were considered low quality in this sensitivity analysis. The evidence on pain relief and global efficacy for tetrazepam vs. placebo for chronic LBP changed from strong to moderate, and the moderate evidence on muscle spasm to limited. The evidence that flupirtin is more effective than placebo for patients with chronic LBP changed from moderate to limited. There were no other implications on results.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-06-20 15:29:12 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Literature search and selection</HEADING>
<P>The results of this review must be interpreted against several potential sources of bias involving the literature search and selection process. A language restriction was applied to the selection process in which studies not published in English, Dutch, German, Spanish or Portuguese were not admitted for further review. Although we acknowledge that systematic reviews should aim at inclusion of all relevant trials, independent of language, identifying trials published in any language is difficult, time consuming and costly. We will attempt to include other language trials in a future update of this review. In addition, no efforts were undertaken to track down and include the results of unpublished studies. It was noted that no studies were identified which demonstrated negative results for muscle relaxants. This suggests the possibility of publication bias. It has been demonstrated that medication trials with positive outcomes are more likely to be published (<LINK REF="REF-Gotzsche-1987" TYPE="REFERENCE">Gotzsche 1987</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Methodological quality analysis</HEADING>
<P>Using a cut-off point of 6/11 criteria, 77% of the included studies were found to be of high quality. A large proportion of these high quality studies fulfilled six criteria indicating that there is still room for improvement in the quality of execution and reporting of trials involving muscle relaxants. The most common methodological flaws involved the concealment of treatment allocation, compliance and randomisation procedure, which were only adequate in 2, 4 and 6 of the 30 trials, respectively. Most authors failed to explicitly specify the method or person responsible for concealing the treatment allocation and did not evaluate compliance or failed to explicitly report compliance data. Taking into account the type of side effects associated with muscle relaxants and the fact that the majority of the studies involved patients treated outside the controlled environment of a secondary care setting (i.e. outpatient or primary care setting), more attention should have been devoted to compliance. Compliance gives an indication of the tolerability and acceptability of these drugs to patients. In many studies, authors merely stated that the trial was "randomised", which does not give the reader confidence that a trial has been properly randomised or that the randomisation procedure was adequate. Finally in 13 of the 30 studies (43%) the baseline status of the patients in the various trial arms was found not to be similar. Very often this was the result of authors failing to report information on relevant prognostic factors which must be equally divided between study groups to prevent bias. This was also true of co-interventions. In 18 of the 30 trials (60%) co-interventions were either not avoided or not equally distributed between study groups making it difficult to assess the significance of the trial outcomes. To reduce the impact of these methodological deficiencies on the quality of the review, the authors of the various trials could have been contacted to request missing information and data. This however seemed futile, as many of the studies were over a decade old, rendering the possibility of locating the authors and receiving the desired information unlikely.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Performance of muscle relaxants versus placebo</HEADING>
<P>The results demonstrate strong evidence for significant symptomatic relief and overall improvement within a week of therapy for non-benzodiazepines for acute LBP. Regarding benzodiazepines, there was strong evidence for short-term pain relief and overall improvement with tetrazepam for chronic LBP. However, tetrazepam is only available in some European countries and in Mexico. Also, the evidence for benzodiazepines comes from less trials than for non-benzodiazepines. The evidence of benzodiazepines for acute and non-benzodiazepines for chronic LBP is less convincing.</P>
<P>The results of the review indicate that muscle relaxants could be of benefit to patients, reducing the duration of their discomfort and accelerating recovery. These findings are consistent with the results of a systematic review on cyclobenzaprine for back pain (<LINK REF="REF-Browning-2001" TYPE="REFERENCE">Browning 2001</LINK>) which showed that cyclobenzaprine is more effective than placebo at the price of greater adverse effects. An exception was dantrolene sodium, one of the antispasticity muscle relaxants identified in the review (<LINK REF="STD-Casale-1988" TYPE="STUDY">Casale 1988</LINK>). In comparison with placebo, this drug demonstrated more significant relief of pain and spasm with no side effects at the dose used. The study by Casale involved a very small sample size (n = 20), rendering the applicability of the results uncertain. Although dantrolene circumvents the central nervous system and thus avoids the characteristic side effects, it is associated with severe hepatotoxicity and muscular weakness (<LINK REF="REF-Van-der-Kuy-1997" TYPE="REFERENCE">Van der Kuy 1997</LINK>).</P>
<P>Although a positive treatment effect was found for antispasticity muscle relaxants for acute LBP the clinical relevance of this finding for the low back pain population is questionable as these medications are typically prescribed for neurological disorders such as cerebral palsy, multiple sclerosis and spinal cord injuries.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Performance of muscle relaxants versus muscle relaxants</HEADING>
<P>The results of the analysis of the various muscle relaxants identified in this review showed that one high quality study found carisoprodol to be superior to diazepam. None of the other muscle relaxants was superior to another. They were all similar in performance adhering to the characteristic pattern of good efficacy and limited tolerability.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Muscle relaxants as adjunctive therapy</HEADING>
<P>It has been suggested in the literature that muscle relaxants in practice could be more useful as an adjunct to other therapeutic modalities, specifically analgesics/NSAIDs (<LINK REF="REF-Elenbaas-1980" TYPE="REFERENCE">Elenbaas 1980</LINK>). This was confirmed in this review. There was strong evidence that combination with analgesics or NSAIDs improved and accelerated recovery, but at the cost of increased central nervous system adverse effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Adverse effects </HEADING>
<P>The results indicate that muscle relaxants are associated with adverse events. Central nervous system events were more prevalent in patients on muscle relaxants with the most common complaints being drowsiness and dizziness. These effects were consistently reported with all benzodiazepines and non-benzodiazepines reviewed. The incidence of other central nervous system events was negligible. For the gastrointestinal events, the difference with placebo was not significant with the most common complaint being nausea. These adverse effects, especially those involving the central nervous system adverse effects, indicate that muscle relaxants must be used with caution. These findings concur with the recommendations on use of muscle relaxants in the management of low back pain as cited in the UK, American and Dutch guidelines (<LINK REF="REF-Bigos-1994" TYPE="REFERENCE">Bigos 1994</LINK>; <LINK REF="REF-Faas-1996" TYPE="REFERENCE">Faas 1996</LINK>; <LINK REF="REF-Waddell-1996" TYPE="REFERENCE">Waddell 1996</LINK>) and other guidelines (<LINK REF="REF-Koes-2001" TYPE="REFERENCE">Koes 2001</LINK>). Although conclusions cannot be made about this risk of dependency from the trials included in this review, there is sufficient indirect evidence from other sources that a substantial risk of dependency can develop when using muscle relaxants. Health care professionals should be reluctant in prescribing muscle relaxants, particularly in patients who are prone to addiction.</P>
<P>Chlorzoxazone is implicated to serious (including fatal) hepatocellular toxicity, however this is a rare event. Another drug, chlormezanone has been implicated in the genesis of Stevens-Johnson syndrome and toxic epidermal necrolysis. Rare side effects are rarely seen in clinical trials with small sample sizes. A case-control study compared 245 people who were hospitalised because of these conditions and 1147 patients hospitalised for other reasons. Data was obtained through surveillance networks in France, Germany, Italy and Portugal. Among the 245 cases, 13 (5%) used chlormezanone 1 to 21 days before the index day, while only one among the control group used this drug. Based on the findings in this study, chlormezanone was discontinued in 1996 world-wide (<LINK REF="REF-Roujeau-1995" TYPE="REFERENCE">Roujeau 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Minimally clinical important difference</HEADING>
<P>When evaluating the effectiveness of a treatment intervention, statistical significance is a necessary but insufficient criterion (<LINK REF="REF-Farrar-2000" TYPE="REFERENCE">Farrar 2000</LINK>; <LINK REF="REF-Farrar-2001" TYPE="REFERENCE">Farrar 2001</LINK>). The issue of clinical importance must also be considered, a concept that adds to the challenge of interpreting results of trials to guide patient care (<LINK REF="REF-Farrar-2000" TYPE="REFERENCE">Farrar 2000</LINK>; <LINK REF="REF-Beaton-2002" TYPE="REFERENCE">Beaton 2002</LINK>). But what constitutes a clinically importance change or difference in scores in an outcome of interest? For outcomes such as survival, death or hospitalization, the answer may be clear, but for subjective outcomes such as pain, clinical importance is often difficult to determine (<LINK REF="REF-Farrar-2000" TYPE="REFERENCE">Farrar 2000</LINK>; <LINK REF="REF-Farrar-2001" TYPE="REFERENCE">Farrar 2001</LINK>; <LINK REF="REF-Testa-2000" TYPE="REFERENCE">Testa 2000</LINK>).</P>
<P>The concept termed minimally clinical importance difference (MCID) has varying definitions. They all contain the common idea of being the smallest change or difference in scores that has been defined in some way as being important (<LINK REF="REF-Beaton-2002" TYPE="REFERENCE">Beaton 2002</LINK>). Among other things, the determination of a MCID is dependent on the nature of scores compared (e.g. within or between group), population (e.g. acute or chronic LBP), intervention (e.g. muscle relaxants versus placebo or versus active treatments), and who's perspective of importance is taken into consideration (e.g. patient or clinician). Attempts to ascertain MCID values for pain intensity in the LBP population revealed a paucity of literature. Although not necessarily generalizable to the population of the current review, Farrar (<LINK REF="REF-Farrar-2000" TYPE="REFERENCE">Farrar 2000</LINK>) suggests that a two point or 30% reduction on an 11-point pain intensity rating scale relates to clinical importance for individuals with chronic pain and Gallagher (<LINK REF="REF-Gallagher-2002" TYPE="REFERENCE">Gallagher 2002</LINK>) found the MCID for acute abdominal pain to be 16mm on a pain intensity visual analogue scale (95% CI, 13-18mm). Because of the heterogeneity of how data were reported, differences in scales used, lack of relevant criteria for MCID in the low back pain population and specifically in acute low back pain, we were not able to include the MCID in our results. In the trials we reviewed, most studies reported pain outcome data as a summary statistic for each group (i.e., mean scores). If the differences in the scores had been large, the clinical importance may have been more obvious but because the changes were often small, it was difficult to determine what should be considered clinically important. This has to do in part with the nature of a mean score when considering whether to apply the results to an individual patient (<LINK REF="REF-Farrar-2000" TYPE="REFERENCE">Farrar 2000</LINK>; <LINK REF="REF-Gallagher-2002" TYPE="REFERENCE">Gallagher 2002</LINK>); for example, if a mean change of 10 mm in pain on a VAS in a population is required before the treatment can be considered to produce an important effect, it does not imply that the same change of 10 mm is clinically important for an individual, (<LINK REF="REF-Testa-2000" TYPE="REFERENCE">Testa 2000</LINK>). Thus, to facilitate more easily understandable clinical importance of results of efficacy trials, we suggest future trials incorporate the recommendation of Farrar (<LINK REF="REF-Farrar-2000" TYPE="REFERENCE">Farrar 2000</LINK>) that investigators report the proportion of subjects who observe a clinically important improvement in the groups being compared.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>The results of this review illustrate strong evidence that non-benzodiazepines are effective for acute LBP. The evidence on benzodiazepines for acute and non-benzodiazepines for chronic LBP is less convincing. It is unknown if muscle relaxants are more effective than analgesics or NSAIDs, because there are no trials that directly compared these drugs. Muscle relaxants must be used with caution. The mechanism by which they induce their beneficial effects is also responsible for the intractable side effects associated with the central nervous system (drowsiness, dizziness). Furthermore, the risk of long-term dependence of muscle relaxants is substantial. Other systematic reviews have shown that analgesics and NSAIDs are also effective for acute LBP without having a high risk of dependency. Clinical guidelines have therefore recommended not using muscle relaxants for acute LBP or using them only for a selection of patients that do not respond to analgesics or NSAIDs. It must be left to the discretion of the physician to weigh the pros and cons, taking into account the needs and preferences of the individual patient, to determine whether or not a specific patient is a suitable candidate for a course of muscle relaxants.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Large high quality trials are needed that directly compare muscle relaxants to analgesics or NSAIDs. Another area of interest is the use of peripherally acting muscle relaxants for low back pain. These agents could potentially induce the same beneficial effects as those that act through the central nervous system, but without the associated side effects. Future studies should focus on reducing the incidence and severity of side effects.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Andrea Furlan is supported by a CIHR fellowship and University of Toronto Centre for Study of Pain. The authors would like to thank Victoria Pennick and Doreen Day for copy-editing and English proofing the final copy of the manuscript</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>One of the authors (Lex Bouter) is co-ordinating editor of the Cochrane Back Review Group. Editors are required to conduct at least one Cochrane review. This requirement ensures that editors are aware of the processes and commitment needed to conduct reviews. None of the editors are first authors. This involvement does not seem to be a source of conflict of interest in the Back Review Group. Any editor who is a author is excluded from editorial decisions on the review in which they are contributors.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Tony Touray and Maurits van Tulder identified and selected studies, assessed the methodological quality of studies, performed the data extraction, and conducted the data analyses. Andrea Furlan and Sherra Solway were involved in assessing the methodological quality of selected studies, data extraction and in the writing and editing of the final review document. Lex Bouter was involved in writing of the review protocol and in writing of the final review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-03-27 21:51:49 +0100" MODIFIED_BY="Shireen Harbin">
<STUDIES MODIFIED="2008-06-23 09:25:24 -0400" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-06-23 09:08:14 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Arbus-1990" NAME="Arbus 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Arbus L, Fajadet B, Aubert D, Morre M, Goldfinger E</AU>
<TI>Activity of tetrazepam in low back pain</TI>
<SO>Clinical Trials Journal</SO>
<YR>1990</YR>
<VL>27</VL>
<NO>4</NO>
<PG>258-267</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169172"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169171"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baptista-1988" NAME="Baptista 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baptista R, Brizzi J, Dutra F, Josef H, Keisermann M, de Lucca R.</AU>
<TO>Terapeutica da lombalgia com a tizanidina (DS 103-282), un novo agente mioespasmolitico. Estudo multicentrico, duplo-cego e comparativo</TO>
<SO>Folha Medica</SO>
<YR>1988</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5353791"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169173"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barrata-1982" NAME="Barrata 1982" YEAR="1982">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Barrata R</AU>
<TI>A double-blind study of cyclobenzaprine and placebo in the treatment of acute muskuloskeletal conditions of the low back</TI>
<SO>Current Therapeutic Research</SO>
<YR>1982</YR>
<VL>32</VL>
<NO>5</NO>
<PG>646-652</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169176"/><IDENTIFIER TYPE="MEDLINE" VALUE="77002518"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169175"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Basmajian-1978" NAME="Basmajian 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Basmajian J</AU>
<TI>Cyclobenzaprine hydrochloride effect on skeletal muscle spasm in the lumbar region and neck: Two double-blind controlled clinical and laboratory studies</TI>
<SO>Arch Phys Med Rehabil</SO>
<YR>1978</YR>
<VL>59</VL>
<PG>58-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169178"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169177"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berry-1988a" MODIFIED="2008-06-23 09:08:05 -0400" MODIFIED_BY="[Empty name]" NAME="Berry 1988a" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berry H, Hutchinson D</AU>
<TI>A multicentre placebo-controlled study in general practice to evaluate the efficacy and safety of tizanidine in acute low-back pain</TI>
<SO>The Journal of International Medical Research</SO>
<YR>1988</YR>
<VL>16</VL>
<PG>75-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169180"/><IDENTIFIER TYPE="MEDLINE" VALUE="88242918"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169179"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berry-1988b" MODIFIED="2008-06-23 09:08:14 -0400" MODIFIED_BY="[Empty name]" NAME="Berry 1988b" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berry H, Hutchinson D</AU>
<TI>Tizanidine and Ibuprofen in acute low-back pain: Results of a double-blind multicentre study in general practice</TI>
<SO>The Journal of International Medical Research</SO>
<YR>1988</YR>
<VL>16</VL>
<PG>83-91</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169182"/><IDENTIFIER TYPE="MEDLINE" VALUE="88242919"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169181"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bianchi-1978" NAME="Bianchi 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Bianchi M</AU>
<TI>Evaluation of cyclobenzaprine for skeletal muscle spasm of local origin</TI>
<SO>Clinical evaluation of Flexeril (Cyclobenzaprine HCL/MSD)</SO>
<YR>1978</YR>
<PG>25-9</PG>
<PB>Postgraduate Medicine Communications</PB>
<CY>Minneapolis</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169184"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169183"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borenstein-1990" NAME="Borenstein 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borenstein D, Lacks S, Wiesel S</AU>
<TI>Cyclobenzaprine and naproxen versus naproxen alone in the treatment of acute low back pain and muscle spasm</TI>
<SO>Clinical Therapeutics</SO>
<YR>1990</YR>
<VL>12</VL>
<NO>2</NO>
<PG>125-131</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169186"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169185"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boyles-1983" NAME="Boyles 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boyles W, Glassman J, Soyka J</AU>
<TI>Management of acute musculokeltal conditions: Thoracolumbar strain or sprain. A doubleblind evaluation comparing the efficacy and safety of carisoprodol with diazepam</TI>
<SO>Today's Therapeutic Trends</SO>
<YR>1983</YR>
<VL>1</VL>
<PG>1-16</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169188"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169187"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bragstad-1979" NAME="Bragstad 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bragstad A, Blikra G</AU>
<TI>Evaluation of a new skeletal muscle relaxant in the treatment of low back pain (a comparison of DS 103-282 with chlorzoxazone)</TI>
<SO>Current Therapeutic Research</SO>
<YR>1979</YR>
<VL>26</VL>
<NO>1</NO>
<PG>39-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169190"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169189"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casale-1988" NAME="Casale 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casale R</AU>
<TI>Acute low back pain: Symptomatic treatment with a muscle relaxant drug</TI>
<SO>The Clinical Journal of Pain</SO>
<YR>1988</YR>
<VL>4</VL>
<PG>81-88</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169192"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169191"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corts-Giner-1989" NAME="Corts Giner 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corts Giner JR</AU>
<TO>Estudio DS 103-282: relajante muscular en lumbalgia aguda o lumbago (Estudio doble ciego de tizanidina + paracetamol vs. placebo + paracetamol)</TO>
<SO>Rev Esp de Cir Ost</SO>
<YR>1989</YR>
<VL>24</VL>
<NO>140</NO>
<PG>119-124</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169194"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169193"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dapas-1983" NAME="Dapas 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dapas F</AU>
<TI>Baclofen for the treatment of acute low-back syndrome</TI>
<SO>Spine</SO>
<YR>1985</YR>
<VL>10</VL>
<NO>4</NO>
<PG>345-349</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169196"/><IDENTIFIER TYPE="MEDLINE" VALUE="86019192"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169195"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gold-1978" NAME="Gold 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gold R</AU>
<TI>Orphenadrine Citrate: Sedative or Muscle Relaxant?</TI>
<SO>Clinical Therapeutics</SO>
<YR>1978</YR>
<VL>1</VL>
<NO>6</NO>
<PG>451-453</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169198"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169197"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hennies-1981" NAME="Hennies 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hennies O</AU>
<TI>A new skeletal muscle relaxant (DS 103-282) compared to diazepam in the treatment of muscle spasm of local origin</TI>
<SO>J Int Med Res</SO>
<YR>1981</YR>
<VL>9</VL>
<PG>62-68</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169200"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169199"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hindle-1972" NAME="Hindle 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hindle T</AU>
<TI>Comparison of carisoprodol, butabarbital, and placebo in treatment of the low back syndrome</TI>
<SO>California Medicine</SO>
<YR>1972</YR>
<VL>117</VL>
<PG>7-11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169202"/><IDENTIFIER TYPE="MEDLINE" VALUE="72257742"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169201"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hingorani-1966" NAME="Hingorani 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hingorani K</AU>
<TI>Diazepam in backache: A double-blind controlled trial</TI>
<SO>Annals of Physical Medicine</SO>
<YR>1966</YR>
<VL>8</VL>
<NO>8</NO>
<PG>303-306</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169204"/><IDENTIFIER TYPE="MEDLINE" VALUE="67057625"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169203"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hingorani-1971" NAME="Hingorani 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hingorani K</AU>
<TI>Orphenadine/Paracetamol in backache: A double-blind controlled trial</TI>
<SO>The British Journal of Clinical Practice</SO>
<YR>1971</YR>
<VL>25</VL>
<NO>5</NO>
<PG>227-231</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169206"/><IDENTIFIER TYPE="MEDLINE" VALUE="71209734"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169205"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klinger-1988" NAME="Klinger 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klinger N, Wilson R, Kanniainen C.,Wagenknecht K, Re O, Gold R</AU>
<TI>Intravenous orphenadrine for the treatment of lumbar paravertebral muscle strain</TI>
<SO>Current Therapeutic Research</SO>
<YR>1988</YR>
<VL>43</VL>
<NO>2</NO>
<PG>247-254</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169208"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169207"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lepisto-1979" NAME="Lepisto 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lepisto P</AU>
<TI>A comparative trial of dS 103-282 and placebo in the treatment of acute skeletal muscle spasms due to disorders of the back</TI>
<SO>Therapeutic Research</SO>
<YR>1979</YR>
<VL>26</VL>
<NO>4</NO>
<PG>454-59</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169210"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169209"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moll-1973" NAME="Moll 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moll W.</AU>
<TI>[Therapy of acute lumbovertebral syndromes through optimal muscle relaxation using diazepam. Results of a double-blind study on 68 cases]</TI>
<TO>Zur therapie akuter lumbovertebraler syndrome durch optimale medikamentose muskelrelaxation mittels diazepam</TO>
<SO>Med. Welt</SO>
<YR>1973</YR>
<VL>24</VL>
<NO>45</NO>
<PG>1747-1751</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169212"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169211"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pipino-1991" NAME="Pipino 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pipino F, Menarini C, Lombardi G, Guerzoni P, Ferrini A, Pizzoli A, Grangie A, Beltrame A, Sorbilli G, Gottardo R, Cilento F</AU>
<TI>A direct myotonolytic (Pridinol Mesilate) for the management of chronic low back pain: A multicentre, comparative clinical evaluation</TI>
<SO>European Journal of Clinical Research</SO>
<YR>1991</YR>
<VL>1</VL>
<PG>55-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169214"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169213"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pratzel-1996" NAME="Pratzel 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pratzel HG, Alken R-G, Ramm S</AU>
<TI>Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: Results of a prospective placebo-controlled double-blind trial</TI>
<SO>Pain</SO>
<YR>1996</YR>
<VL>67</VL>
<PG>417-425</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169216"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169215"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rollings-1983" NAME="Rollings 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rollings H</AU>
<TI>Management of acute musculoskeleal conditions - Thoracolumbar strain or sprain: A double-blind evaluation comparing the efficacy and safety of carisoprodol with cyclobenzaprine hydrochloride</TI>
<SO>Current Therapeutic Research</SO>
<YR>1983</YR>
<VL>34</VL>
<NO>6</NO>
<PG>917-928</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169218"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169217"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salzmann-1992" NAME="Salzmann 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salzmann E, Pforringer W, Paal G, Gierend M</AU>
<TI>Treatment of chronic low-back syndrome with tetrazepam in a placebo controlled double-blind trial</TI>
<SO>J Drug Dev</SO>
<YR>1992</YR>
<VL>4</VL>
<PG>219-228</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169220"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169219"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sirdalud-1998" NAME="Sirdalud 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sirdalud Ternelin Asia-Pacific Study Group</AU>
<TI>Efficacy and gastroprotective effects of tizanidine plus diclofenac versus placebo plus diclofenac in patients with painful muscle spasms</TI>
<SO>Current Therapeutic Research</SO>
<YR>1998</YR>
<VL>59</VL>
<NO>1</NO>
<PG>13-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169222"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169221"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sweetman-1987" NAME="Sweetman 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sweetman B, Baig A, Parsons D</AU>
<TI>Mefenamic acid, chlormezanone-paracetamol, ethoheptazine-aspirin-meprobamate: a comparative study in acute low back pain</TI>
<SO>The British Journal of Clinical Practice</SO>
<YR>1987</YR>
<VL>41</VL>
<NO>2</NO>
<PG>619-624</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169224"/><IDENTIFIER TYPE="MEDLINE" VALUE="88050545"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169223"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tervo-1976" NAME="Tervo 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tervo T, Petaja L, Lepisto P</AU>
<TI>A controlled clinical trial of a muscle relaxant analgesic combination in the treatment of acute lumbago</TI>
<SO>The British Journal of Clinical Practice</SO>
<YR>1976</YR>
<VL>30</VL>
<NO>3</NO>
<PG>62-64</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169226"/><IDENTIFIER TYPE="MEDLINE" VALUE="76161087"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169225"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weber-1980" NAME="Weber 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weber H</AU>
<TI>Comparison of the effect of diazepam and levomepromazine on pain in patients with acute lumbago-sciatica</TI>
<SO>J Oslo City Hosp</SO>
<YR>1980</YR>
<VL>30</VL>
<NO>5</NO>
<PG>65-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169228"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169227"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Worz-1996" NAME="Worz 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Worz R, Bolten W, Heller J, Krainick U, Pergande G</AU>
<TI>[Flupirtine in comparison with chlormezanone in chronic musculoskeletal back pain. Results of a multicenter randomized double-blind study]</TI>
<TO>Flupirtin im vergleich zu chlormezanon und placebo bei chronische muskuloskelettalen ruckenschmerzen</TO>
<SO>Fortschritte der Therapie</SO>
<YR>1996</YR>
<VL>114</VL>
<NO>35-36</NO>
<PG>500-504</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169230"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169229"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-06-23 09:25:06 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Aiken-1978a" MODIFIED="2008-06-23 09:23:03 -0400" MODIFIED_BY="[Empty name]" NAME="Aiken 1978a" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Aiken DW</AU>
<TI>A comparative study of the effects of cyclobenzaprine, diazepam, and placebo on acute skeletal muscle spasm of local origin</TI>
<SO>Clinical evaluation of Flexeril (Cyclobenzaprine HCL/MSD)</SO>
<YR>1978</YR>
<PG>34-8</PG>
<PB>Postgraduate Medicine Communications</PB>
<CY>Minneapolis</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169232"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169231"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aiken-1978b" MODIFIED="2008-06-23 09:23:27 -0400" MODIFIED_BY="[Empty name]" NAME="Aiken 1978b" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Aiken DW</AU>
<TI>Cyclobenzaprine in the treatment of acute skeletal muscle spasm of local origin</TI>
<SO>Clinical evaluation of Flexeril (Cyclobenzaprine HCL/MSD)</SO>
<YR>1978</YR>
<PG>30-3</PG>
<PB>Postgraduate Medicine Communications</PB>
<CY>Minneapolis</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169234"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169233"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aoki-1995" MODIFIED="2008-06-23 09:23:09 -0400" MODIFIED_BY="[Empty name]" NAME="Aoki 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aoki T, Kawaji W, Miyoshi K, Tateishi A, Sugawara S, Tsukamato I, Ogawa N</AU>
<TI>Clinical evaluation of NK433 (Lanperisone Hydrochloride), a new centrally acting muscle relaxant on lumbago</TI>
<SO>Japanese Pharmacology and Therapeutics</SO>
<YR>1995</YR>
<VL>23</VL>
<NO>10</NO>
<PG>255-284</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169236"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169235"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asia_x002d_Pacific-1998" MODIFIED="2008-06-23 09:23:13 -0400" MODIFIED_BY="[Empty name]" NAME="Asia-Pacific 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sirdalud Ternelin Asia-Pacific Study Group</AU>
<TI>Efficacy and gastroprotective effects of tizanidine plus diclofenac versus placebo plus diclofenac in patients with painful muscle spasms</TI>
<SO>Current Therapeutic Research</SO>
<YR>1998</YR>
<VL>59</VL>
<NO>1</NO>
<PG>13-21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169238"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169237"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Basmajian-1988" MODIFIED="2008-06-23 09:23:20 -0400" MODIFIED_BY="[Empty name]" NAME="Basmajian 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Basmajian JV</AU>
<TI>Acute back pain and spasm: a controlled multicenter trial of combined analgesic and antispasm agents</TI>
<SO>Spine</SO>
<YR>1989</YR>
<VL>14</VL>
<PG>438-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169240"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169239"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bercel-1977" MODIFIED="2008-06-23 09:23:32 -0400" MODIFIED_BY="[Empty name]" NAME="Bercel 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bercel NA</AU>
<TI>Cyclobenzaprine in the treatment of skeletal muscle spasm in osteoarthritis of the cervical and lumbar spine</TI>
<SO>Curr Ther Res</SO>
<YR>1977</YR>
<VL>22</VL>
<NO>4</NO>
<PG>462-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169242"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169241"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bobulesco-1970" MODIFIED="2008-06-23 09:23:50 -0400" MODIFIED_BY="[Empty name]" NAME="Bobulesco 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bobulesco V, Triandat I</AU>
<TI>[On the clinical trial of an association of chlorzoxazone and dimethyl-amino-antipyrine (Oferal)]</TI>
<TO>Contributions a l'etude de l'experimentation clinique d'une association entre le chlorzoxosone et le dimethyl-amino-antypirine (Oferol)</TO>
<SO>Revista medico-Chirurgica a Societatii de medici Si naturalisti Din lasi</SO>
<YR>1970</YR>
<VL>74</VL>
<NO>3</NO>
<PG>729-733</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169244"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169243"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bouchier_x002d_Hayes-1984" MODIFIED="2008-06-23 09:23:58 -0400" MODIFIED_BY="[Empty name]" NAME="Bouchier-Hayes 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bouchier-Hayes. T</AU>
<TI>Chlormezanone in low back pain and wry neck: an "analgesic" sparing effect</TI>
<SO>Brit. J. Clin. Pract.</SO>
<YR>1984</YR>
<VL>38</VL>
<NO>7/8</NO>
<PG>259-262</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169246"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169245"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-1978" MODIFIED="2008-06-23 09:24:02 -0400" MODIFIED_BY="[Empty name]" NAME="Brown 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown BR, Womble J</AU>
<TI>Cyclobenzaprine in intractable pain syndromes with muscle spasm</TI>
<SO>JAMA</SO>
<YR>1978</YR>
<VL>240</VL>
<NO>11</NO>
<PG>1151-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169248"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169247"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fryda_x002d_Kaurimsky-1981" MODIFIED="2008-06-23 09:24:05 -0400" MODIFIED_BY="[Empty name]" NAME="Fryda-Kaurimsky 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fryda-Kaurimsky Z, Muller-Fassbender H</AU>
<TI>Tizanidine (DS 103-282) in the treatment of acute paravertebral spasm: A controlled trial comparing tizanidine and diazepam</TI>
<SO>J Int Res</SO>
<YR>1981</YR>
<VL>9</VL>
<PG>501-505</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169250"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169249"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gabric-1992" MODIFIED="2008-06-23 09:24:16 -0400" MODIFIED_BY="[Empty name]" NAME="Gabric 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gabric S</AU>
<TI>The effect of tizanidine and tenoxicam in patients with low back pain by electrokinesiologic analyses</TI>
<SO>Pharmaca</SO>
<YR>1992</YR>
<VL>30</VL>
<NO>1-4</NO>
<PG>31-45</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169252"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169251"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hasue-1997" MODIFIED="2008-06-23 09:24:20 -0400" MODIFIED_BY="[Empty name]" NAME="Hasue 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hasue M, Tachibana S, Kunogi J, Hirabayashi S</AU>
<TI>Clinical evaluation of Eperisone Hydrochloride Tape (E2000) in lumbago, cerviobrachial syndrome, and periarthritis humeroscapularis</TI>
<SO>Jpn Pharmacol Ther</SO>
<YR>1997</YR>
<VL>25</VL>
<NO>4</NO>
<PG>207-225</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169254"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169253"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hofferberth-1990" NAME="Hofferberth 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hofferberth R, Schreiner H</AU>
<TO>Ein beitrag zur medikamentosen therapie des akuten LWS-syndroms</TO>
<SO>Zeitschrift fur Allgemeinmedizin</SO>
<YR>1994</YR>
<VL>70</VL>
<NO>18</NO>
<PG>738-742</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169256"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169255"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuroki-1995" MODIFIED="2008-06-23 09:24:26 -0400" MODIFIED_BY="[Empty name]" NAME="Kuroki 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuroki Y, Sugimori H, Yasuno K, Ishibashi Y, Hirai T, Okumo H, Uchida T</AU>
<TI>The clinical evaluation of lanperisone hydrochloride (NK433), a new centrally acting muscle relaxant, on cervicobrachial syndrome and lumbago with myotonic pains</TI>
<SO>Jpn Pharmacol Ther</SO>
<YR>1995</YR>
<VL>23</VL>
<NO>10</NO>
<PG>287-299</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169258"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169257"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Larouche-1999" MODIFIED="2008-06-23 09:24:29 -0400" MODIFIED_BY="[Empty name]" NAME="Larouche 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Larouche SJ, Block G, Raskin S, Ahrens S, Korn S</AU>
<TI>Controlled trial of cyclobenzaprine for acute musculoskeletal spasm</TI>
<SO>Clin Pharmacol Ther</SO>
<YR>1999</YR>
<VL>65</VL>
<PG>120</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169260"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169259"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marcel-1990" MODIFIED="2008-06-23 09:24:34 -0400" MODIFIED_BY="[Empty name]" NAME="Marcel 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marcel C, Rezvani Y, Revel M</AU>
<TI>[Evaluation of thiocolchicoside as monotherapy in low back pain. Results of a randomized study versus placebo]</TI>
<TO>Evaluation du thocolchicoside en monotherapie dans le lumbago douloreuz: Resultats d'une etude randomisee contre placebo</TO>
<SO>La Presse Medicale</SO>
<YR>1990</YR>
<VL>24</VL>
<NO>19</NO>
<PG>1133-1136</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169262"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169261"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGuinness-1969" NAME="McGuinness 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McGuinness BW, Lloyd-Jones M, Fowler PD</AU>
<TI>A double-blind comparative trial of 'Parazolidin' and paracetamol</TI>
<SO>Br J Clin Pract</SO>
<YR>1969</YR>
<VL>23</VL>
<NO>11</NO>
<PG>452-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169264"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169263"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGuinness-1983" NAME="McGuinness 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McGuinness B</AU>
<TI>A double-blind comparison in general practice of a combination tablet containing orphenadrine citrate and paracetamol ('Norgesic') with paracetamol alone</TI>
<SO>J Int Med Res</SO>
<YR>1983</YR>
<VL>11</VL>
<NO>42</NO>
<PG>42-45</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169266"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169265"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meignany-1991" MODIFIED="2008-06-23 09:24:38 -0400" MODIFIED_BY="[Empty name]" NAME="Meignany 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meignany F</AU>
<TO>Interet de la pommade Srilane dans ke traitement symptomatique des lombalgies chroniques</TO>
<SO>Rhumatologie- Revue International de Rhumatologie</SO>
<YR>1991</YR>
<VL>21</VL>
<NO>1</NO>
<PG>23-26</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169268"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169267"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Middleton-1984" NAME="Middleton 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Middleton R</AU>
<TI>A comparison of two analgesic muscle relaxant combinations in acute back pain</TI>
<SO>The British Journal of Clinical Practice</SO>
<YR>1984</YR>
<VL>38</VL>
<NO>3</NO>
<PG>107-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169270"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169269"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nibbelink-1978" MODIFIED="2008-06-23 09:24:42 -0400" MODIFIED_BY="[Empty name]" NAME="Nibbelink 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nibbelink DW, Strickland SC, McLean LF, Gould AL</AU>
<TI>Cyclobenzaprine, diazepam and placebo in the treatment of skeletal muscle spasm of local origin</TI>
<SO>Clin Ther</SO>
<YR>1978</YR>
<VL>1</VL>
<NO>6</NO>
<PG>409-24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169272"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169271"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Preston-1984" MODIFIED="2008-06-23 09:24:44 -0400" MODIFIED_BY="[Empty name]" NAME="Preston 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Preston EJ, Miller CB, Herbertson RK</AU>
<TI>A double-blind, multicenter trial of Methacarbamol (Robaxin) and cyclobenzaprine (Flexeril) in acute musculoskeletal conditions</TI>
<SO>Today's Ther Trends</SO>
<YR>1984</YR>
<VL>1</VL>
<PG>1-11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169274"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169273"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scheiner-1978" MODIFIED="2008-06-23 09:24:47 -0400" MODIFIED_BY="[Empty name]" NAME="Scheiner 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Scheiner JJ</AU>
<TI>Cyclobenzaprine in the treatment of local muscle spasm: comparison with diazepam and placebo</TI>
<SO>Clinical evaluation of Flexeril (Cyclobenzaprine HCL/MSD)</SO>
<YR>1978</YR>
<PG>39-47</PG>
<PB>Postgraduate Medicine Communications</PB>
<CY>Minneapolis</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169276"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169275"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stehmann-1990" MODIFIED="2008-06-23 09:24:50 -0400" MODIFIED_BY="[Empty name]" NAME="Stehmann 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stehman M</AU>
<TI>Double-blind clinical study of Idrocilamide ointment in the treatment of acute low back pain</TI>
<SO>Acta Belgica-Medica Physica</SO>
<YR>1990</YR>
<VL>13</VL>
<NO>1</NO>
<PG>29-32</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169278"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169277"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steingard-1980" MODIFIED="2008-06-23 09:24:52 -0400" MODIFIED_BY="[Empty name]" NAME="Steingard 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steingard PM, Schildberg WL, Peterson KD</AU>
<TI>Multiclinic study of a muscle relaxant for treatment of acute musculoskeletal disorders</TI>
<SO>Osteopath Ann</SO>
<YR>1980</YR>
<VL>8</VL>
<NO>10</NO>
<PG>44-58</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169280"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169279"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tessari-1968" MODIFIED="2008-06-23 09:24:55 -0400" MODIFIED_BY="[Empty name]" NAME="Tessari 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tessari L, Fasoli M</AU>
<TI>[Polycentric clinical trials of a muscle relaxant]</TI>
<TO>Il "Musco-Ril": attivita antiflogistica ed analgesica: Sperimentazione clinica policentria su un farmaco decontratturante</TO>
<SO>Minerva Medica</SO>
<YR>1968</YR>
<VL>59</VL>
<NO>87</NO>
<PG>4645-4664</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169282"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169281"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valtonen-1975" MODIFIED="2008-06-23 09:25:00 -0400" MODIFIED_BY="[Empty name]" NAME="Valtonen 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valtonen EJ</AU>
<TI>A double-blind trial of methocarbamol versus placebo in painful muscle spasm</TI>
<SO>Curr. Med. Res. Opin</SO>
<YR>1975</YR>
<VL>3</VL>
<PG>382-385</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169284"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169283"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vernon-1972" MODIFIED="2008-06-23 09:25:03 -0400" MODIFIED_BY="[Empty name]" NAME="Vernon 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vernon W</AU>
<TI>A double-blind evaluation of Parafon Forte in the treatment of musculo-skeletal back conditions</TI>
<SO>Current Therapeutic Research</SO>
<YR>1972</YR>
<VL>14</VL>
<NO>12</NO>
<PG>801-806</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169286"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169285"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yakhno-1994" MODIFIED="2008-06-23 09:25:06 -0400" MODIFIED_BY="[Empty name]" NAME="Yakhno 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yakhno N, Damulin I, Chernenko O, Yanakaeva T, Kondratyeva O, Kuriyanova P</AU>
<TI>Sirdalud efficacy in chemotherapy of spinal pain</TI>
<SO>Terapevticheskii Arkhiv</SO>
<YR>1994</YR>
<VL>66</VL>
<NO>10</NO>
<PG>10-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169288"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169287"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2008-06-23 09:25:24 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Havel-2001" MODIFIED="2008-06-23 09:25:24 -0400" MODIFIED_BY="[Empty name]" NAME="Havel 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Havel C, Sieder A, Herkner H, Domanovits H, Schmied M, Segel R, Koreny M, Laggner AN, Mullner M</AU>
<TI>Which treatment for low back pain? A factorial randomised controlled trial comparing intravenous analgesics with oral analgesics in the emergency department and a centrally acting muscle relaxant with placebo over three days</TI>
<SO>BMC Emerg Med</SO>
<YR>2001</YR>
<VL>1</VL>
<NO>1</NO>
<PG>2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3169290"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3169289"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-08-13 14:07:08 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-08-13 14:07:08 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abbruzzese-2002" NAME="Abbruzzese 2002" TYPE="JOURNAL_ARTICLE">
<AU>Abbruzzese G</AU>
<TI>The medical management of spasticity</TI>
<SO>Eur J Neurol</SO>
<YR>2002</YR>
<VL>9</VL>
<NO>Suppl 1</NO>
<PG>30-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beaton-2002" NAME="Beaton 2002" TYPE="JOURNAL_ARTICLE">
<AU>Beaton DE, Boers M, Wells GA</AU>
<TI>Many faces of the minimal clinically important difference (MCID): A literature review and directions for future research</TI>
<SO>Current Opinion in Rheumatology</SO>
<YR>2002</YR>
<VL>14</VL>
<PG>109-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bigos-1994" NAME="Bigos 1994" TYPE="BOOK">
<AU>Bigos S, Bowyer O, Braen G</AU>
<SO>Acute low back paroblems in adults. Clinical Practice Guideline no. 14. AHCPR publication no. 95-0642</SO>
<YR>1994</YR>
<PB>Agency for Health Care Policy and Research, Public Health Services, US Dept. of Health and Human Services</PB>
<CY>Rockville, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Browning-2001" NAME="Browning 2001" TYPE="JOURNAL_ARTICLE">
<AU>Browning R, Jackson JL, O'Malley PG</AU>
<TI>Cyclobenzaprine and back pain: a meta-analysis</TI>
<SO>Arch Intern Med</SO>
<YR>2001</YR>
<VL>161</VL>
<NO>July 9</NO>
<PG>1613-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cherkin-1998" NAME="Cherkin 1998" TYPE="JOURNAL_ARTICLE">
<AU>Cherkin DC, Wheeler KJ, Barlow W, Deyo RA</AU>
<TI>Medication use for low back pain in primary care</TI>
<SO>Spine</SO>
<YR>1998</YR>
<VL>23</VL>
<NO>5</NO>
<PG>607-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Di-Iorio-2000" NAME="Di Iorio 2000" TYPE="JOURNAL_ARTICLE">
<AU>Di Iorio D, Henley E, Doughty A</AU>
<TI>A survey of primary care physician practice patterns and adherence to acute low back problem guidelines</TI>
<SO>Arch Fam Med</SO>
<YR>2000</YR>
<VL>9</VL>
<NO>10</NO>
<PG>1015-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elder-1991" NAME="Elder 1991" TYPE="JOURNAL_ARTICLE">
<AU>Elder NC</AU>
<TI>Abuse of skeletal muscle relaxants</TI>
<SO>American Family Physician</SO>
<YR>1991</YR>
<VL>44</VL>
<PG>1223-1226</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elenbaas-1980" NAME="Elenbaas 1980" TYPE="JOURNAL_ARTICLE">
<AU>Elenbaas JK</AU>
<TI>Centrally acting oral skeletal muscle relaxants</TI>
<SO>Am J Hosp Pharm</SO>
<YR>1980</YR>
<VL>37</VL>
<PG>1313-1323</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Faas-1996" NAME="Faas 1996" TYPE="JOURNAL_ARTICLE">
<AU>Faas A, Chavannes AW, Koes BW, van den Hoogen JMM, Mens JMA, Smeele LJM, Romeijnders ACM, van der Laan JR</AU>
<TI>NGH-Practice Guideline 'Low Back Pain'</TI>
<TO>NHG-standaard lage rugpijn</TO>
<SO>Huisarts Wet</SO>
<YR>1996</YR>
<VL>39</VL>
<PG>18-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farrar-2000" NAME="Farrar 2000" TYPE="JOURNAL_ARTICLE">
<AU>Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL</AU>
<TI>Defining the clincially important difference in pain outcome measures</TI>
<SO>Pain</SO>
<YR>2000</YR>
<VL>88</VL>
<PG>287-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farrar-2001" NAME="Farrar 2001" TYPE="JOURNAL_ARTICLE">
<AU>Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM</AU>
<TI>Clinical importance of changes in chronic pain intensity measured on an 11-point numerical rating scale</TI>
<SO>Pain</SO>
<YR>2001</YR>
<VL>94</VL>
<PG>149-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gallagher-2002" NAME="Gallagher 2002" TYPE="JOURNAL_ARTICLE">
<AU>Gallagher EJ, Bijur PE, Latimer C, Silver W</AU>
<TI>Reliability and validity of a visual analog scale for acute abdominal pain in the ED</TI>
<SO>American Journal of Emergency Medicine</SO>
<YR>2002</YR>
<VL>20</VL>
<PG>287-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gotzsche-1987" NAME="Gotzsche 1987" TYPE="JOURNAL_ARTICLE">
<AU>Gotzsche PC</AU>
<TI>Reference bias in reports of drug trials</TI>
<SO>Br Med J (Clin Res Ed)</SO>
<YR>1987</YR>
<VL>295</VL>
<PG>654-656</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jackson-1993" NAME="Jackson 1993" TYPE="BOOK_SECTION">
<AU>Jackson MD, Ryan DM</AU>
<TI>Drugs of Importance in Rehabilitation</TI>
<SO>Rehabilitation Medicine: Principles and Practice</SO>
<YR>1993</YR>
<EN>2</EN>
<ED>JA DeLisa</ED>
<PB>J.B. Lippincott Company</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnson-1989" NAME="Johnson 1989" TYPE="JOURNAL_ARTICLE">
<AU>Johnson 1989</AU>
<TI>The myth of skeletal muscle spasm</TI>
<SO>Am J Phys Med Rehabil</SO>
<YR>1989</YR>
<VL>68</VL>
<PG>1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koes-2001" NAME="Koes 2001" TYPE="JOURNAL_ARTICLE">
<AU>Koes BW, van Tulder MW, Ostelo R, Kim Burton A, Waddell G</AU>
<TI>Clinical guidelines for the management of low back pain in primary care: an international comparison</TI>
<SO>Spine</SO>
<YR>2001</YR>
<VL>26</VL>
<NO>22</NO>
<PG>2504-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Littrell-1993" NAME="Littrell 1993" TYPE="JOURNAL_ARTICLE">
<AU>Littrell R, Hayes L, Stilllner V</AU>
<TI>Carisoprodol (Soma): A new and cautious perspective on an old agent</TI>
<SO>Southern Medical Journal</SO>
<YR>1993</YR>
<VL>68</VL>
<NO>7</NO>
<PG>753-756</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lofland-2001" NAME="Lofland 2001" TYPE="JOURNAL_ARTICLE">
<AU>Lofland JH, Szarlej D, Buttaro T, Shermock S, Jalali S</AU>
<TI>Cyclobenzaprine hydrochloride is a commonly prescribed centrally acting muscle relaxant, which is structurally similar to tricyclic antidepressants (TCAs) and differs from amitriptyline by only one double bond</TI>
<SO>Clin J Pain</SO>
<YR>2001</YR>
<VL>17</VL>
<PG>103-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosche-2002" NAME="Rosche 2002" TYPE="JOURNAL_ARTICLE">
<AU>Rosche J</AU>
<TI>Treatment of spasticity</TI>
<SO>Spinal Cord</SO>
<YR>2002</YR>
<VL>40</VL>
<PG>261-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roujeau-1995" NAME="Roujeau 1995" TYPE="JOURNAL_ARTICLE">
<AU>Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F, et al</AU>
<TI>Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis</TI>
<SO>N Engl J Med</SO>
<YR>1995</YR>
<VL>333</VL>
<NO>24</NO>
<PG>1600-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Testa-2000" NAME="Testa 2000" TYPE="JOURNAL_ARTICLE">
<AU>Testa MA</AU>
<TI>Interpretation of quality of life outcomes: Issues that affect magnitude and meaning</TI>
<SO>Medical Care</SO>
<YR>2000</YR>
<VL>38</VL>
<NO>9 suppl</NO>
<PG>166-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-der-Kuy-1997" NAME="Van der Kuy 1997" TYPE="BOOK">
<AU>Van der Kuy, A</AU>
<SO>Pharmaco-therapeutic guide (Farmaco-therapeutisch kompas)</SO>
<YR>1997</YR>
<PB>ZiekenfondsRaad</PB>
<CY>Amstelveen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Tulder-1997a" MODIFIED="2008-06-23 09:25:41 -0400" MODIFIED_BY="[Empty name]" NAME="Van Tulder 1997a" TYPE="JOURNAL_ARTICLE">
<AU>Van Tulder MW, Koes BW, Bouter LM</AU>
<TI>Conservative treatment of acute and chronic nonspecific low back pain: a systematic review of randomized controlled trials of the most common interventions</TI>
<SO>Spine</SO>
<YR>1997</YR>
<VL>22</VL>
<NO>18</NO>
<PG>2128-2156</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Tulder-1997b" MODIFIED="2008-06-23 09:25:49 -0400" MODIFIED_BY="[Empty name]" NAME="Van Tulder 1997b" TYPE="JOURNAL_ARTICLE">
<AU>Van Tulder MW, Assendelft WJ, Koes BW, Bouter LM</AU>
<TI>Method guidelines for systematic reviews in the Cochrance Collaboration Back Review Group for Spinal Disorders</TI>
<SO>Spine</SO>
<YR>1997</YR>
<VL>22</VL>
<PG>2323-2330</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Waddell-1996" NAME="Waddell 1996" TYPE="BOOK">
<AU>Waddell G, Feder G, McIntosh A, Lewis M, Hutchinson A</AU>
<SO>Low Back Pain Evidence review</SO>
<YR>1996</YR>
<PB>Royal College of General Practitioners</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-06-23 09:26:20 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-van-Tulder-2000" MODIFIED="2008-06-23 09:26:20 -0400" MODIFIED_BY="[Empty name]" NAME="van Tulder 2000" TYPE="COCHRANE_REVIEW">
<AU>Tulder MW van, Touray T, Bouter LM</AU>
<TI>Muscle relaxants for non-specific low-back pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-06-23 09:26:16 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2008-06-23 09:26:16 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004252"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-07-07 10:21:16 -0400" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-07-07 10:21:16 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Arbus-1990">
<CHAR_METHODS>
<P>Randomised, placebo-controlled, double-blind trial.<BR/>Sponsored by Sanofi.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 50<BR/>Male/Female (%): ?<BR/>Age: 18-80<BR/>Diagnosis: Chronic LBP with or without radiological abnormality. Placebo responders were excluded. Setting: outpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I) Tetrazepam 50 mg t.i.d. / 10 days. N=25.<BR/>(R) Placebo t.i.d. / 10 days. N=24.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean (SD) pain at baseline, day 7 and day 14 (from 1 to 5): (I) 3.4 (0.82), 2.5 (0.94) and 1.73 (1.31); (R): 3.36 (0.62), 3.1 (0.71) and 2.38 (1.08). [stat. sign. day 7]<BR/>Number of patients with difference in pain scores of at least 1 point at day 7 and day 14: (I): 4 and 15; (R): 1 and 8. [stat. sign. day 7 and 14]<BR/>Number of patients with at least 1.5 points decrease in muscle spasm (score 1 to 3), at day 7 and day 14: (I): 2 and 11; (R): 0 and 4. [stat. sign. day 7 and 14]<BR/>Overall efficacy by physician: (I): 64%, (R): 29.2%. [stat. sign.]</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Other outcomes measured in this trial:<BR/>Pain assessed by physician. Significant on day 7 (p&lt;0.02) but no longer on day 14 (p=0.25).<BR/>Range of motion (finger-floor distance, cm) at baseline, day 7 and day 14: (I): 29 (+/- 14), 22 (+/- 13), 16.9 (+/- 11.8); (R): 33.8 (+/- 14.6), 32.1 (+/- 14.1), 25.7 (+/- 13.3). [no difference between groups]</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-06-20 15:34:49 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baptista-1988">
<CHAR_METHODS>
<P>Multicentre, double-blind, placebo controlled trial.<BR/>Sponsorship: none declared.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-06-20 15:34:49 -0400" MODIFIED_BY="[Empty name]">
<P>N=267<BR/>Male/Female (%): 35.6/60.4<BR/>Age: 17-64. Mean=41,7<BR/>Diagnosis: painful spasms of paravertebral muscles (acute LBP).<BR/>Setting: outpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I) Tizanidine 2mg t.i.d. / 8 days. N=89.<BR/>(I2) Tizanidine 4mg t.i.d. / 8 days. N=89.<BR/>(R) Placebo t.i.d. / 8 days. N=89.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>No differences in percentage pain at rest, muscle spasm and daily inactivity at baseline, day 3 and day 7. <BR/>Global measure of improvement at day 7: (inefficacious + somewhat efficacious) / (satisfactory + excellent): (I): 29/47; (R): 32/43.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The authors found a statistically significant difference between groups on percentage of spontaneous pain in relation to baseline for the group of patients with "moderate pain" only on day 3 (tizanidine 6mg/d = 48%, placebo = 68%). <BR/>The authors concluded that tizanidine is effective.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Barrata-1982">
<CHAR_METHODS>
<P>Randomised, placebo-controlled, double-blind trial.<BR/>Merck Sharp &amp; Dohme performed statistical evaluation of data.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 120<BR/>Male/Female (%): 59/41<BR/>Mean age: 36 (21-60)<BR/>Diagnosis: Acute LBP. Patients with moderate to severe degree of muscle spasm and local pain. <BR/>Setting: Primary care.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I) Cyclobenzaprine 10 mg t.i.d. - q.i.d. / 10 days. N=58.<BR/>(R) Placebo t.i.d. - q.i.d. / 10 days. N=59.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Proportion of patients who showed improvement (&gt; 2 points): in pain, at days 2-4, 5-7 and 8-12: (I): 21%, 53% and 81%; (R): 0%, 15% and 49% [stat. sign.] Proportion of patients improved (&gt; 2 points) in muscle spasm, at days 2-4, 5-7 and 8-12: (I): 10%, 44% and 72%; (R): 0%, 8% and 39% [stat. sign.] Physicians' global evaluation (5-point ordinal scale): (I): 23, 18, 10, 7 and 0; (R): 2, 13, 24, 20 and 0. [stat. sign.].<BR/>Proportion of patients improved (&gt;2 points) in ADL at days 2-4, 5-7 and 8-12: (I): 21%, 53% and 78%; (R): 2%, 28% and 47%. [significant on days 5-7 and 8-12].</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The analysis of mean decreases in the ordinal scales is not appropriate.<BR/>The analysis of proportions is appropriate, and the difference of 2 points is clinically important.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Basmajian-1978">
<CHAR_METHODS>
<P>Randomised, placebo-controlled, double-blind trial.<BR/>Supported by Merck Sharp &amp; Dohme.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 76<BR/>Male/Female (%): ?<BR/>Mean age: ?<BR/>Diagnosis: Chronic LBP. Patients with clinically palpable muscle spasm, limitation of motion, limitation of ADL, local pain and tenderness on palpation.<BR/>Setting: outpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I) Cyclobenzaprine 10 mg t.i.d. / 14 days. N=34.<BR/>(I2) Diazepam 5 mg t.i.d. / 14 days. N=36.<BR/>(R) Placebo<BR/>t.i.d. / 14 days. N=35.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean decrease of muscle spasm (1-5 point scale) from baseline to days 13-18: (I): 3.2 to 2.2; (I2): 2.9 to 1.9; (R): 3.2 to 2.1. [no differences among groups]</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No measurement of pain, global efficacy or activity of dailiy living.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Berry-1988a">
<CHAR_METHODS>
<P>Randomised, placebo-controlled, double-blind trial.<BR/>Sandoz Ltd. supplied medication. TIL (Medical) Ltd. organized and monitored study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 112<BR/>Male/Female (%): 51/49<BR/>Mean age: 41 (16-69)<BR/>Diagnosis: Acute LBP.<BR/>Setting: Primary care.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I) Tizanidine 4 mg t.i.d. / 7days. N=59.<BR/>(R) Placebo t.i.d. / 7days. N=53.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain at night, at rest and on movement. Mean (SD) pain at rest (diary; 100 mm VAS) at baseline, day 3 and day 7: (I): 51 (29.4), 39 (29.6) and 19 (23.2); (R): 51(26.9), 34 (27.9) and 19 (22.9) [no differences]. Proportion of patients improved (4-point scale), on day 3 and 7: (I): 47%, 75% (R): 37%, 63%. [stat. sign. on day 7].<BR/>Global efficacy: (I): very helpful at day 3 = 17%, some help at day 7 = 84%; (R): very helpful at day 3 = 8% and some help at day 7 = 44%. [no differences].</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Other outcomes: no differences in rescue analgesic consumption (aspirine) and restriction of movement.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Berry-1988b">
<CHAR_METHODS>
<P>Randomised, placebo-controlled, double-blind trial.<BR/>Sandoz Ltd. supplied medication; TIL (Medical) Ltd. organized and monitored study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 105<BR/>Male/Female (%): 55/45<BR/>Age: 42.5 (20-66)<BR/>Diagnosis: Acute LBP.<BR/>Setting: Primary care.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I) Tizanidine 4 mg plus ibuprofen 400 mg t.i.d. / 7 days. N=51.<BR/>(R) Placebo plus ibuprofen 400 mg t.i.d. / 7 days. N=54.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean (SD) change in pain at rest (diary; 100 mm VAS) from baseline to day 3 and day 7: (I): 18 (25.3) and 29 (43.3); (R): 16 (24.9) and 33 (32.9). [no differences].<BR/>Proportion of patients with moderate + severe pain / no pain + mild pain at rest, on day 3 and day 7: (I): 5/46 and 3/43; (R): 15/39 and 12/40 ) [stat. sign.]<BR/>Global efficacy (% improved) on day 3 and day 7: (I) 76% and 85%; (R): 67% and 81%. [no statistical testing].</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Other outcomes:<BR/>pain on movement stat. sign. better in (I) than (R) on day 3, not day 7. No differences in pain at night, % of patients with moderate + severe pain and<BR/>restriction of movement.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bianchi-1978">
<CHAR_METHODS>
<P>Randomised, placebo-controlled, double-blind trial.<BR/>Merck Sharp &amp; Dohme provided editorial assistance.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 48<BR/>Male/Female (%): 54/46<BR/>Mean age: 46 (19-67)<BR/>Diagnosis: Acute LBP (75%) or neck pain (25%). Moderate to severe muscle spasm. <BR/>Setting: Outpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I) Cyclobenzaprine 10 mg t.i.d. - q.i.d. / 14 days. N=24.<BR/>(R) Placebo t.i.d. - q.i.d. / 14 days. N=24.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean spontaneous pain (1-5 point scale) at baseline, day 7 and day 14: (I): 3.7, 1.3, 1.0 (R): 3.6, 1.9, 1.3 [stat. sign. on day 7, not day 14].<BR/>Mean muscle consistency (1 to 5) at baseline, day 7 and day 14: (I): 3.7, 1.3, 1.0 (R): 3.9, 2.2, 1.3 [stat. sign. on day 7, not on day 14].<BR/>Mean limitation of daily activities (1 to 5) at baseline, day 7 and day 14: (I): 1.4, 1.0 (R): 2.0, 1.2 [stat. sign. on day 7, not on day 14].<BR/>Global improvement (4-point scale) on day 4, 7 and 14: complete + satisfactory / unsatisfactory + worsening: (I): 20/3, 20/2 and 20/0; (R): 9/13, 14/6 and 15/0 [stat. sign. on day 4 and 7, not on day 14].</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Other outcomes: <BR/>pain on palpation and limitatrion of motion stat. sign. better in (I) on day 7, not on day 14.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-07 10:21:16 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Borenstein-1990">
<CHAR_METHODS>
<P>Randomised,<BR/>open-label trial.<BR/>Supported by Merck Sharp &amp; Dohme.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-07 10:21:16 -0400" MODIFIED_BY="[Empty name]">
<P>N = 40<BR/>Male/Female (%): 70/30<BR/>Mean age: 34.5 (20-57)<BR/>Diagnosis: Acute, mild to moderate LBP.<BR/>Setting: outpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I) Cyclobenzaprine 10 mg / 8 hrs / 14 days plus naproxen 500 mg initially, followed by 250 mg / 6 hrs / 14 days. N=20.<BR/>(R) Placebo plus<BR/>naproxen 500 mg initially, followed by 250 mg /6 hrs / 14 days. N=20.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain (0 to 20 NRS). [no difference between groups]. Descriptive pain scale (from 0 to 3). [no difference between groups]. Number of days to resolution of pain: (I): 8.5, (R): 12.5. [no differences]<BR/>Muscle spasm (0=none to 3=severe). (I): 2.0; (R): 3.0. [stat. sign.]. <BR/>Functional capacity (0-3 scale): (I): 9; (R): 15. [no differences]. <BR/>Global efficacy (0=poor to 4=excellent). [no differences].</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Other outcomes:<BR/>Tenderness to palpation and<BR/>Schober's test stat. sign. better in (I). No differences in<BR/>ROM.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Boyles-1983">
<CHAR_METHODS>
<P>Randomised, double-blind trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 80<BR/>Male/Female (%): 48/52<BR/>Mean age: 39 (19-65)<BR/>Diagnosis: Acute LBP.<BR/>Setting: outpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I1) Carisoprodol 350 mg q.i.d. / 7 days. N=40.<BR/>(I2) Diazepam 5mg q.i.d. / 7 days.N=40.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain (100-mm VAS) day 7 - baseline (I): 58 (I2): 48; muscle stiffness (I): 59 (I2): 42; activity (I): 58 (I2): 41; sleep impairment (I): 52 (I2): 40; tension (I): 51 (I2):38 and overall relief: (I): 75, (I2): 56. [stat. sign. for muscle stiffness, activity, tension and relief]. <BR/>Overall improvement (very good + excellent): (I): 70%, (I2): 45%.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bragstad-1979">
<CHAR_METHODS>
<P>Randomised, double-blind trial.<BR/>Sponsorship not declared, but most likely Sandoz Ltd supplied the medication.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 27<BR/>Male/Female (%): ?<BR/>Mean age: 37 (21-63)<BR/>Diagnosis: Acute LBP and muscle spasms of disc origin. <BR/>Setting: secondary care - hospitalized (7), ambulant (20).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I1) Tizanidine 2 mg t.i.d, 7 days. N=14.<BR/>(I2): Chlorzoxazone 500 mg t.i.d, 7 days. N=13.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Difference (4-point scale) at baseline and day 7 for pain (I): 2.29, 0.83 (I2): 2.31, 0.73, for muscle tension (I): 2.57, 0.71 (I2): 2.69, 0.44; for limitation of movement (I): 2.0, 1.0 (I2): 2.15, 0.9. [no differences].<BR/>Overall effectiveness by patient at end of the trial: excellent/good (I):11 (I2): 9; moderate/poor (I):3 (I2): 3.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Casale-1988">
<CHAR_METHODS>
<P>Randomised, placebo-controlled, double-blind trial.<BR/>Medication supplied by Boots-Formenti Pharmaceuticals.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 20<BR/>Male/Female (%): 75/25<BR/>Mean age: 46.9 (37-58)<BR/>Diagnosis: acute episode of chronic LBP.<BR/>Setting: Secondary care.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I) Dantrolene sodium 25 mg o.i.d. / 4 days, N=10.<BR/>(R) Placebo o.i.d. / 4 days. N=10.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain during maximal voluntary movements (% variation on VAS): (I): 50%; (R): 8.6%. [stat. sign.]<BR/>Muscle spasm (5-points) proportion improved on day 3 and 4: (I): 85%, 85%; (R): 10%, 30%.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Other outcomes:<BR/>Pain behavior stat. sign. better in (I) than (R) on day 4.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Corts-Giner-1989">
<CHAR_METHODS>
<P>Placebo-controlled, double-blind trial.<BR/>Sponsorship: none declared.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=50<BR/>Male/Female (%): 46/54<BR/>Mean age: 50 (range 32-63) in muscle relaxant group and 53 (41-68) in placebo group.<BR/>Diagnosis: Acute LBP.<BR/>Setting: ?</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I) Tizanidine 4mg t.i.d. + paracetamol 500mg / 7 days. N=26.<BR/>(R) Placebo t.i.d. + paracetamol 500mg / 7 days. N=24.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain (4-point scale) on movement at baseline, day 3 and day 7: (I): 2.0, 1.1, 0.3; (R): 2.0, 1.8, 1.4. Pain at rest: (I): 1.8, 0.6, 0.2; (R): 1.8, 1.2, 1.0; Pain at night: (I): 1.8, 0.3, 0.1; (R): 1.7, 1.0, 0.8. [stat. sign.]<BR/>Muscle spasm (4-point scale) at baseline, day 3 and day 7: (I): 2.0, 1.1, 0.3; (R): 2.1, 1.7, 1.5. [stat. sign.].<BR/>Activity daily living (4-point scale) at baseline, day 3 and day 7: (I): 2.0, 0.8, 0.5; (R): 1.9, 1.6, 1.2. [stat. sign.].<BR/>Global efficacy (1=excellent, 2=good, 3=moderate and 4=poor) at the end of treatment: (I): 20, 3, 0, 3; (R): 4, 3, 3, 14.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Other outcomes:<BR/>ROM stat. sign. better in (I) than (R) at day 3 and 7.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Dapas-1983">
<CHAR_METHODS>
<P>Randomised, placebo-controlled, double-blind trial.<BR/>Sponsored by Ciba-Geigy.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 200<BR/>Male/Female (%): 48/52<BR/>Mean age: 42.2 (17-74)<BR/>Diagnosis: Acute LBP; muscle spasm and functional disability &lt; 2 wks of at least moderate severity.<BR/>Setting: outpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I) Baclofen 10 mg, 1-2 tablets t.i.d. -q.i.d. / 10 days. N=100.<BR/>(R) Placebo 1-2 tablets t.i.d. -q.i.d. / 10 days. N=100.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>For group of patients with severe pain at baseline (63 baclofen, 60 placebo):<BR/>Local pain (5-point scale) at baseline, day 4 and day 10: (I): 4.1, 2.6, 2.0 (R): 4.1, 3.0, 2.5 [stat. sign.]<BR/>Muscle spasm (5-point scale) at baseline, day 4 and day 10: (I): 3.8, 2.5, 1.5 (R): 3.8, 2.8, 2.0 [stat. sign. on day 10].<BR/>Patient's opinion (5-point scale) at baseline, day 4 and day 10: (I): 4.0, 2.7, 1.8 (R): 4.0, 3.0, 2.2 [stat. sign.]<BR/>Data for patients with moderate pain (N=77) not given. Authors reported that baclofen was sign. better in daily activity on day 4. No differences on day 10.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Other outcomes:<BR/>Active SLR and ROM stat. sign. better in (I) than (R) at day 10.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gold-1978">
<CHAR_METHODS>
<P>Randomised, placebo-controlled, double-blind trial.<BR/>Supported by Riker Laboratories, Inc.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 60<BR/>Male/Female (%): ?<BR/>Mean age: ?<BR/>Diagnosis: Acute LBP and muscle spams. Limited work and daily activities.<BR/>Setting: outpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I) Orphenadrine 100 mg b.i.d. / 7 days. N=20.<BR/>(RI) Phenobarbital 32 mg b.i.d. / 7 days. N=20.<BR/>(R2) Placebo b.i.d. / 7 days. N=20.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reduced pain at 2 days: (I): 9/20; (R1): 3/20; (R2): 4/20 [ I stat. sign. better than R1 and R2].<BR/>Overall improvement at 2 days: (I): 7/20; (R1): 3/20; (R2): 0/20. [ I stat. sign. better than R2].</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Other data not shown. Authors concluded that orphenadrine is better than placebo and phenobarbital based on the results after 48-hrs.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hennies-1981">
<CHAR_METHODS>
<P>Randomised, double-blind trial.<BR/>Sponsorship not declared but most likely Sandoz Ltd supplied medication.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 30<BR/>Male/Female (%): 33/67<BR/>Mean age: 47.5 (25-70)<BR/>Diagnosis: Acute spasm of back (80%) and neck (20%) muscles, actual no. of weeks of duration unknown).<BR/>Setting: 'ambulant patients'.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I1) Tizanidine, 4mg t.i.d., 7 days. N=15.<BR/>(I2) Diazepam 5mg t.i.d., 7 days. N=15.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain (4-point scale) at baseline, day 3 and day 7: (I): 2.3, 1.3, 0.6; (R): 2.2, 1.7, 1.1. Number of cases with pain improvement on day 3 and 7: (I): 13, 13; (R): 8, 11. [stat. sign. on day 3].<BR/>Percentage of pain relief at end of trial: (I): 77.4%, (R): 47.8%.<BR/>Patient self assessment of pain (4-point scale) at baseline, day 3 and day 7: (I): 2.2, 1.1, 0.5; (R): 2.2, 1.7, 1.0. Number of cases with self assessment of pain on day 3 and 7: (I): 12, 13; (R): 8, 12. <BR/>Number of cases with improvement of muscle tension on day 3 and 7: (I): 10, 9; (R): 11, 12.<BR/>Daily activities at baseline and after 7 days: (I): 2.1, 0.4, (R): 2.2, 0.8. Number of cases with improvement of daily activities on day 3 and 7: (I): 12, 13; (R): 10, 14.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Other outcomes:<BR/>Forward flexion and lateral flexion stat. sign. better in (I) than (R) on day 3 and 7.<BR/>The analysis of covariance always showed a sign. difference in favour of tizanidine in all parameters evaluated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hindle-1972">
<CHAR_METHODS>
<P>Randomised, placebo-controlled, double-blind trial.<BR/>Medications were provided by Wallace Pharmaceuticals.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 48<BR/>Male/Female (%): 56/44<BR/>Mean age: 38.4 (18-70)<BR/>Diagnosis: Acute LBP. Mexican migrant farm laborers with acute lumbar strain and spasm<BR/>Setting: outpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I) Carisoprodol 350 mg q.i.d. / 4 days. N=16.<BR/>(R1) Butabarbital 15 mg q.i.d. / 4 days. N=16.<BR/>(R2) Placebo q.i.d. / 4 days. N=16.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain (100 mm VAS) at baseline, day 2 and day 4: (I): 86.0, 33.0, 15.5; (R1): 75.2, 58.7, 49.1 (R2): 65.5, 58.5, 64.0. [(I) stat. sign. better than (R1) and (R2)].<BR/>Muscle spasm (4-point scale) at baseline, day 2 and day 4: (I): 3.1, 2.4, 1.8 (R1): 3.1, 2,8, 2.6 (R2): 3.0, 2.9, 2.9. [no differences].<BR/>Interference with daily activities (4-point scale) at baseline, day 2 and day 4: (I): 3.7, 2.4, 1,8 (R1): 3.3, 2.9, 2.7 (R2): 3.1, 3.1, 3.4. [(I) stat. sign. better than (R2)].<BR/>Number of patients with global improvement excellent/good (I): 12 (R1): 2 (R2): 2. [(I) stat. sign. better than (R1) and (R2)].</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The three groups were significantly different at baseline on scores of pain, daily activities, global severity and patient estimate of pain. The carisoprodol group showed more severe factors than the other groups.<BR/>Other outcomes:<BR/>Pain evaluated by investigator stat. sign. better in (I) than (R2) at day 2 and 4. No differences in<BR/>limitation of motion.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hingorani-1966">
<CHAR_METHODS>
<P>Double-blind,<BR/>placebo-controlled trial.<BR/>Roche Ltd. ackowledged for their "help and cooperation".</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 50<BR/>Male/Female (%): 80/20<BR/>Mean age: ?<BR/>Diagnosis: Acute LBP severe enough to require admission to hospital. Causes were: lumbar spondylosis (28 patients), prolapsed intervertebral disk (19), post-laminectomy (2) and sprain (1)<BR/>Setting: secondary care.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I) Diazepam injections: 10 mg IM / 6 hrs / 24 hrs<BR/>Oral: 2 mg q.i.d. / 5 days plus calcium aspirin 10g t.i.d. /5 days. N=25.<BR/>(R) Placebo injections: water IM / 6 hrs / 24 hrs<BR/>Oral: placebo q.i.d. / 5 days<BR/>plus calcium aspirin 10 g t.i.d. / 5 days. N=25.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Subjective results (pain and tenderness), number of patients improved, no change and worse at the end of treatment: (I) 19, 5, 1 (R): 18, 5, 2. [no differences].<BR/>Objective results (range of motion, straight leg raising and neurological signs), number of patients improved, no change and worse at the end of treatment: (I): 16, 7, 2 (R): 15, 8, 2. [no differences].</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>All patients were hospitalized and treated with complete bed rest and 8/25 in (I) and 6/25 in (R) received additional therapy.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hingorani-1971">
<CHAR_METHODS>
<P>Randomised, placebo-controlled, double-blind trial.<BR/>Cooperation and assistance from Riker Laboratories Inc. is acknowledged.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 99<BR/>Male/Female (%): 61/39<BR/>Mean age: 43.5 <BR/>Diagnosis: Acute LBP of sufficient severity to require inpatient treatment. Causes were: prolapsed intervertebral disc, acute sprain, spondylarthrosis and spondylolisthesis and acute post-laminectomy backache.<BR/>Setting: secondary care.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I) Orphenadrine 35 mg + paracetamol 450 mg 2 tablets t.i.d. / 7 days. N=48.<BR/>(R) Aspirin 100 mg t.i.d. / 7 days. N=50.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of patients with improvement in pain (4-point scale) at the end of the trial: (I): 37 (R): 34 [no differences].</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Other outcomes:<BR/>no differences in tenderness and SLR. Mean improvement in finger-floor distance stat. sign. better in (I) than (R).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Klinger-1988">
<CHAR_METHODS>
<P>Randomised, placebo-controlled, double-blind trial.<BR/>Four authors were affiliated with the Clinical Research Department of Riker Laboratories.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 80<BR/>Male/Female (%): 81/19<BR/>Mean age: 33.8 (14-62)<BR/>Diagnosis: Acute LBP and muscle spasms.<BR/>Setting: tertiary care.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I) Orphenadrine 60 mg intravenously, single dose. N=40.<BR/>(R) Placebo intravenously, single dose. N=40.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of patients with self assessment of pain as none, slight, moderate or severe (45 min. after injection): (I): 5, 30, 5, 0 (R): 0, 4, 31, 5. <BR/>Physician's assessment of spasm (%, better): (I): 95% (R): 10%. [(I) stat. sign. better than (R)]<BR/>Global improvement (%, better): (I): 92% (R): 12% [(I) stat. sign. better than (R)].</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Other outcomes:<BR/>No difference in physician's assessement of pain 45 min. after injection. Global improvement by physician (I) stat. sign. better than (R).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lepisto-1979">
<CHAR_METHODS>
<P>Randomised, placebo-controlled, double-blind trial.<BR/>Sponsorship: none declared.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=30<BR/>Male/Female(%): 50/50.<BR/>Mean age: 42.5 (18-62) (I) and 40.8 (27-59) (R)<BR/>Diagnosis: moderate to severe acute spasms due to disk prolapse in lumbar (n=26) and thoracic (n=4) regions. <BR/>Setting: secondary care - hospitalized patients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I): Tizanidine 2mg, t.i.d., 7 days. N=15.<BR/>(R): Placebo, t.i.d., 7 days. N=15.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean back pain (4-point scale) at baseline, days 2, 3, 5 and 7: (I): 2.5, 2.0, 1.7, 1.3, 1.0 (R): 2.6, 2.2, 1.9, 1.4, 1.0. [no difference].<BR/>Number of patients with decreased pain on days 2, 3, 5 and 7: (I): 8, 9, 11, 13. (R): 6, 10, 13, 12. [no difference].<BR/>Mean score of muscle spasm (4-point scale), at baseline, days 2, 3, 5 and 7. (I): 2.9, 1.9, 1.3, 1.0, 0.7 (R): 2.7, 2.3, 1.8, 1.2, 1.2. [stat. sign. only on day 3].<BR/>Number of patients with decreased spasm on days 2, 3, 5 and 7: (I): 15, 15, 15, 15 (R): 6, 10, 14, 12 [stat. sign. on days 2, 3 and 7].<BR/>Patient's assessment of overall response (excellent, good, moderate, poor): (I): 6, 6, 2, 1 (R): 2, 4, 7, 2 [no difference].</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Some outcomes (e.g. overall improvement) were not statistically significant, but difference was important. This might be due to lack of power.<BR/>Other outcomes:<BR/>no difference in limitation of movement. Physician's assessment of overall response stat. sign. better in (I).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Moll-1973">
<CHAR_METHODS>
<P>Randomised, placebo-controlled, double-blind trial</P>
<P>Sponsorship not declared</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 68<BR/>Male/Female (%): 56/44<BR/>Mean age: 45.6 (23-72)<BR/>Diagnosis: Acute LBP<BR/>Setting: ?</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I) Diazepam IM injection 10 mg (2 ml) + 2 tablets t.i.d. for 5 days. Day 5-10 2 tablets t.i.d. or less if good response. N=33.<BR/>(R) Placebo IM injection (2 ml) +<BR/>2 placebo tablets t.i.d. for 5 days. Day 5-10 2 placebo tablets t.i.d. or less if good response. N=35.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Patients' assessment 1 hr after IM injection, 24 hrs, between 48-72 hs and either at day 5 or day 10 to 14. Therapeutic effect at end of treatment period (0=no, 1=moderate, 2=good, 3=very good). Mean (SD) and number of patients with scores of 2 and 3: (I): 1.8 (1.2) 21; (R): 0.3 (0.8) 6. [(I) stat. sign better than (R)]</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Groups were not similar at baseline.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Pipino-1991">
<CHAR_METHODS>
<P>Randomized single-blind clinical trial.<BR/>Sponsorhip: none declared.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=120<BR/>Male/Female (%): 42.5/57.5<BR/>Mean age: 54.4 (20-77) (I) and 51.7 (24-76) (R)<BR/>Diagnosis: chronic LBP with muscle spasm<BR/>Setting: secondary care - inpatients and outpatients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I1) Pridinol mesilate 4mg IM injection b.i.d. x 3 days followed by 2mg b.i.d. orally x 4 days. N=60.<BR/>(I2) Thiocolchicoside 4mg IM injection b.i.d x 3 days followed by 8mg b.i.d. orally x 4 days. N=60.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean (SD) pain intensity (VAS) at baseline, day 4 and day 7: (I): 62.8 (10.8); 45.8 (12.4); 30.0 (13.9); (I2) 63.5 (10.8); 46.4 (12.4); 30.1 (15.5). [no differences].<BR/>Patient rated global efficacy: (I) 47/60 = good &amp; very good; (I2) 39/60 = good &amp; very good.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Other outcomes:<BR/>no differences in fingertip-floor distance at day 4 and 7.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Pratzel-1996">
<CHAR_METHODS>
<P>Randomised, placebo-controlled, double-blind trial.<BR/>One of the authors affiliated with Strathmann AG.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 112<BR/>Male/Female (%): 78/27<BR/>Mean age: 50.8 (I) and 47.8 (R)<BR/>Diagnosis: chronic LBP with painful reflex muscle spasms.<BR/>Setting: secondary care - rehabilitation centers.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I) Tolperisone<BR/>100 mg t.i.d., 21 days. N=67.<BR/>(R) Placebo t.i.d./ 21 days. N=70.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical global impression of efficacy on day 10 and day 21 (1=very good, 4=ineffective) (I): 2.65, 2.20 (R): 2.85, 2.45. [no differences].<BR/>Number of patients with overall assessment of efficacy by the patient after 21 days: very good / good / moderate/ ineffective: (I): 15, 17, 19, 5; (R): 6, 21, 15, 14. [(I) sign. better than (R)].</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Other outcomes: pressure pain threshold sign. more improved in (I) at day 10 and day 21.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rollings-1983">
<CHAR_METHODS>
<P>Randomised, placebo-controlled, double-blind trial.<BR/>Sponsorship: none declared.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 78<BR/>Male/Female (%): 53/47<BR/>Mean age: 42 (19-65)<BR/>Diagnosis: Acute LBP of at least moderate intensity with muscle spasms of 7 days or less.<BR/>Setting: outpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I1) Carisoprodol 350 mg q.i.d. / 7 days. N=39.<BR/>(I2) Cyclobenzaprine10 mg q.i.d. / 7 days. N=39.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain (100 mm VAS) at baseline and day 8: (I):70, 30; (I2):74, 28. Muscle spasm: (I): 64, 22; (I2): 67, 25. Activity impairment: (I): 74, 32; (I2): 76, 26. Physician's evaluation of muscle spasm using a 5-point scale, at baseline, day 4 and day 8: (I): 3.46, 2.39, 1.83; (I2): 3.77, 2.74, 2.0. Overall improvement (very good to excellent) at end of treatment: (I): 70%, (I2): 70%. No differences between groups.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Other outcomes:<BR/>no difference in physician's evaluation of mobility restriction and overall improvement.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Salzmann-1992">
<CHAR_METHODS>
<P>Randomised, placebo-controlled double-blind trial.<BR/>Sponsored by Sanofi Winthrop</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=152 <BR/>Male/Female (%): 59/41<BR/>Mean age: 44.4(I) and 46.3 (R)<BR/>Diagnosis: chronic LBP without benefit from physiotherapy<BR/>Setting: secondary care - outpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I): Tetrazepam 50 mg t.i.d / 14 days plus physiotherapy. N=79.<BR/>(R): Placebo t.i.d / 14 days plus physiotherapy. N=73.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Percentage of patients reporting &gt;66.6% reduction of daytime pain at day 3, 7 and 14: (I): 7.3, 29.1, 45.5; (R): 2.1, 8.3, 27.1. [stat. sign. difference at day 7]. Clinical global impression (marked, moderate, slight / unchanged, deteriorated) at baseline, day 3, 7 and 14: (I): 5/50, 39/16, 46/9, 45/8 (R): 1/47, 31/17, 41/7, 39/9 [no differences].</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Other outcomes:<BR/>no difference in mobility measures (rotation, flexion, finger-floor distance, Schober test) and overall improvement in % (response in at least two of three pain and moblity criteria) on day 3, 7.<BR/>Medication most helpful: (I): 84% (R): 56%. [stat. sign.].<BR/>Data only presented for 103 patients in per protocol analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sirdalud-1998">
<CHAR_METHODS>
<P>Randomised, placebo-controlled, double-blind trial.<BR/>Sponsored by Novartis Pharma AG, Basel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N= 405<BR/>Male/Female (%): 48/52<BR/>Mean age: 40<BR/>Diagnosis: patients with local pain syndromes (back, neck or shoulder) of recent onset and clinically discernible muscle spasms; &gt; 50% low back<BR/>Setting: not specified.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I) Tizanidine 2mg plus diclofenac 50mg b.i.d. / 7 days. N=185.<BR/>(R): Placebo plus diclofenac 50mg b.i.d. / 7 days. N=176.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean pain at rest (4-point scale) at baseline, day 4 and day 8: (I): 1.98, 0.89, 0.53 (R): 1.87, 1.21, 0.92. [stat. sign.].<BR/>Mean muscle tension (4-point scale at baseline, day 4 and day 8: (I): 1.98, 0.77, 0.29 (R): 1.99, 1.20, 0.77. [stat. sign.].<BR/>Mean disability score (5-point scale) at baseline, day 4 and day 8: (I): 2.01, 0.98, 0.61 (R): 1.97, 1.27, 0.92. [stat. sign.]<BR/>Overall assessment of efficacy at end of treatment (good/very good): (I): 72% (R): 58% [stat. sign.]</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Other outcomes:<BR/>pain at movement, pain at night, pain at palpation and restriction of movement stat. sign. at day 4 and day 8.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sweetman-1987">
<CHAR_METHODS>
<P>Randomised, placebo-controlled, double-blind trial.<BR/>Sponsorship: none declared.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 122<BR/>Male/Female (%): 53/47<BR/>Mean age: 41.3 (?)<BR/>Diagnosis: Acute LBP (1- 28 days).<BR/>Setting: Outpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Chlormezanone: excluded from this review <BR/>(I) Meprobamate 150 mg plus<BR/>ethoheptazine 75 mg plus aspirin 250 mg 2 tablets t.i.d. / 7days. N=40.<BR/>(R) Mefenamic acid 500 mg t.i.d. / 7 days. N=40.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of patients experiencing moderate and severe pain at baseline, day 1 and day 7: (I):25/40, 17/40, 8/41; (R): 27/37, 19/32, 6/39 [no differences].<BR/>Pain diary (4-point scale) (25% failed to complete). Day 0 and day 7: 1.45, 0.8; (R): 1.4, 0.7. [no differences]<BR/>Patient's overall assessment (some and marked improvement) on day 7: (I2): 22; (R): 24 [no difference].</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tervo-1976">
<CHAR_METHODS>
<P>Randomised, placebo-controlled, double-blind trial.<BR/>Sponsorship: none declared.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 50<BR/>Male/Female (%): 34/66<BR/>Mean age: ?<BR/>Diagnosis: Acute LBP. 38/50 no previous episodes. 37/50 acute onset of symptoms. 16/50 work injury.<BR/>Setting: outpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I) Orphenadrine 60 mg (2ml) IM followed by orphenadrine (35 mg) + paracetamol (450 mg) 2 tablets t.i.d., 7 days. N=25.<BR/>(R) Saline 2ml IM followed by paracetamol (450 mg) 2 tablets t.i.d., 7 days. N=25.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean (SE) duration of disability: (I): 8.6 (0.6) days; (R): 12.9 (1.2) days. [stat. sign.].<BR/>Subjective impressions of the treatments: no difference between groups (15 minutes after injection and in the first follow-up visit).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Baseline measurments, 15 minutes after injection. Follow-up visits at 14-21 days only 36%. Because of high drop-out rate these data were not analysed.<BR/>Other outcomes: objective clinical examinations (patient's gait, sitting posture, scoliosis, spinal flexion, muscle spasm and Lasegue) no differences.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Weber-1980">
<CHAR_METHODS>
<P>Double-blind, controlled clinical trial.<BR/>Sponsorship: none declared.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 78<BR/>Male/Female (%): 60/40<BR/>Mean age: 46.2 (I) and 47.4 (R)<BR/>Diagnosis: Acute lumbagosciatica and cervical pain; majority LBP<BR/>Setting: Secondary care - hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I) Diazepam t.i.d (7mg, 7mg, 10mg) / 6 days +<BR/>paralgin Forte (paracetamol 400mg, codeine 20 mg, promethazine 5mg) t.i.d. / 3 days, then prn. N=33.<BR/>(R) Levomepromazine t.i.d (7.5mg + 7.5mg + 15mg) 6 days + paralgin Forte t.i.d. / 3 days, then prn. N=45.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain intensity (10-point scale) daily during 6 days. (I) 21/33 patients with satisfactory effect ; mean grade 5.30 (R) 26/45 satisfactory effect; mean grade 5.82. [no differences].</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Worz-1996">
<CHAR_METHODS>
<P>Randomised, placebo-controlled, double-blind trial.<BR/>One author affiliated with ASTA Medica.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 107<BR/>Male/Female (%): 43/57<BR/>Mean age: 49.7<BR/>Diagnosis: Chronic LBP<BR/>Setting: ?</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(I) Flupirtin 100 mg q.i.d. / 7 days. N=53.<BR/>(I2) Chlormezanone. Excluded from this review.<BR/>(R) Placebo<BR/>q.i.d. / 7 days. N=54.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reduction in pain intensity by 2 categories (5-point verbal scale) at day 7: (I): 54.3%; (R): 33.4%. [no difference].<BR/>Reduction in muscle spasm by 2 categories (5-point verbal scale) at day 7 (I): 47.8%; (R): 33.4%. [no differences].<BR/>Overall assessment by the physician (very good + good + satisfactory): (I): 84.8%; (R): 54.3%. [(I) better than (R)].</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Other outcomes:<BR/>Assessment of general health no figures reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Aiken-1978a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Neck and low back pain; less than 50% low back pain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Aiken-1978b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Neck and low back pain; less than 50% low back pain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Aoki-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Japanese study. Excluded by language restriction criterion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Asia_x002d_Pacific-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Mixed study population of back and neck pain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Basmajian-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study population included patients with neck and back pain; unknown percentage back pain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bercel-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Osteoarthritis of back and neck; unknown percentage back pain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bobulesco-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>French study. Excluded by language restriction criterion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bouchier_x002d_Hayes-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study population included patients with back and neck pain; unknown percentage back pain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brown-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Neck and back pain; unknown percentage back pain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fryda_x002d_Kaurimsky-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study population included patients with back and neck pain; unknown percentage back pain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gabric-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Serbocroatian study. Excluded by language restriction criterion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hasue-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Japanese study. Excluded by language restriction criterion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hofferberth-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Drug: chlormezanone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kuroki-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Japanese study. Excluded by language restriction criterion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Larouche-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Back and neck pain. Excluded because it is an abstract.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Marcel-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>French study. Excluded by language restriction criterion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McGuinness-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study population included patients with various musculoskeletal disorders; less than 50% back pain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McGuinness-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study population included patients with various musculoskeletal disorders; less than 50% back pain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meignany-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>French study. Excluded by language restriction criterion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Middleton-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Drug: chlormezanone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nibbelink-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Neck and back pain; less than 50% back pain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Preston-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Muscle spasm and pain of posttraumatic and inflammatory origin; unknown percentage back pain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Scheiner-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Neck and back pain; less than 50% back pain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stehmann-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>French study. Excluded by language restriction criterion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Steingard-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Neck and low back pain; unknown percentage low back pain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tessari-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Italian study. Excluded by language restriction criterion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Valtonen-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Neck and back pain; less than 50% back pain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vernon-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study population consisted of a mix of musculoskeletal syndromes; percentage of back pain unknown.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yakhno-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Russian study. Excluded by language restriction criterion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Havel-2001">
<CHAR_STUDY_NAME/>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-07-07 10:22:57 -0400" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2008-07-07 10:22:57 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:20:14 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Arbus-1990">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 12:18:32 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Baptista-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 12:39:59 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barrata-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:20:46 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Basmajian-1978">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:20:52 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berry-1988a">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:21:02 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berry-1988b">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 12:42:39 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bianchi-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:21:18 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borenstein-1990">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:42:17 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boyles-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:21:32 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bragstad-1979">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:21:36 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casale-1988">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:44:09 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Corts-Giner-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:21:42 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dapas-1983">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:21:48 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gold-1978">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:21:52 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hennies-1981">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 14:02:14 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hindle-1972">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:22:02 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hingorani-1966">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 14:04:00 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hingorani-1971">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:22:08 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klinger-1988">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:22:15 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lepisto-1979">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:22:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moll-1973">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:22:23 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pipino-1991">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:22:27 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pratzel-1996">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:22:26 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rollings-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:22:33 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salzmann-1992">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:22:39 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sirdalud-1998">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:22:44 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sweetman-1987">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:25:05 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tervo-1976">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:25:41 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Weber-1980">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:22:57 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Worz-1996">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Arbus-1990">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Baptista-1988">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Barrata-1982">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Basmajian-1978">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Berry-1988a">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Berry-1988b">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bianchi-1978">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Borenstein-1990">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Boyles-1983">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bragstad-1979">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Casale-1988">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Corts-Giner-1989">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Dapas-1983">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Gold-1978">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hennies-1981">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Hindle-1972">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Hingorani-1966">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hingorani-1971">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Klinger-1988">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lepisto-1979">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Moll-1973">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pipino-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Pratzel-1996">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Rollings-1983">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Salzmann-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sirdalud-1998">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Sweetman-1987">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Tervo-1976">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Weber-1980">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Worz-1996">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2008-07-07 10:22:25 -0400" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>All outcomes - providers?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3">
<NAME>All outcomes - outcome assessors?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes - patients?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 12:08:23 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arbus-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 12:08:24 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arbus-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 12:08:25 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arbus-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 12:37:47 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baptista-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 12:37:48 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baptista-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 12:37:49 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baptista-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 12:40:03 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barrata-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 12:40:04 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barrata-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 12:40:05 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barrata-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 12:40:32 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Basmajian-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 12:40:33 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Basmajian-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 12:40:34 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Basmajian-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 12:41:32 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berry-1988a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 12:41:33 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berry-1988a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 12:41:34 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berry-1988a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 12:42:09 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berry-1988b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 12:42:10 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berry-1988b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 12:42:11 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berry-1988b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 12:42:43 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bianchi-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 12:42:45 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bianchi-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 12:42:45 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bianchi-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 13:41:43 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Borenstein-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 13:41:44 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Borenstein-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 13:41:45 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Borenstein-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 13:42:21 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boyles-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 13:42:21 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boyles-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 13:42:22 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boyles-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 13:42:55 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bragstad-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 13:42:56 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bragstad-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 13:42:57 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bragstad-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 13:43:28 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casale-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 13:43:29 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casale-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 13:43:29 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casale-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 13:49:12 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corts-Giner-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 13:49:12 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corts-Giner-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 13:49:13 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corts-Giner-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 13:52:17 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dapas-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 13:52:19 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dapas-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 13:52:18 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dapas-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 13:52:54 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gold-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 13:52:54 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gold-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 13:52:55 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gold-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 13:54:11 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hennies-1981">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 13:54:12 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hennies-1981">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 13:54:13 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hennies-1981">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 14:02:49 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hindle-1972">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 14:02:50 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hindle-1972">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 14:02:50 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hindle-1972">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 14:03:23 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hingorani-1966">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 14:03:24 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hingorani-1966">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 14:03:24 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hingorani-1966">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 14:04:11 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hingorani-1971">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 14:04:11 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hingorani-1971">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 14:04:12 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hingorani-1971">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 15:18:19 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klinger-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 15:18:20 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klinger-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 15:18:20 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klinger-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 15:19:08 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lepisto-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 15:19:08 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lepisto-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 15:19:09 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lepisto-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 15:20:19 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moll-1973">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 15:19:57 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moll-1973">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 15:20:21 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moll-1973">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 15:20:52 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pipino-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-07-07 10:22:24 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pipino-1991">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-07-07 10:22:25 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pipino-1991">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 15:21:25 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pratzel-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 15:21:26 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pratzel-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 15:21:27 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pratzel-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 15:22:29 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rollings-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 15:22:29 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rollings-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 15:22:30 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rollings-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 15:22:59 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Salzmann-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 15:22:59 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Salzmann-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 15:23:00 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Salzmann-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 15:24:08 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sirdalud-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 15:24:09 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sirdalud-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 15:24:10 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sirdalud-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 15:24:40 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sweetman-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 15:24:41 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sweetman-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 15:24:41 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sweetman-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 15:25:09 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tervo-1976">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 15:25:10 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tervo-1976">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 15:25:10 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tervo-1976">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 15:25:51 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weber-1980">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 15:25:52 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weber-1980">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 15:25:52 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weber-1980">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-23 15:26:30 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Worz-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-06-23 15:26:31 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Worz-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-06-23 15:26:31 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Worz-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="GROUP" NO="11">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="GROUP" NO="12">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2008-07-07 10:22:40 -0400" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>All outcomes - ITT analysis?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes - drop-outs?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 12:08:29 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arbus-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 12:08:30 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arbus-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 12:37:53 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baptista-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 12:37:54 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baptista-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 12:40:09 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barrata-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 12:40:10 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Barrata-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 12:40:37 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Basmajian-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 12:40:38 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Basmajian-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 12:41:40 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berry-1988a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 12:41:41 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berry-1988a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 12:42:15 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berry-1988b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 12:42:15 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berry-1988b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 12:42:50 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bianchi-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-07 10:21:08 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bianchi-1978">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 13:41:49 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borenstein-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 13:41:50 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borenstein-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 13:42:27 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boyles-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 13:42:28 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Boyles-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 13:43:01 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bragstad-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 13:43:02 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bragstad-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 13:43:35 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casale-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 13:43:35 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casale-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 13:49:20 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corts-Giner-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 13:49:20 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corts-Giner-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 13:52:27 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dapas-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 13:52:28 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dapas-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 13:53:39 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gold-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 13:53:40 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gold-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 13:54:17 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hennies-1981">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 13:54:18 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hennies-1981">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 14:02:53 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hindle-1972">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 14:02:56 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hindle-1972">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 14:03:28 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hingorani-1966">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 14:03:29 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hingorani-1966">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 14:04:15 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hingorani-1971">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 15:10:44 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hingorani-1971">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 15:18:25 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klinger-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-07 10:22:10 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klinger-1988">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 15:19:25 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lepisto-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 15:19:26 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lepisto-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 15:19:59 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moll-1973">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 15:20:24 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moll-1973">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 15:20:57 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pipino-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 15:20:59 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pipino-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 15:21:31 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pratzel-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 15:21:31 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pratzel-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 15:22:34 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rollings-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 15:22:35 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rollings-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 15:23:04 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Salzmann-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-07 10:22:34 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salzmann-1992">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-07 10:22:40 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sirdalud-1998">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 15:24:18 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sirdalud-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 15:24:44 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sweetman-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 15:24:45 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sweetman-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 15:25:15 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tervo-1976">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 15:25:16 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tervo-1976">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 15:25:56 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Weber-1980">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 15:25:57 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Weber-1980">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-23 15:26:34 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Worz-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-06-23 15:26:37 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Worz-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2008-07-07 10:22:52 -0400" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Similarity of baseline characteristics?</NAME>
<DESCRIPTION>
<P>Were the groups similar at baseline regarding the most important prognostic indicators?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 12:08:34 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Arbus-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:20:37 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baptista-1988">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 12:40:15 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barrata-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 12:40:43 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Basmajian-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 12:41:49 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berry-1988a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 12:42:22 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berry-1988b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 12:42:56 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bianchi-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:41:56 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Borenstein-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:42:35 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boyles-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:43:05 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bragstad-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:43:44 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casale-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:49:32 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corts-Giner-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:52:35 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dapas-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:53:45 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gold-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:54:23 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hennies-1981">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 14:02:59 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hindle-1972">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 14:03:33 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hingorani-1966">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:18:04 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hingorani-1971">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:18:30 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Klinger-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:19:33 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lepisto-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:20:07 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moll-1973">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:21:02 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pipino-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:21:37 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pratzel-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:22:38 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rollings-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:22:35 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salzmann-1992">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:24:22 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sirdalud-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:24:50 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sweetman-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:25:20 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tervo-1976">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:22:52 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weber-1980">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:26:40 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Worz-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2008-07-07 10:22:52 -0400" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Co-interventions avoided or similar?</NAME>
<DESCRIPTION>
<P>Were co-interventions avoided or similar?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:20:28 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Arbus-1990">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 12:38:02 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Baptista-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 12:40:19 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Barrata-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 12:40:47 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Basmajian-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:20:54 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berry-1988a">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:21:03 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berry-1988b">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:21:08 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bianchi-1978">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:21:20 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borenstein-1990">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:42:35 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boyles-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:43:10 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bragstad-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:43:48 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casale-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:49:33 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Corts-Giner-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:52:35 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dapas-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:53:51 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gold-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:54:27 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hennies-1981">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 14:03:03 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hindle-1972">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 14:03:36 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hingorani-1966">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:18:07 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hingorani-1971">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:18:34 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klinger-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:19:40 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lepisto-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:20:27 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moll-1973">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:21:08 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pipino-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:21:38 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pratzel-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:22:44 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rollings-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:23:17 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Salzmann-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:24:26 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sirdalud-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:24:54 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sweetman-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:25:26 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tervo-1976">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:22:52 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weber-1980">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:26:45 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Worz-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2008-07-07 10:22:41 -0400" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Compliance acceptable?</NAME>
<DESCRIPTION>
<P>Was the compliance acceptable in all groups?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:20:28 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Arbus-1990">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 12:38:03 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Baptista-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 12:40:20 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Barrata-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 12:40:49 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Basmajian-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:20:55 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berry-1988a">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 12:42:27 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Berry-1988b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:21:09 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bianchi-1978">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:21:21 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borenstein-1990">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:21:28 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boyles-1983">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:43:11 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bragstad-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:43:49 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Casale-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:49:35 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Corts-Giner-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:52:36 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dapas-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:53:52 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gold-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:54:28 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hennies-1981">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 14:03:04 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hindle-1972">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 14:03:39 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hingorani-1966">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:18:08 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hingorani-1971">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:18:35 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klinger-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:22:17 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lepisto-1979">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:20:28 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moll-1973">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:21:09 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pipino-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:21:39 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pratzel-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:22:45 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rollings-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:23:17 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Salzmann-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:22:41 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sirdalud-1998">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:24:54 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sweetman-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:25:27 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tervo-1976">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:26:07 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Weber-1980">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:26:46 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Worz-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2008-07-07 10:22:53 -0400" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Timing outcome assessments similar?</NAME>
<DESCRIPTION>
<P>Was the timing of the outcome assessment in all groups similar?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 12:08:40 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arbus-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 12:38:05 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baptista-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 12:40:21 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Barrata-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 12:40:51 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Basmajian-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 12:41:55 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berry-1988a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 12:42:28 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berry-1988b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 12:43:02 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bianchi-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:42:03 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borenstein-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:42:40 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boyles-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:43:16 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bragstad-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:43:51 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casale-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:49:36 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corts-Giner-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:52:37 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dapas-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:53:54 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gold-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 13:54:36 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hennies-1981">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 14:03:06 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hindle-1972">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 14:03:42 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hingorani-1966">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:18:09 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hingorani-1971">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:18:35 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klinger-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:19:37 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lepisto-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:20:31 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moll-1973">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:21:09 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pipino-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:21:40 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pratzel-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:22:46 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rollings-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:23:18 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Salzmann-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:24:27 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sirdalud-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:24:55 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sweetman-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:25:30 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tervo-1976">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 10:22:53 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weber-1980">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-23 15:26:48 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Worz-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-06-23 15:28:22 -0400" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-06-23 09:27:11 -0400" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2008-06-23 09:20:36 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Benzodiazepines versus placebo for chronic low back pain</NAME>
<DICH_OUTCOME CHI2="3.513167196377278" CI_END="0.9013202035640223" CI_START="0.7082867640661317" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7989951003415405" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="115" I2="14.606967664574801" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.045120893886335785" LOG_CI_START="-0.14979087389658646" LOG_EFFECT_SIZE="-0.09745588389146112" METHOD="MH" MODIFIED="2008-06-23 09:20:24 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3190585232130341" P_Q="0.32364657889828163" P_Z="2.6248798956432707E-4" Q="0.9741539823748475" RANDOM="YES" SCALE="5.00146348088557" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0029945653959374294" TOTALS="SUB" TOTAL_1="157" TOTAL_2="141" WEIGHT="200.0" Z="3.6497575043020896">
<NAME>Pain (dichotomous)</NAME>
<GROUP_LABEL_1>Muscle relaxant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours myorelaxant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.906994105998747" CI_END="0.9415522106486802" CI_START="0.7197552737655506" DF="1" EFFECT_SIZE="0.8232175709616506" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="67" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.02615559262243158" LOG_CI_START="-0.14281514429095504" LOG_EFFECT_SIZE="-0.0844853684566933" MODIFIED="2008-06-23 09:20:24 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3409133577940462" P_Z="0.004527936562181754" STUDIES="2" TAU2="0.0" TOTAL_1="80" TOTAL_2="72" WEIGHT="100.0" Z="2.8388293462024925">
<NAME>: 5 - 7 days follow-up</NAME>
<DICH_DATA CI_END="1.0602887254224438" CI_START="0.7246048559670737" EFFECT_SIZE="0.8765217391304347" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.025424143362487887" LOG_CI_START="-0.13989875985069825" LOG_EFFECT_SIZE="-0.057237308244105216" ORDER="6" O_E="0.0" SE="0.0971114917089948" STUDY_ID="STD-Arbus-1990" TOTAL_1="25" TOTAL_2="24" VAR="0.009430641821946167" WEIGHT="49.79371848209177"/>
<DICH_DATA CI_END="0.9349999766435431" CI_START="0.6399843541596619" EFFECT_SIZE="0.7735537190082644" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="44" LOG_CI_END="-0.029188399976231415" LOG_CI_START="-0.19383064318045834" LOG_EFFECT_SIZE="-0.11150952157834487" ORDER="6" O_E="0.0" SE="0.09671166865041082" STUDY_ID="STD-Salzmann-1992" TOTAL_1="55" TOTAL_2="48" VAR="0.009353146853146855" WEIGHT="50.20628151790824"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9826568359683736" CI_END="0.9279274972402911" CI_START="0.5376187814424633" DF="1" EFFECT_SIZE="0.7063081836799572" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="48" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-0.032485955654583606" LOG_CI_START="-0.26952556782932857" LOG_EFFECT_SIZE="-0.15100576174195604" MODIFIED="2008-06-23 09:20:24 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3215439793272896" P_Z="0.01251837110252015" STUDIES="2" TAU2="0.0" TOTAL_1="77" TOTAL_2="69" WEIGHT="100.0" Z="2.4971847680385597">
<NAME>: 8-14 days follow-up</NAME>
<DICH_DATA CI_END="1.0062657749565307" CI_START="0.5560973362216235" EFFECT_SIZE="0.7480519480519481" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="35" LOG_CI_END="0.0027127017464817563" LOG_CI_START="-0.2548491852450214" LOG_EFFECT_SIZE="-0.1260682417492698" ORDER="6" O_E="0.0" SE="0.1512931273707117" STUDY_ID="STD-Salzmann-1992" TOTAL_1="55" TOTAL_2="48" VAR="0.022889610389610394" WEIGHT="84.69907342997857"/>
<DICH_DATA CI_END="1.0326280857863361" CI_START="0.2558342410104595" EFFECT_SIZE="0.513986013986014" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.01394393296778746" LOG_CI_START="-0.5920413297295213" LOG_EFFECT_SIZE="-0.28904869838086694" ORDER="39" O_E="0.0" SE="0.3559587429838277" STUDY_ID="STD-Arbus-1990" TOTAL_1="22" TOTAL_2="21" VAR="0.1267066267066267" WEIGHT="15.30092657002143"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2011872712180485" CI_END="0.9655196294740992" CI_START="0.4151108455061888" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6330858312613034" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="38" I2="16.74903456261546" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.015238892381090908" LOG_CI_START="-0.38183591976057885" LOG_EFFECT_SIZE="-0.1985374060708349" METHOD="MH" MODIFIED="2008-06-23 09:20:36 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.27308457447931933" P_Q="1.0" P_Z="0.03376143191808993" Q="0.0" RANDOM="YES" SCALE="5.062061452233393" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.015671375682897174" TOTALS="SUB" TOTAL_1="78" TOTAL_2="73" WEIGHT="100.0" Z="2.1229095514734273">
<NAME>Global efficacy (dichotomous, assessed by the patient)</NAME>
<GROUP_LABEL_1>Muscle relaxant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours myorelaxant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2011872712180485" CI_END="0.9655196294740992" CI_START="0.4151108455061888" DF="1" EFFECT_SIZE="0.6330858312613034" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="38" I2="16.74903456261546" ID="CMP-001.02.01" LOG_CI_END="-0.015238892381090908" LOG_CI_START="-0.38183591976057885" LOG_EFFECT_SIZE="-0.1985374060708349" MODIFIED="2008-06-23 09:20:36 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.27308457447931933" P_Z="0.03376143191808993" STUDIES="2" TAU2="0.015671375682897174" TOTAL_1="78" TOTAL_2="73" WEIGHT="100.0" Z="2.1229095514734273">
<NAME>: 8 - 14 days follow-up</NAME>
<DICH_DATA CI_END="1.2887677745694441" CI_START="0.45982641811485614" EFFECT_SIZE="0.769811320754717" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" LOG_CI_END="0.1101746680833828" LOG_CI_START="-0.3374060811052009" LOG_EFFECT_SIZE="-0.11361570651090906" ORDER="6" O_E="0.0" SE="0.2629111476338147" STUDY_ID="STD-Salzmann-1992" TOTAL_1="53" TOTAL_2="48" VAR="0.0691222715501295" WEIGHT="54.68771354431499"/>
<DICH_DATA CI_END="0.8903421903386906" CI_START="0.28079091692251357" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" LOG_CI_END="-0.05044304637322001" LOG_CI_START="-0.5516169449547423" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="6" O_E="0.0" SE="0.29439202887759486" STUDY_ID="STD-Arbus-1990" TOTAL_1="25" TOTAL_2="25" VAR="0.08666666666666664" WEIGHT="45.31228645568501"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-06-23 09:21:36 -0400" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Non-benzodiazapines versus placebo for acute low back pain</NAME>
<DICH_OUTCOME CHI2="6.640522082807448" CI_END="0.8423008724318888" CI_START="0.6785456548909463" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7560023790303252" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="180" I2="9.6456585012462" I2_Q="78.18616149077333" ID="CMP-002.01" LOG_CI_END="-0.07453274947804672" LOG_CI_START="-0.16842092619118884" LOG_EFFECT_SIZE="-0.12147683783461775" METHOD="MH" NO="1" P_CHI2="0.35537380093591764" P_Q="0.032267225638866304" P_Z="3.941057323116274E-7" Q="4.584245911498" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0035655510275480915" TOTALS="SUB" TOTAL_1="277" TOTAL_2="261" WEIGHT="200.0" Z="5.071782953866573">
<NAME>Pain (dichotomous)</NAME>
<GROUP_LABEL_1>Muscle relaxant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Myorelaxant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.29287283036805" CI_END="0.8984685382663489" CI_START="0.7084572988629315" DF="3" EFFECT_SIZE="0.79782616761642" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="111" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-0.0464971260080331" LOG_CI_START="-0.149686321036944" LOG_EFFECT_SIZE="-0.09809172352248856" NO="1" P_CHI2="0.7308263007564497" P_Z="1.9432162384800774E-4" STUDIES="4" TAU2="0.0" TOTAL_1="150" TOTAL_2="144" WEIGHT="99.99999999999999" Z="3.7262863661582557">
<NAME>: 2-4 days follow-up</NAME>
<DICH_DATA CI_END="1.0814061697989674" CI_START="0.4370755995296998" EFFECT_SIZE="0.6875" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.03398884304800442" LOG_CI_START="-0.35944343804340384" LOG_EFFECT_SIZE="-0.16272729749769974" ORDER="4" O_E="0.0" SE="0.23110406943429385" STUDY_ID="STD-Gold-1978" TOTAL_1="20" TOTAL_2="20" VAR="0.053409090909090906" WEIGHT="6.87905002019736"/>
<DICH_DATA CI_END="0.9091996936043565" CI_START="0.6949201311077975" EFFECT_SIZE="0.7948717948717948" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="58" LOG_CI_END="-0.04134071930205984" LOG_CI_START="-0.15806510708239324" LOG_EFFECT_SIZE="-0.09970291319222656" ORDER="6" O_E="0.0" SE="0.06856448317720594" STUDY_ID="STD-Barrata-1982" TOTAL_1="58" TOTAL_2="58" VAR="0.004701088353357356" WEIGHT="78.15292551022088"/>
<DICH_DATA CI_END="1.1605044938462594" CI_START="0.6062983231873402" EFFECT_SIZE="0.8388157894736842" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="32" LOG_CI_END="0.0646468265229613" LOG_CI_START="-0.21731363287255848" LOG_EFFECT_SIZE="-0.07633340317479859" ORDER="7" O_E="0.0" SE="0.16562496957571227" STUDY_ID="STD-Berry-1988a" TOTAL_1="57" TOTAL_2="51" VAR="0.027431630546955618" WEIGHT="13.393436721452169"/>
<DICH_DATA CI_END="3.0927915802339063" CI_START="0.4655987843484408" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.49035065436976916" LOG_CI_START="-0.3319881622745195" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="8" O_E="0.0" SE="0.483045891539648" STUDY_ID="STD-Lepisto-1979" TOTAL_1="15" TOTAL_2="15" VAR="0.2333333333333334" WEIGHT="1.57458774812959"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.404628999765865" CI_END="0.7571958063172415" CI_START="0.44969723053841687" DF="2" EFFECT_SIZE="0.5835313676882906" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="69" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="-0.12079180001506129" LOG_CI_START="-0.3470797870275373" LOG_EFFECT_SIZE="-0.23393579352129928" NO="2" P_CHI2="0.816838072192469" P_Z="5.069295847733289E-5" STUDIES="3" TAU2="0.0" TOTAL_1="127" TOTAL_2="117" WEIGHT="100.0" Z="4.052408932969706">
<NAME>: 5-7 days follow-up</NAME>
<DICH_DATA CI_END="0.7501981686217775" CI_START="0.4164528437049969" EFFECT_SIZE="0.5589473684210526" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="50" LOG_CI_END="-0.12482400038048018" LOG_CI_START="-0.38043416803427715" LOG_EFFECT_SIZE="-0.2526290842073787" ORDER="6" O_E="0.0" SE="0.15014667777057658" STUDY_ID="STD-Barrata-1982" TOTAL_1="57" TOTAL_2="59" VAR="0.02254402484554135" WEIGHT="78.37304991890304"/>
<DICH_DATA CI_END="1.2416065133440786" CI_START="0.37691520370684295" EFFECT_SIZE="0.6840909090909091" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.09398398218567611" LOG_CI_START="-0.4237563439703643" LOG_EFFECT_SIZE="-0.16488618089234408" ORDER="7" O_E="0.0" SE="0.3041232304400058" STUDY_ID="STD-Berry-1988a" TOTAL_1="55" TOTAL_2="43" VAR="0.09249093929326486" WEIGHT="19.10288724596468"/>
<DICH_DATA CI_END="3.436173203095408" CI_START="0.1293428526955729" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5360750466763062" LOG_CI_START="-0.8882575647876688" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="8" O_E="0.0" SE="0.8366600265340756" STUDY_ID="STD-Lepisto-1979" TOTAL_1="15" TOTAL_2="15" VAR="0.7" WEIGHT="2.52406283513229"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="34.652944681597255" CI_END="0.7349112509003322" CI_START="0.4102317283566875" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5490755072352239" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="116" I2="91.3427270681756" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.13376510387014381" LOG_CI_START="-0.3869707532378944" LOG_EFFECT_SIZE="-0.26036792855401913" METHOD="MH" NO="2" P_CHI2="1.4422868510610698E-7" P_Q="0.7861946577067543" P_Z="5.558527986729688E-5" Q="0.07357946051182877" RANDOM="YES" SCALE="1000.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.38401829548402777" TOTALS="SUB" TOTAL_1="145" TOTAL_2="147" WEIGHT="200.0" Z="4.030808664572957">
<NAME>Muscle spasm</NAME>
<GROUP_LABEL_1>Muscle relaxant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Myorelaxant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.252989086271285" CI_END="8.40393143129551" CI_START="0.014997427624259757" DF="1" EFFECT_SIZE="0.35501739872870464" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="63" I2="80.9632195388811" ID="CMP-002.02.01" LOG_CI_END="0.9244825002865713" LOG_CI_START="-1.8239832252371788" LOG_EFFECT_SIZE="-0.4497503624753039" NO="1" P_CHI2="0.021909156483557513" P_Z="0.521233743120714" STUDIES="2" TAU2="4.378583071109492" TOTAL_1="73" TOTAL_2="73" WEIGHT="100.0" Z="0.641444791761012">
<NAME>: 2-4 days follow-up</NAME>
<DICH_DATA CI_END="0.9847354906340625" CI_START="0.8178756606893395" EFFECT_SIZE="0.8974358974358975" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="58" LOG_CI_END="-0.006680409487071602" LOG_CI_START="-0.08731271586537548" LOG_EFFECT_SIZE="-0.046996562676223555" ORDER="6" O_E="0.0" SE="0.04736381590296946" STUDY_ID="STD-Barrata-1982" TOTAL_1="58" TOTAL_2="58" VAR="0.0022433310568903825" WEIGHT="59.497649810438574"/>
<DICH_DATA CI_END="1.511358498056095" CI_START="0.00546823458533967" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.17936749230765678" LOG_CI_START="-2.2621528626241068" LOG_EFFECT_SIZE="-1.041392685158225" ORDER="8" O_E="0.0" SE="1.4341611422075908" STUDY_ID="STD-Lepisto-1979" TOTAL_1="15" TOTAL_2="15" VAR="2.0568181818181817" WEIGHT="40.50235018956142"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9127238672183342" CI_END="0.7385785415628936" CI_START="0.4112535313274106" DF="1" EFFECT_SIZE="0.5511288718443162" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="53" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="-0.13160331436200196" LOG_CI_START="-0.3858903598518812" LOG_EFFECT_SIZE="-0.2587468371069415" NO="2" P_CHI2="0.3393928609235468" P_Z="6.644273622084537E-5" STUDIES="2" TAU2="0.0" TOTAL_1="72" TOTAL_2="74" WEIGHT="100.0" Z="3.988677290785872">
<NAME>: 5-7 days follow-up</NAME>
<DICH_DATA CI_END="2.5475015595668227" CI_START="0.008011050351928473" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.40611445855130324" LOG_CI_START="-2.0963105385798166" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="8" O_E="0.0" SE="1.469936830518334" STUDY_ID="STD-Lepisto-1979" TOTAL_1="15" TOTAL_2="15" VAR="2.1607142857142856" WEIGHT="1.0325862375744561"/>
<DICH_DATA CI_END="0.7501981686217775" CI_START="0.4164528437049969" EFFECT_SIZE="0.5589473684210526" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="50" LOG_CI_END="-0.12482400038048018" LOG_CI_START="-0.38043416803427715" LOG_EFFECT_SIZE="-0.2526290842073787" ORDER="52" O_E="0.0" SE="0.15014667777057658" STUDY_ID="STD-Barrata-1982" TOTAL_1="57" TOTAL_2="59" VAR="0.02254402484554135" WEIGHT="98.96741376242555"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.598839636864165" CI_END="0.8277537090291879" CI_START="0.6398223238942999" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7277467291051064" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="156" I2="24.229102764254314" I2_Q="67.34736532524497" ID="CMP-002.03" LOG_CI_END="-0.08209886456888629" LOG_CI_START="-0.19394061111816438" LOG_EFFECT_SIZE="-0.13801973784352536" METHOD="MH" MODIFIED="2008-06-23 09:21:02 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.25222485568729236" P_Q="0.0801165829405972" P_Z="1.3152388819363124E-6" Q="3.062540006222337" RANDOM="YES" SCALE="204.1915759763056" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.013958702223257501" TOTALS="SUB" TOTAL_1="255" TOTAL_2="248" WEIGHT="200.0" Z="4.837437248170652">
<NAME>Physical outcomes (e.g. limitation of motion)</NAME>
<GROUP_LABEL_1>Muscle relaxant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Myorelaxant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6329685479391421" CI_END="0.8783991284573721" CI_START="0.6642520499215872" DF="2" EFFECT_SIZE="0.7638575925702022" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="95" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="-0.05630810379828865" LOG_CI_START="-0.17766709665684946" LOG_EFFECT_SIZE="-0.11698760022756902" NO="1" P_CHI2="0.7287065189968498" P_Z="1.5762970449997632E-4" STUDIES="3" TAU2="0.0" TOTAL_1="129" TOTAL_2="123" WEIGHT="99.99999999999999" Z="3.7787308164469597">
<NAME>: 2-4 days follow-up</NAME>
<DICH_DATA CI_END="0.881548612707143" CI_START="0.6455664223768581" EFFECT_SIZE="0.7543859649122807" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="57" LOG_CI_END="-0.05475373367851238" LOG_CI_START="-0.19005906650729737" LOG_EFFECT_SIZE="-0.12240640009290486" ORDER="6" O_E="0.0" SE="0.07947902227582775" STUDY_ID="STD-Barrata-1982" TOTAL_1="58" TOTAL_2="58" VAR="0.006316914981921523" WEIGHT="80.44778656799933"/>
<DICH_DATA CI_END="1.1654178912361426" CI_START="0.5986250437510197" EFFECT_SIZE="0.8352534562211982" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="31" LOG_CI_END="0.06648168099755727" LOG_CI_START="-0.2228451182085537" LOG_EFFECT_SIZE="-0.07818171860549819" ORDER="7" O_E="0.0" SE="0.1699519940444237" STUDY_ID="STD-Berry-1988a" TOTAL_1="56" TOTAL_2="50" VAR="0.02888368027967583" WEIGHT="17.594081616787776"/>
<DICH_DATA CI_END="1.5509351337896784" CI_START="0.2105378910638429" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.19059363428922826" LOG_CI_START="-0.6766697316618172" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="8" O_E="0.0" SE="0.5094347941825426" STUDY_ID="STD-Lepisto-1979" TOTAL_1="15" TOTAL_2="15" VAR="0.25952380952380955" WEIGHT="1.9581318152128844"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8059318046540793" CI_END="0.7717885088924317" CI_START="0.3975486909564271" DF="2" EFFECT_SIZE="0.553916520249576" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="61" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="-0.11250169189802393" LOG_CI_START="-0.40060967224356286" LOG_EFFECT_SIZE="-0.2565556820707934" NO="2" P_CHI2="0.40536564410895903" P_Z="4.8187412964624825E-4" STUDIES="3" TAU2="0.0" TOTAL_1="126" TOTAL_2="125" WEIGHT="100.0" Z="3.4906349784881936">
<NAME>: 5-7 days follow-up</NAME>
<DICH_DATA CI_END="0.7969548274843168" CI_START="0.3847991928054163" EFFECT_SIZE="0.5537757437070938" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="46" LOG_CI_END="-0.09856629432569092" LOG_CI_START="-0.41476584765429014" LOG_EFFECT_SIZE="-0.25666607098999056" ORDER="6" O_E="0.0" SE="0.1857371828382516" STUDY_ID="STD-Barrata-1982" TOTAL_1="57" TOTAL_2="66" VAR="0.034498301088690106" WEIGHT="83.0210213435927"/>
<DICH_DATA CI_END="1.5101835521939606" CI_START="0.2813637032037515" EFFECT_SIZE="0.6518518518518519" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.1790297359424014" LOG_CI_START="-0.5507319286320763" LOG_EFFECT_SIZE="-0.18585109634483746" ORDER="7" O_E="0.0" SE="0.4286656141495475" STUDY_ID="STD-Berry-1988a" TOTAL_1="54" TOTAL_2="44" VAR="0.18375420875420875" WEIGHT="15.586495734815262"/>
<DICH_DATA CI_END="1.511358498056095" CI_START="0.00546823458533967" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.17936749230765678" LOG_CI_START="-2.2621528626241068" LOG_EFFECT_SIZE="-1.041392685158225" ORDER="8" O_E="0.0" SE="1.4341611422075908" STUDY_ID="STD-Lepisto-1979" TOTAL_1="15" TOTAL_2="15" VAR="2.0568181818181817" WEIGHT="1.3924829215920491"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="27.412792808442372" CI_END="0.9044236205639794" CI_START="0.40249161349282725" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6033431215501016" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="146" I2="74.4644770457529" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.04362810383813488" LOG_CI_START="-0.39524316436874063" LOG_EFFECT_SIZE="-0.21943563410343775" METHOD="MH" MODIFIED="2008-06-23 09:21:14 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="2.8080795216856025E-4" P_Q="0.4485465530207139" P_Z="0.014431268128994493" Q="0.5743223396069267" RANDOM="YES" SCALE="52.065003550975035" SORT_BY="USER" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.1636316571692341" TOTALS="SUB" TOTAL_1="285" TOTAL_2="260" WEIGHT="200.0" Z="2.446345381898175">
<NAME>Global efficacy (assessed by the patient)</NAME>
<GROUP_LABEL_1>Muscle relaxant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Myorelaxant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="26.398525309029605" CI_END="0.959549621731375" CI_START="0.25085596827490464" DF="3" EFFECT_SIZE="0.4906207796936882" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="91" I2="88.63572883378508" ID="CMP-002.04.01" LOG_CI_END="-0.017932561432017824" LOG_CI_START="-0.6005755619353188" LOG_EFFECT_SIZE="-0.3092540616836683" NO="1" P_CHI2="7.86990702061896E-6" P_Z="0.03746949321457012" STUDIES="4" TAU2="0.3336739850241506" TOTAL_1="116" TOTAL_2="106" WEIGHT="99.99999999999999" Z="2.080611360469898">
<NAME>: 2-4 days follow-up</NAME>
<DICH_DATA CI_END="0.912082885603881" CI_START="0.47547261450716666" EFFECT_SIZE="0.6585365853658537" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" LOG_CI_END="-0.03996569333305207" LOG_CI_START="-0.3228744917884443" LOG_EFFECT_SIZE="-0.18142009256074818" ORDER="4" O_E="0.0" SE="0.1661820286338354" STUDY_ID="STD-Gold-1978" TOTAL_1="20" TOTAL_2="20" VAR="0.027616466640856888" WEIGHT="32.42080447292713"/>
<DICH_DATA CI_END="0.6704707821643041" CI_START="0.07267175318674304" EFFECT_SIZE="0.22073578595317725" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.173620143123786" LOG_CI_START="-1.138634362441336" LOG_EFFECT_SIZE="-0.656127252782561" ORDER="6" O_E="0.0" SE="0.5668541293245553" STUDY_ID="STD-Bianchi-1978" TOTAL_1="23" TOTAL_2="22" VAR="0.3213236039322996" WEIGHT="17.883007951263682"/>
<DICH_DATA CI_END="1.0397436706881018" CI_START="0.7837655975958485" EFFECT_SIZE="0.9027266028002948" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="46" LOG_CI_END="0.01692628533069755" LOG_CI_START="-0.1058138032490691" LOG_EFFECT_SIZE="-0.04444375895918577" ORDER="7" O_E="0.0" SE="0.0720981356049922" STUDY_ID="STD-Berry-1988a" TOTAL_1="59" TOTAL_2="50" VAR="0.005198141157715844" WEIGHT="34.56562575194045"/>
<DICH_DATA CI_END="0.6120366466835854" CI_START="0.045385808069330374" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.2132225729917428" LOG_CI_START="-1.3430799277755445" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="7" O_E="0.0" SE="0.6636838030841121" STUDY_ID="STD-Hindle-1972" TOTAL_1="14" TOTAL_2="14" VAR="0.4404761904761906" WEIGHT="15.130561823868728"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.527416180046994" CI_END="1.128483026504881" CI_START="0.4088178274208871" DF="3" EFFECT_SIZE="0.6792230702626882" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="55" I2="33.73703939077983" ID="CMP-002.04.02" LOG_CI_END="0.05249503124656262" LOG_CI_START="-0.3884701740726977" LOG_EFFECT_SIZE="-0.16798757141306758" NO="2" P_CHI2="0.20985787520364851" P_Z="0.1353552113408972" STUDIES="4" TAU2="0.09434485435291533" TOTAL_1="169" TOTAL_2="154" WEIGHT="100.0" Z="1.4933132403568437">
<NAME>: 5-7 days follow-up</NAME>
<DICH_DATA CI_END="1.3329445056855327" CI_START="0.06889061334733548" EFFECT_SIZE="0.30303030303030304" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.12481206886154295" LOG_CI_START="-1.161839948617318" LOG_EFFECT_SIZE="-0.5185139398778875" ORDER="6" O_E="0.0" SE="0.7557857640972878" STUDY_ID="STD-Bianchi-1978" TOTAL_1="22" TOTAL_2="20" VAR="0.5712121212121212" WEIGHT="10.080883816678213"/>
<DICH_DATA CI_END="2.1028334683970145" CI_START="0.37156043554098506" EFFECT_SIZE="0.8839285714285714" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3228048805703135" LOG_CI_START="-0.42997053671557695" LOG_EFFECT_SIZE="-0.05358282807263171" ORDER="7" O_E="0.0" SE="0.44218400641214456" STUDY_ID="STD-Berry-1988a" TOTAL_1="56" TOTAL_2="44" VAR="0.19552669552669552" WEIGHT="23.14612298736256"/>
<DICH_DATA CI_END="0.9946179264083801" CI_START="0.1117123552280416" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="-0.0023437175650041966" LOG_CI_START="-0.9518987918743207" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="8" O_E="0.0" SE="0.5577733510227171" STUDY_ID="STD-Lepisto-1979" TOTAL_1="15" TOTAL_2="15" VAR="0.3111111111111111" WEIGHT="16.5477958534221"/>
<DICH_DATA CI_END="1.3186035748620228" CI_START="0.6065647004275307" EFFECT_SIZE="0.8943256578947368" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="32" LOG_CI_END="0.1201142488236899" LOG_CI_START="-0.2171228674437722" LOG_EFFECT_SIZE="-0.048504309310041197" ORDER="64" O_E="0.0" SE="0.1980947514461557" STUDY_ID="STD-Baptista-1988" TOTAL_1="76" TOTAL_2="75" VAR="0.039241530550514214" WEIGHT="50.225197342537136"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="34.7419439881346" CI_END="2.001499754529078" CI_START="1.24740480671416" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5800887362540066" ESTIMABLE="YES" EVENTS_1="243" EVENTS_2="121" I2="36.675967218433" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.3013555411777347" LOG_CI_START="0.09600741321632637" LOG_EFFECT_SIZE="0.19868147719703058" METHOD="MH" MODIFIED="2008-06-23 09:21:36 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.04121777446505748" P_Q="0.40891720920142116" P_Z="1.4903792374911038E-4" Q="1.7884853278908746" RANDOM="YES" SCALE="202.54901269172493" SORT_BY="USER" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.14137724307413527" TOTALS="SUB" TOTAL_1="1211" TOTAL_2="929" WEIGHT="300.0" Z="3.7926670534301494">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Muscle relaxant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Myorelaxant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.383596916293724" CI_END="1.9782807389870125" CI_START="1.1417938504188474" DF="7" EFFECT_SIZE="1.502926738792488" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="58" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="0.2962879226208143" LOG_CI_START="0.057587699612726875" LOG_EFFECT_SIZE="0.17693781111677057" NO="1" P_CHI2="0.49573910863344206" P_Z="0.003664706730639078" STUDIES="8" TAU2="0.0" TOTAL_1="409" TOTAL_2="315" WEIGHT="100.00000000000003" Z="2.905667476317954">
<NAME>Total</NAME>
<DICH_DATA CI_END="39.05869370178205" CI_START="0.6400623684672634" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5917177144358472" LOG_CI_START="-0.19377770576380962" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="4" O_E="0.0" SE="1.0488088481701514" STUDY_ID="STD-Gold-1978" TOTAL_1="20" TOTAL_2="20" VAR="1.0999999999999999" WEIGHT="1.7872617806318023"/>
<DICH_DATA CI_END="2.462159871783517" CI_START="0.9088955180518696" EFFECT_SIZE="1.4959432048681542" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="17" LOG_CI_END="0.39131624891178834" LOG_CI_START="-0.04148603816584708" LOG_EFFECT_SIZE="0.17491510537297061" ORDER="6" O_E="0.0" SE="0.25423020583527633" STUDY_ID="STD-Barrata-1982" TOTAL_1="58" TOTAL_2="59" VAR="0.06463299755904699" WEIGHT="30.417712823839064"/>
<DICH_DATA CI_END="4.980153758705091" CI_START="0.8031880527801325" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.6972427514999416" LOG_CI_START="-0.09518276017197919" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="6" O_E="0.0" SE="0.46547466812563143" STUDY_ID="STD-Bianchi-1978" TOTAL_1="24" TOTAL_2="24" VAR="0.2166666666666667" WEIGHT="9.073790578592225"/>
<DICH_DATA CI_END="1.863711670384142" CI_START="0.6104902361550716" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="15" LOG_CI_END="0.2703787247310249" LOG_CI_START="-0.2143212775305378" LOG_EFFECT_SIZE="0.028028723600243534" ORDER="6" O_E="0.0" SE="0.2847151806321486" STUDY_ID="STD-Baptista-1988" TOTAL_1="178" TOTAL_2="89" VAR="0.081062734082397" WEIGHT="24.25267271020781"/>
<DICH_DATA CI_END="9.330281198816802" CI_START="0.7621539972463947" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9698947328412636" LOG_CI_START="-0.11795726829670147" LOG_EFFECT_SIZE="0.4259687322722811" ORDER="7" O_E="0.0" SE="0.6390096504226938" STUDY_ID="STD-Klinger-1988" TOTAL_1="40" TOTAL_2="40" VAR="0.40833333333333327" WEIGHT="4.814664388640774"/>
<DICH_DATA CI_END="3.5914625306104146" CI_START="1.0654092753987905" EFFECT_SIZE="1.9561128526645768" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="11" LOG_CI_END="0.5552713398396163" LOG_CI_START="0.027516473410869442" LOG_EFFECT_SIZE="0.29139390662524284" ORDER="7" O_E="0.0" SE="0.31000582096896745" STUDY_ID="STD-Berry-1988a" TOTAL_1="58" TOTAL_2="52" VAR="0.0961036090346435" WEIGHT="20.456962838786644"/>
<DICH_DATA CI_END="68.56773372198825" CI_START="0.13125707255384883" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8361197955452926" LOG_CI_START="-0.8818772861059678" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="7" O_E="0.0" SE="1.5965649400644928" STUDY_ID="STD-Hindle-1972" TOTAL_1="16" TOTAL_2="16" VAR="2.5490196078431375" WEIGHT="0.7712721991803392"/>
<DICH_DATA CI_END="2.1477719307179903" CI_START="0.32333248913086166" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.3319881622745195" LOG_CI_START="-0.4903506543697692" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="8" O_E="0.0" SE="0.483045891539648" STUDY_ID="STD-Lepisto-1979" TOTAL_1="15" TOTAL_2="15" VAR="0.2333333333333334" WEIGHT="8.425662680121352"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="14.016994564844953" CI_END="3.3684897153845164" CI_START="1.2335998553064094" DF="7" EFFECT_SIZE="2.0384720811184702" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="46" I2="50.06062128641891" ID="CMP-002.05.02" LOG_CI_END="0.5274352257101989" LOG_CI_START="0.09117430976684311" LOG_EFFECT_SIZE="0.30930476773852095" NO="2" P_CHI2="0.050879969765522226" P_Z="0.005449447287189886" STUDIES="8" TAU2="0.22391344735776114" TOTAL_1="409" TOTAL_2="315" WEIGHT="100.0" Z="2.7791909972184636">
<NAME>Central Nervous System</NAME>
<DICH_DATA CI_END="39.05869370178205" CI_START="0.6400623684672634" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5917177144358472" LOG_CI_START="-0.19377770576380962" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="4" O_E="0.0" SE="1.0488088481701514" STUDY_ID="STD-Gold-1978" TOTAL_1="20" TOTAL_2="20" VAR="1.0999999999999999" WEIGHT="4.960303206825984"/>
<DICH_DATA CI_END="3.909122817553514" CI_START="1.5727437554690442" EFFECT_SIZE="2.4795258620689653" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="16" LOG_CI_END="0.5920793153920466" LOG_CI_START="0.19665796950751596" LOG_EFFECT_SIZE="0.3943686424497813" ORDER="6" O_E="0.0" SE="0.23227245593980342" STUDY_ID="STD-Barrata-1982" TOTAL_1="58" TOTAL_2="59" VAR="0.05395049378830792" WEIGHT="23.633912667482683"/>
<DICH_DATA CI_END="10.628118044602203" CI_START="1.0454448345870804" EFFECT_SIZE="3.3333333333333335" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="1.026456369395998" LOG_CI_START="0.019301121164677307" LOG_EFFECT_SIZE="0.5228787452803376" ORDER="6" O_E="0.0" SE="0.5916079783099616" STUDY_ID="STD-Bianchi-1978" TOTAL_1="24" TOTAL_2="24" VAR="0.35" WEIGHT="11.442513063115348"/>
<DICH_DATA CI_END="1.4033668753816477" CI_START="0.40082177359860177" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.1471712213671279" LOG_CI_START="-0.3970486945837278" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="6" O_E="0.0" SE="0.3196774725615638" STUDY_ID="STD-Baptista-1988" TOTAL_1="178" TOTAL_2="89" VAR="0.10219368646334938" WEIGHT="20.13759110860527"/>
<DICH_DATA CI_END="8.474374370557875" CI_START="1.3696520364353133" EFFECT_SIZE="3.406896551724138" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="5" LOG_CI_END="0.9281076458198131" LOG_CI_START="0.13661024755753096" LOG_EFFECT_SIZE="0.532358946688672" ORDER="7" O_E="0.0" SE="0.4649294897145742" STUDY_ID="STD-Berry-1988a" TOTAL_1="58" TOTAL_2="52" VAR="0.21615943040625435" WEIGHT="14.922555899957635"/>
<DICH_DATA CI_END="9.330281198816802" CI_START="0.7621539972463947" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9698947328412636" LOG_CI_START="-0.11795726829670147" LOG_EFFECT_SIZE="0.4259687322722811" ORDER="7" O_E="0.0" SE="0.6390096504226938" STUDY_ID="STD-Klinger-1988" TOTAL_1="40" TOTAL_2="40" VAR="0.40833333333333327" WEIGHT="10.386786171232844"/>
<DICH_DATA CI_END="68.56773372198825" CI_START="0.13125707255384883" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8361197955452926" LOG_CI_START="-0.8818772861059678" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="7" O_E="0.0" SE="1.5965649400644928" STUDY_ID="STD-Hindle-1972" TOTAL_1="16" TOTAL_2="16" VAR="2.5490196078431375" WEIGHT="2.3682548362181666"/>
<DICH_DATA CI_END="3.766239014647583" CI_START="0.4148701115152691" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5759078779346776" LOG_CI_START="-0.38208785191856476" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="8" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Lepisto-1979" TOTAL_1="15" TOTAL_2="15" VAR="0.3166666666666667" WEIGHT="12.148083046562073"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.005862811814554" CI_END="3.1876239193835785" CI_START="0.2851615923507778" DF="6" EFFECT_SIZE="0.9534085759352329" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="17" I2="50.024416453471325" ID="CMP-002.05.03" LOG_CI_END="0.5034670770368017" LOG_CI_START="-0.5449089688390267" LOG_EFFECT_SIZE="-0.020720945901112498" NO="3" P_CHI2="0.06183824142073724" P_Z="0.9382444029020247" STUDIES="7" TAU2="1.22186226987265" TOTAL_1="393" TOTAL_2="299" WEIGHT="99.99999999999997" Z="0.0774766036510405">
<NAME>Gastrointestinal</NAME>
<DICH_DATA CI_END="186.617886315178" CI_START="0.6483837234960623" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2709532661827994" LOG_CI_START="-0.18816789586634924" LOG_EFFECT_SIZE="1.0413926851582251" ORDER="4" O_E="0.0" SE="1.444499943433743" STUDY_ID="STD-Gold-1978" TOTAL_1="20" TOTAL_2="20" VAR="2.0865800865800868" WEIGHT="11.462670546374861"/>
<DICH_DATA CI_END="4.68348737507903" CI_START="0.5656120426363281" EFFECT_SIZE="1.6275862068965516" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6705693538730273" LOG_CI_START="-0.24748135240276398" LOG_EFFECT_SIZE="0.21154400073513166" ORDER="6" O_E="0.0" SE="0.5392675292906873" STUDY_ID="STD-Barrata-1982" TOTAL_1="58" TOTAL_2="59" VAR="0.2908094681472823" WEIGHT="25.070597804207875"/>
<DICH_DATA CI_END="41.92946336844045" CI_START="0.721449729374992" EFFECT_SIZE="5.5" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.6225193041489414" LOG_CI_START="-0.14179392516045378" LOG_EFFECT_SIZE="0.7403626894942439" ORDER="6" O_E="0.0" SE="1.0363663243876757" STUDY_ID="STD-Baptista-1988" TOTAL_1="178" TOTAL_2="89" VAR="1.0740551583248212" WEIGHT="16.51783478270109"/>
<DICH_DATA CI_END="3.958599447956658" CI_START="0.010104583837257678" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5975415597610922" LOG_CI_START="-1.9954815684331297" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="6" O_E="0.0" SE="1.5231546211727816" STUDY_ID="STD-Bianchi-1978" TOTAL_1="24" TOTAL_2="24" VAR="2.32" WEIGHT="10.707244343257143"/>
<DICH_DATA CI_END="1.0064964934263643" CI_START="0.016298301742008824" EFFECT_SIZE="0.12807881773399016" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.0028122661712871237" LOG_CI_START="-1.7878576460560767" LOG_EFFECT_SIZE="-0.8925226899423949" ORDER="7" O_E="0.0" SE="1.0518483704013752" STUDY_ID="STD-Berry-1988a" TOTAL_1="58" TOTAL_2="52" VAR="1.1063849943160289" WEIGHT="16.28846958697276"/>
<DICH_DATA CI_END="7.9453474498525" CI_START="0.01398442444617999" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9001128936458906" LOG_CI_START="-1.8543554030852154" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="7" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Klinger-1988" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="9.876580526047027"/>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.87991577648491" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="8" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Lepisto-1979" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="10.076602410439222"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2008-06-23 09:27:11 -0400" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Non-benzodiazepines versus placebo for chronic low back pain</NAME>
<DICH_OUTCOME CHI2="0.3636426946751973" CI_END="1.5733718733548807" CI_START="0.6655904091503285" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0233382768820356" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.19683138216465337" LOG_CI_START="-0.17679294465468018" LOG_EFFECT_SIZE="0.010019218754986564" METHOD="MH" MODIFIED="2008-06-23 09:27:11 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5464903557385121" P_Q="1.0" P_Z="0.9162822320683855" Q="0.0" RANDOM="YES" SCALE="5.00146348088557" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="121" TOTAL_2="125" WEIGHT="100.00000000000001" Z="0.10511792998156476">
<NAME>Adverse Events</NAME>
<GROUP_LABEL_1>Muscle Relaxant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.3636426946751973" CI_END="1.5733718733548807" CI_START="0.6655904091503285" DF="1" EFFECT_SIZE="1.0233382768820356" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="30" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.19683138216465337" LOG_CI_START="-0.17679294465468018" LOG_EFFECT_SIZE="0.010019218754986564" NO="1" P_CHI2="0.5464903557385121" P_Z="0.9162822320683855" STUDIES="2" TAU2="0.0" TOTAL_1="121" TOTAL_2="125" WEIGHT="100.00000000000001" Z="0.10511792998156476">
<NAME>Total</NAME>
<DICH_DATA CI_END="3.264942369567679" CI_START="0.5252321216122473" EFFECT_SIZE="1.3095238095238095" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.5138755198225358" LOG_CI_START="-0.27964872162984905" LOG_EFFECT_SIZE="0.11711339909634338" ORDER="6" O_E="0.0" SE="0.4661200674374761" STUDY_ID="STD-Worz-1996" TOTAL_1="54" TOTAL_2="55" VAR="0.21726791726791725" WEIGHT="22.169193491938724"/>
<DICH_DATA CI_END="1.553343858447491" CI_START="0.5858167530784589" EFFECT_SIZE="0.9539260220635951" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.19126760466358708" LOG_CI_START="-0.2322382126040735" LOG_EFFECT_SIZE="-0.020485303970243195" ORDER="7" O_E="0.0" SE="0.2487694134506294" STUDY_ID="STD-Pratzel-1996" TOTAL_1="67" TOTAL_2="70" VAR="0.06188622106857019" WEIGHT="77.83080650806129"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2008-06-23 09:22:34 -0400" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Non-benzodiazepines + analgesics/NSAIDs versus placebo + analgesics/NSAIDs for acute low back pain</NAME>
<DICH_OUTCOME CHI2="6.279736926488781" CI_END="1.091787716119245" CI_START="0.37262398437807825" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6378293571758792" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="125" I2="84.0757660439267" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.03813820367974316" LOG_CI_START="-0.42872919466839676" LOG_EFFECT_SIZE="-0.19529549549432684" METHOD="MH" MODIFIED="2008-06-23 09:22:08 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.012212720038041303" P_Q="1.0" P_Z="0.10105784491265944" Q="0.0" RANDOM="YES" SCALE="5.062061452233393" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.12653002653483078" TOTALS="SUB" TOTAL_1="242" TOTAL_2="227" WEIGHT="100.0" Z="1.6397466983820292">
<NAME>Pain (dichotomous)</NAME>
<GROUP_LABEL_1>Muscle relaxant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Myorelaxant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.279736926488781" CI_END="1.091787716119245" CI_START="0.37262398437807825" DF="1" EFFECT_SIZE="0.6378293571758792" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="125" I2="84.0757660439267" ID="CMP-004.01.01" LOG_CI_END="0.03813820367974316" LOG_CI_START="-0.42872919466839676" LOG_EFFECT_SIZE="-0.19529549549432684" NO="1" P_CHI2="0.012212720038041303" P_Z="0.10105784491265944" STUDIES="2" TAU2="0.12653002653483078" TOTAL_1="242" TOTAL_2="227" WEIGHT="100.0" Z="1.6397466983820292">
<NAME>: 2-4 days follow-up</NAME>
<DICH_DATA CI_END="0.6500835383359994" CI_START="0.37087647594957096" EFFECT_SIZE="0.4910200523103749" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="93" LOG_CI_END="-0.1870308311922611" LOG_CI_START="-0.4307707123421627" LOG_EFFECT_SIZE="-0.30890077176721187" ORDER="6" O_E="0.0" SE="0.14317401271932262" STUDY_ID="STD-Sirdalud-1998" TOTAL_1="185" TOTAL_2="176" VAR="0.020498797918152754" WEIGHT="51.15166974607501"/>
<DICH_DATA CI_END="1.1605044938462594" CI_START="0.6062983231873402" EFFECT_SIZE="0.8388157894736842" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="32" LOG_CI_END="0.0646468265229613" LOG_CI_START="-0.21731363287255848" LOG_EFFECT_SIZE="-0.07633340317479859" ORDER="93" O_E="0.0" SE="0.16562496957571227" STUDY_ID="STD-Berry-1988b" TOTAL_1="57" TOTAL_2="51" VAR="0.027431630546955618" WEIGHT="48.848330253925"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.379591674262212" CI_END="1.0093213433812651" CI_START="0.15678547639166887" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.39780262399123373" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="62" I2="68.01566524231475" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.004029457058554394" LOG_CI_START="-0.8046941700641499" LOG_EFFECT_SIZE="-0.4003323565027977" METHOD="MH" MODIFIED="2008-06-23 09:22:34 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.02464747357109298" P_Q="0.914958887920538" P_Z="0.052327091260775595" Q="0.011403214159162404" RANDOM="YES" SCALE="20.18780305814245" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.4071899475484803" TOTALS="SUB" TOTAL_1="149" TOTAL_2="154" WEIGHT="200.0" Z="1.9404329842152201">
<NAME>Global efficacy (assessed by the patient)</NAME>
<GROUP_LABEL_1>Muscle relaxant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Myorelaxant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.28151802000262" CI_END="1.316427358594644" CI_START="0.12960141637572986" DF="1" EFFECT_SIZE="0.413050663030126" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="35" I2="76.64379793969925" ID="CMP-004.02.01" LOG_CI_END="0.11939689942241218" LOG_CI_START="-0.887390252162937" LOG_EFFECT_SIZE="-0.3839966763702624" NO="1" P_CHI2="0.038529096428474574" P_Z="0.1348904604795267" STUDIES="2" TAU2="0.5405609382916585" TOTAL_1="77" TOTAL_2="78" WEIGHT="100.0" Z="1.4950918964026823">
<NAME>: 2-4 days follow-up</NAME>
<DICH_DATA CI_END="1.3150134626771954" CI_START="0.3789085894066509" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.11893019901322069" LOG_CI_START="-0.4214655496745188" LOG_EFFECT_SIZE="-0.15126767533064908" ORDER="7" O_E="0.0" SE="0.3174311377812761" STUDY_ID="STD-Berry-1988b" TOTAL_1="51" TOTAL_2="54" VAR="0.10076252723311548" WEIGHT="54.534759521277316"/>
<DICH_DATA CI_END="0.554512596769631" CI_START="0.08507197414678336" EFFECT_SIZE="0.2171945701357466" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="17" LOG_CI_END="-0.2560885836078752" LOG_CI_START="-1.0702134890111716" LOG_EFFECT_SIZE="-0.6631510363095234" ORDER="96" O_E="0.0" SE="0.47822099941717283" STUDY_ID="STD-Corts-Giner-1989" TOTAL_1="26" TOTAL_2="24" VAR="0.22869532428355963" WEIGHT="45.465240478722684"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.960515739142101" CI_END="1.773601288441302" CI_START="0.07781350568956677" DF="1" EFFECT_SIZE="0.3714971520067821" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="27" I2="79.84080582369151" ID="CMP-004.02.02" LOG_CI_END="0.24885599560188984" LOG_CI_START="-1.1089450182107479" LOG_EFFECT_SIZE="-0.430044511304429" NO="2" P_CHI2="0.02593262792369022" P_Z="0.21441200012145012" STUDIES="2" TAU2="1.0176860068736955" TOTAL_1="72" TOTAL_2="76" WEIGHT="100.0" Z="1.2415247084535121">
<NAME>: 5-7 days follow-up</NAME>
<DICH_DATA CI_END="1.908992730169729" CI_START="0.32800678650714227" EFFECT_SIZE="0.7913043478260869" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.28080427451562445" LOG_CI_START="-0.48411717058066056" LOG_EFFECT_SIZE="-0.1016564480325181" ORDER="7" O_E="0.0" SE="0.4493186432717777" STUDY_ID="STD-Berry-1988b" TOTAL_1="46" TOTAL_2="52" VAR="0.20188724319159101" WEIGHT="52.16023882191608"/>
<DICH_DATA CI_END="0.486841250393246" CI_START="0.05450459098899364" EFFECT_SIZE="0.16289592760180996" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="17" LOG_CI_END="-0.31261263081343066" LOG_CI_START="-1.2635669150222162" LOG_EFFECT_SIZE="-0.7880897729178235" ORDER="98" O_E="0.0" SE="0.5585952538438658" STUDY_ID="STD-Corts-Giner-1989" TOTAL_1="26" TOTAL_2="24" VAR="0.31202865761689286" WEIGHT="47.83976117808391"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="49.80614571812866" CI_END="1.7386694525076605" CI_START="0.7113514167202662" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1121173401442737" ESTIMABLE="YES" EVENTS_1="178" EVENTS_2="189" I2="83.93772518501041" I2_Q="79.31317428519438" ID="CMP-004.03" LOG_CI_END="0.24021702386754593" LOG_CI_START="-0.1479157992160256" LOG_EFFECT_SIZE="0.04615061232576018" METHOD="MH" MODIFIED="2008-06-23 09:22:34 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="4.452722812686716E-8" P_Q="0.007954730073218674" P_Z="0.6411469358444377" Q="9.667988832953688" RANDOM="YES" SCALE="517.8220189316155" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.5056012102161067" TOTALS="SUB" TOTAL_1="768" TOTAL_2="750" WEIGHT="300.0" Z="0.4660957932098625">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.420235662840275" CI_END="2.749295221313485" CI_START="0.6180189198408209" DF="2" EFFECT_SIZE="1.303501616032635" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="95" I2="83.89724595980302" ID="CMP-004.03.01" LOG_CI_END="0.43922137720372256" LOG_CI_START="-0.20899822935019274" LOG_EFFECT_SIZE="0.11511157392676495" NO="1" P_CHI2="0.0020090121253977244" P_Z="0.4863629171005446" STUDIES="3" TAU2="0.3456635587149024" TOTAL_1="256" TOTAL_2="250" WEIGHT="100.0" Z="0.6961052606834838">
<NAME>Total</NAME>
<DICH_DATA CI_END="7.7319789505847645" CI_START="1.1639969608711023" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.8882906630418067" LOG_CI_START="0.0659518463975182" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="3" O_E="0.0" SE="0.48304589153964794" STUDY_ID="STD-Borenstein-1990" TOTAL_1="20" TOTAL_2="20" VAR="0.23333333333333334" WEIGHT="25.04051734651369"/>
<DICH_DATA CI_END="0.936842004160058" CI_START="0.533675743569189" EFFECT_SIZE="0.7070854638422206" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="74" LOG_CI_END="-0.02833364551258072" LOG_CI_START="-0.27272253613861197" LOG_EFFECT_SIZE="-0.15052809082559632" ORDER="6" O_E="0.0" SE="0.14355524409824988" STUDY_ID="STD-Sirdalud-1998" TOTAL_1="185" TOTAL_2="176" VAR="0.020608108108108106" WEIGHT="39.583683457331844"/>
<DICH_DATA CI_END="2.3536196216650658" CI_START="0.8719041016631133" EFFECT_SIZE="1.4325259515570934" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="17" LOG_CI_END="0.3717362760264454" LOG_CI_START="-0.059531279297743225" LOG_EFFECT_SIZE="0.15610249836435108" ORDER="7" O_E="0.0" SE="0.253328696806257" STUDY_ID="STD-Berry-1988b" TOTAL_1="51" TOTAL_2="54" VAR="0.0641754286255565" WEIGHT="35.37579919615445"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.060891393913435" CI_END="6.45982320881512" CI_START="1.183848433605303" DF="2" EFFECT_SIZE="2.765402608504404" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="23" I2="50.74972940675907" ID="CMP-004.03.02" LOG_CI_END="0.810220632470831" LOG_CI_START="0.07329610385448262" LOG_EFFECT_SIZE="0.4417583681626568" NO="2" P_CHI2="0.1312772437349422" P_Z="0.018781054594120675" STUDIES="3" TAU2="0.27298919759228163" TOTAL_1="256" TOTAL_2="250" WEIGHT="100.0" Z="2.349848479310843">
<NAME>Central Nervous System</NAME>
<DICH_DATA CI_END="276.029038509477" CI_START="1.0469912932369894" EFFECT_SIZE="17.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.440954772648721" LOG_CI_START="0.01994307010782674" LOG_EFFECT_SIZE="1.2304489213782739" ORDER="3" O_E="0.0" SE="1.4221142582737276" STUDY_ID="STD-Borenstein-1990" TOTAL_1="20" TOTAL_2="20" VAR="2.0224089635854345" WEIGHT="8.16325192189546"/>
<DICH_DATA CI_END="2.9808349254064517" CI_START="1.0205324587497953" EFFECT_SIZE="1.744144144144144" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="18" LOG_CI_END="0.47433792605942765" LOG_CI_START="0.008826822312007168" LOG_EFFECT_SIZE="0.2415823741857174" ORDER="6" O_E="0.0" SE="0.2734435266583619" STUDY_ID="STD-Sirdalud-1998" TOTAL_1="185" TOTAL_2="176" VAR="0.07477136227136227" WEIGHT="53.88165195643919"/>
<DICH_DATA CI_END="9.04031394322619" CI_START="1.4335785329347757" EFFECT_SIZE="3.6" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="5" LOG_CI_END="0.9561835124934308" LOG_CI_START="0.15642148904114367" LOG_EFFECT_SIZE="0.5563025007672873" ORDER="7" O_E="0.0" SE="0.4697841714617377" STUDY_ID="STD-Berry-1988b" TOTAL_1="51" TOTAL_2="54" VAR="0.22069716775599132" WEIGHT="37.955096121665356"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.033337478890408" CI_END="0.9964077089869027" CI_START="0.2265567479857508" DF="2" EFFECT_SIZE="0.4751240787583861" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="71" I2="50.413274106926195" ID="CMP-004.03.03" LOG_CI_END="-0.0015629210818161182" LOG_CI_START="-0.6448229978444026" LOG_EFFECT_SIZE="-0.32319295946310933" NO="3" P_CHI2="0.13309833933585957" P_Z="0.04889705799327059" STUDIES="3" TAU2="0.22385924325456724" TOTAL_1="256" TOTAL_2="250" WEIGHT="100.0" Z="1.9694881852224744">
<NAME>Gastrointestinal</NAME>
<DICH_DATA CI_END="3.9855442667258254" CI_START="0.39204181297015506" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6004876371237167" LOG_CI_START="-0.4066676111076039" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="3" O_E="0.0" SE="0.5916079783099616" STUDY_ID="STD-Borenstein-1990" TOTAL_1="20" TOTAL_2="20" VAR="0.35000000000000003" WEIGHT="24.879578542732148"/>
<DICH_DATA CI_END="0.5849219181107264" CI_START="0.2388104302006469" EFFECT_SIZE="0.37374517374517374" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="56" LOG_CI_END="-0.23290210451085405" LOG_CI_START="-0.6219467090348623" LOG_EFFECT_SIZE="-0.42742440677285815" ORDER="6" O_E="0.0" SE="0.22852672649925376" STUDY_ID="STD-Sirdalud-1998" TOTAL_1="185" TOTAL_2="176" VAR="0.05222446472446473" WEIGHT="51.71393929593693"/>
<DICH_DATA CI_END="0.9760538848434487" CI_START="0.08543395511188363" EFFECT_SIZE="0.2887700534759358" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.010526205648693453" LOG_CI_START="-1.0683694877783676" LOG_EFFECT_SIZE="-0.5394478467135305" ORDER="7" O_E="0.0" SE="0.6213823803316688" STUDY_ID="STD-Berry-1988b" TOTAL_1="51" TOTAL_2="54" VAR="0.38611606258665077" WEIGHT="23.406482161330917"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-07-07 10:22:58 -0400" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2008-07-07 10:22:58 -0400" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Summary of risks of bias</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAcEAAAVrCAIAAADSEYEkAABtDklEQVR42u29v07syLe/bQkJEXSw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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2017-03-27 16:43:06 -0400" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2017-03-27 16:43:06 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2017-03-20 15:10:41 -0400" MODIFIED_BY="[Empty name]">from Ana Royer et al</TITLE>
<DATE_SUBMITTED>
<DATE DAY="26" MONTH="2" YEAR="2017"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2017-03-27 16:43:06 -0400" MODIFIED_BY="[Empty name]">
<P>Comment: We appreciated this extensive review, as this is a common medical condition that we frequently observe as not being optimally managed.</P>
<P>Currently, we are reviewing the use of cyclobenzaprine for pain as part of another project. In the process, we read your article and specifically evaluated the 3 included studies comparing cyclobenzaprine to placebo. We would like to address a few points from this review. </P>
<P>First, we noted that 17 studies were excluded from the review because their results were not presented separately for low back pain patients or because less than 50% of the study population consisted of low back pain patients. We believe that this likely led to many low back pain patients being excluded from the analyses, whose data may be valuable and may add to our knowledge of the condition. Thus, we feel that these studies should be included. In order to determine whether the results are affected by inclusion of patients with other types of pain, sensitivity analyses can be performed.</P>
<P>Secondly, we would like to address the assessments for risk of bias due to blinding. When reviewing the included trials that compared cyclobenzaprine to placebo, we noted that they were all assessed as having a low risk of bias. However, although the studies are described as double-blind, it is not clear in the publications as to who was blinded. The main description of blinding reported was regarding the appearance and/or packaging of the medication. For example, in the Baratta 1982 trial publication, it is mentioned that the patient and the investigator were blinded; however, the role(s) of the investigator were not explicitly stated. Separate individuals may have been responsible for assessing outcomes and/or providing care to patients, and if this is the case, it is unclear whether they were appropriately blinded. The lack of information provided in these publications makes it challenging to not only determine the overall risk of bias due to inadequate blinding, but also to judge the distinct risks of detection and performance biases. 
</P>
<P>Furthermore, when reviewing the risks of bias of the 3 studies comparing cyclobenzaprine to placebo, we judged there was a high risk of compromised blinding of patients, personnel, and outcome assessors. This is due to the high rate of observed adverse drug reactions (ADRs) with cyclobenzaprine. The occurrence of ADRs with cyclobenzaprine was shown to be as high as 43%, a 14% increase compared to placebo, in the Baratta 1982 trial (1). Additionally, the rates of ADRs were significantly greater with cyclobenzaprine compared to placebo in the Basmajian 1978 and Bianchi 1978 trials (2,3). We feel that it is important to factor in the detection and performance biases that could result from unblinding with observation of ADRs, especially when many of the efficacy outcomes in these pain studies were highly subjective. A trial by Quimby et al., which also compared cyclobenzaprine to placebo but in patients with fibromyalgia, demonstrated the significant impact that cyclobenzaprine ADRs can have on unblinding (4). Although it was designed as a randomized double-blinded trial, 67.5% of patients guessed the identity of the test drug correctly, and physicians were able to guess correctly for 77.5% of their patients. Dry mouth, which was an ADR that occurred in 47.5% of the patients, was statistically related to the guesses of both the patients and physicians. Therefore, it is very likely that unblinding due to ADRs occurred in all the studies included in your review that compared cyclobenzaprine to placebo. The risk of unblinding is important, as empirical studies have shown that a lack of blinding in randomized trials is associated with an exaggeration of estimated intervention effects by an average of 9%, measured as odds ratio (5). This estimated effect has been shown to be even more biased in trials with subjective outcomes (6). A recent systematic review by Hrobjartsson et al. found that, in randomized controlled trials involving subjective measurement scales, the use of non-blinded assessors exaggerated the pooled effect size by 68% (7).</P>
<P>To demonstrate the potentially large effect of unblinding on results, we took a finding from the Baratta 1982 trial as an example. In this trial, the proportion of patients whose muscle spasm improved on days 2-4 was greater by 10% in the cyclobenzaprine group, as compared to placebo. If this result was exaggerated by 68%, the &#8220;true&#8221; effect of cyclobenzaprine on improvement of muscle spasm was only 3.2%. </P>
<P>Thus, the impact of unblinding on the risk of bias should not be taken lightly, and accounting for this bias could greatly diminish the statistical and/or clinical significance of reported results. The Cochrane Handbook also states that, regardless of whether blinding was attempted in trials, a trial should be labelled as having a high risk of bias due to blinding if blinding likely could have been broken and if this likely could have influenced the outcome. While our feedback focuses mainly on cyclobenzaprine studies, it is probable that these issues apply to other trials included in your review, as they looked at other muscle relaxants that similarly are associated with easily identifiable ADRs.</P>
<P>In conclusion, we believe that several studies that were excluded from the review should be included, and that the trials' risks of bias due to blinding warrant reassessment.</P>
<P>We hope that you will kindly consider our feedback, and we thank you very much again for conducting this review.</P>
<P>Sincerely, </P>
<P>Anna Royer, B.Sc.(Pharm); Jia (Shermaine) Ngo, B.Sc.(Pharm); Hilary Wu, B.Sc. (Pharm), ACPR; Aaron M Tejani, B.Sc.(Pharm), PharmD</P>
<P>References:</P>
<P>1. Baratta R. A double-blind study of cyclobenzaprine and placebo in the treatment of acute musculoskeletal conditions of the low back. Current Therapeutic Research 1982;32(5):646-652. </P>
<P>2. Basmajian J. Cyclobenzaprine hydrochloride effect on skeletal muscle spasm in the lumbar region and neck: Two double-blind controlled clinical and laboratory studies. Arch Phys Med Rehabil 1978;59:58-63.</P>
<P>3. Bianchi M. Evaluation of cyclobenzaprine for skeletal muscle spasm of local origin. Clinical evaluation of Flexeril (Cyclobenzaprine HCL/MSD). Minneapolis: Postgraduate Medicine Communications, 1978:25&#8211;9.</P>
<P>4. Quimby LG, Gratwick GM, Whitney CD, Block SR. A Randomized Trial of Cyclobenzaprine for the Treatment of Fibromyalgia. Journal of Rheumatology 1989 Nov;19:140-3.</P>
<P>5. Pildal J, Hrobjartsson A, Jorgensen KJ, Hilden J, Altman DG, Gotzsche PC. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. Int J Epidemiol. 2007 Aug; 36(4):847-57. Epub 2007 May 21. </P>
<P>6. Wood L, Egger M, Gluud LL, Schulz K, Juni P, Altman DG, et al. Empirical evidence of bias in treatment controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008; 336:601-605.</P>
<P>7. Hrobjartsson, A et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded outcome assessors. CMAJ, 2013 Mar; 185(4):E201-211.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2017-03-27 16:19:45 -0400" MODIFIED_BY="[Empty name]">
<P>March 20, 2017</P>
<P>Thank you for taking the time to provide feedback on this review. A new team of authors is in the process of updating the review and will take your comments into consideration. Your comments are aligned with the <A HREF="https://www.ncbi.nlm.nih.gov/pubmed/26208232">Furlan 2015</A> method guidelines.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2017-03-27 16:16:37 -0400" MODIFIED_BY="[Empty name]">
<P>Shireen Harbin, Managing Editor, Cochrane Back and Neck </P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-02" MODIFIED="2017-03-10 14:08:38 -0500" MODIFIED_BY="[Empty name]" NO="2">
<TITLE>from Dr Claus Manniche, October 2004</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY>
<P>The report recommends the usage of muscle relaxants for both acute and chronic spinal pain. </P>
<P>There are no references to the frequently observed physical and psychological dependency which the majority of the drugs of this type promote. These side-effects have been clearly described in the literature from both a qualitative and quantitative viewpoint. No reservations or modifications can be seen in the recommendations regarding the serious side-effects of the long-term usage of these drugs. Due to the fact that a potentially significant percentage of the potential users of these drugs develop chronic pain syndromes combined with the fact that a planned short-term prescription will frequently result in a lifelong dependency leads us to question the appropriateness of overall conclusions of the report as well as its inherent deficiencies. </P>
<P>It is our considered opinion - in accordance with the official policy in Denmark - that this family of drugs should simply not be used for the group of patients.</P>
<P>This issue has been discussed with the leadership of the Nordic Cochrane Institute. It has been recommended that this letter be the first step in the process of attaining a modification in the content of the report.</P>
<P>We look forward to receiving a comprehensive response to this letter and enclose a copy of a commentary which will be published in Spine in November, 2004.</P>
<P>Sincerely,<BR/>Claus Manniche, MD, professor and Alan Jordan, DC, PhD<BR/>----------------------------------------------<BR/>To Spine , November, 2004: Back Pain and Muscle Relaxants and The Cochrane Collaboration</P>
<P>MV Tulder et al (1) recently published a Cochrane Collaboration report in Spine dealing with the prescription of muscle relaxants for low-back pain. The conclusions of this report can also be read on the Cochrane library's home page.</P>
<P>The following conclusion was arrived at based upon the results of 30 controlled short-term studies:</P>
<P>"Muscle relaxants are effective in the management of acute and chronic non-specific low back pain, but the adverse effects (most often drowsiness and dizziness) require that they be used with caution."</P>
<P>The Danish MTV-report (2) published in 1999, arrived at a different conclusion:</P>
<P>"Muscle relaxants, for example diazepam, should play no role in the treatment of back pain. The possible positive effects are greatly overshadowed by the risk of physical and psychological dependency, even after short term usage."</P>
<P>The clear difference in these conclusions (1,2) both of which were formed after a thorough analyses, is a prime example of how important it is to carry out the classical MTV process which includes an analysis of the long term side effects and other risks in conjunction with the utilisation of a technology, in addition to reviewing all of the scientific literature relating to possible clinical effects. In this case, 40 years clinical experience regarding the utilisation of muscle relaxants has abundantly demonstrated the massive problems associated with its usage, first and foremost the frequently seen physical and psychological dependence (3). The risk of extremely strong withdrawal symptom is great. As regards low back pain, these risks are in all likelihood increased due to the fact that low back pain frequently develops into chronic symptoms which in turn result in long term medication dependence. It is well known and commonplace for patients to "force" their physicians to renew their prescriptions. </P>
<P>It would have been appropriate if this Cochrane analysis included a discussion of the considerable published literature regarding the overuse and dependence related to drugs of this type and furthermore had incorporated these important factors into its recommendations.</P>
<P>The Danish Ministry of Health has recently begun several initiatives relating to the prescription of muscle relaxants. Among the steps taken are placing this family of drugs on a " national watch list" with the goal of reducing utilisation. This initiative has been instigated due to the widely accepted opinion that there are great risks related to the daily clinical usage of drugs in this group (4).</P>
<P>The recommendations of the MTV report of 1999 (2) are about to be reviewed. It is likely that the recommendations regarding muscle relaxants will remain unchanged. The risks are still greater than the possible benefits.</P>
<P>Claus Manniche, MD, professor and Alan Jordan, DC, PhD<BR/>Spine Centre, Ringe, Denmark</P>
<P>References:<BR/>1. Tulder MW, Touray T, Furlan AD, Solway S and Bouter LM. Muscle relaxants for non-specific low back pain: A systematic review within the framework of the Cochrane collaboration. Spine 2003; 28: 1978-92.</P>
<P>2. Manniche C, Ankjaer-Jensen A, Olesen A et al. Low Back Pain in a MTV-perspective. National Health Department, Copenhagen 1999.</P>
<P>3. Cirkulaere om ordination af afhaengighedsskabende laegemidler. www.indenrigsministeriet.dk, Sundhedsstyrelsen 2003.</P>
<P>4. Clinical use of benzodiazepines. Rasmussen LL. Ugeskr Laeger 2004; 166; 501-2.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY>
<P>- November 2004<BR/>Thank you for taking the time to read and comment on our Muscle Relaxants for LBP Cochrane Review. The Editorial Board discussed your concerns at our last meeting and submit this response.</P>
<P>You express concern that there is no reference in the review to the adverse effects of muscle relaxants. Adverse effects are addressed in each comparison and again in the discussion, under 'adverse effects'.</P>
<P>The conclusions of the review state that "The results of this review illustrate strong evidence that non-benzodiazepines are effective for acute LBP. The evidence on benzodiazepines for acute and non-benzodiazepines for chronic LBP is less convincing. It is unknown if muscle relaxants are more effective than analgesics or NSAIDs, because there are no trials that directly compared these drugs. Muscle relaxants must be used with caution. The mechanism by which they induce their beneficial effects is also responsible for the intractable side effects associated with the central nervous system (drowsiness, dizziness). Therefore, it must be left to the discretion of the physician to weigh the pros and cons, taking into account the needs and preferences of the individual patient, to determine whether or not a specific patient is a suitable candidate for a course of muscle relaxants." </P>
<P>You argue specifically that this review has left out an important discussion of the published literature on the overuse and dependency associated with the prescription of muscle relaxants, in particular as it relates to the use of benzodiazepines.</P>
<P>One of our Editorial Board members looked at your cited references from the Danish Ministry of Health. The almost exclusive focus of these Danish publications is on the treatment of insomnia and anxiety and not on low back pain. None of these publications appear to contain a systematic review of the literature regarding side effects from the use of benzodiazepines, but represent descriptive data based on the Danish prescription habits by medical doctors and overuse by patients, in particular those who are already drug abusers. </P>
<P>Let us emphasize that the primary purpose of Cochrane systematic reviews is to provide a comprehensive and unbiased review of the literature. As such, they can help inform healthcare policy, but were never intended to replace national clinical guidelines or medical technology assessment initiatives, which usually factor in such elements as national, societal, and economic preferences.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Editorial Board, Cochrane Back Review Group</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2008-06-23 08:59:12 -0400" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-06-23 08:58:56 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-06-23 08:58:54 -0400" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-06-23 08:58:56 -0400" MODIFIED_BY="[Empty name]">
<P>1.randomized controlled trial.pt.<BR/>2.controlled clinical trial.pt.<BR/>3.randomized controlled trials.sh.<BR/>4.random allocation.sh.<BR/>5.double blind method.sh.<BR/>6.single blind method.sh.<BR/>7.1 or 2 or 3 or 4 or 5 or 6<BR/>8.(animal not (human and animal)).sh.<BR/>9.7 not 8<BR/>10.clinical trial.pt.<BR/>11.exp clinical trials/<BR/>12.(clin$ adj25 trial$).ti,ab.<BR/>13.((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.<BR/>14.placebos.sh.<BR/>15.placebo$.ti,ab.<BR/>16.random$.ti,ab.<BR/>17.research design.sh.<BR/>18.volunteer$.ti,ab.<BR/>19.10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18<BR/>20.19 not 8<BR/>21.20 not 9<BR/>22.9 or 21<BR/>23.back pain.sh.<BR/>24.low back pain.sh.<BR/>25.back pain.ti,ab.<BR/>26.backache.ti,ab.<BR/>27.23 or 24 or 25 or 26<BR/>28.muscle relaxants, central.sh.<BR/>29.benzodiazepines.sh.<BR/>30.muscle relaxant$.ti,ab.<BR/>31.benzodiazepine$.ti,ab.<BR/>32.28 or 29 or 30 or 31<BR/>33.27 and 32<BR/>34.22 and 33</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-06-23 08:59:12 -0400" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-06-23 08:59:10 -0400" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-06-23 08:59:12 -0400" MODIFIED_BY="[Empty name]">
<P>1.clinical article/<BR/>2.clinical study/<BR/>3.clinical trial/<BR/>4.controlled study/<BR/>5.randomized controlled trial/<BR/>6.major clinical study/<BR/>7.double blind procedure/<BR/>8.multicenter study/<BR/>9.single blind procedure/<BR/>10.phase 3 clinical study/<BR/>11.phase 4 clinical study/<BR/>12.crossover procedure/<BR/>13.placebo/<BR/>14.or/1-13<BR/>15.allocat$.ti,ab.<BR/>16.assign$.ti,ab.<BR/>17.blind$.ti,ab.<BR/>18.(clinic$ adj25 (study or trial)).ti,ab.<BR/>19.compar$.ti,ab.<BR/>20.control$.ti,ab.<BR/>21.cross?over.ti,ab.<BR/>22.factorial$.ti,ab.<BR/>23.follow?up.ti,ab.<BR/>24.placebo$.ti,ab.<BR/>25.prospectiv$.ti,ab.<BR/>26.random$.ti,ab.<BR/>27.((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.<BR/>28.trial.ti,ab.<BR/>29.(versus or vs).ti,ab.<BR/>30.or/15 29<BR/>31.14 or 30<BR/>32.human/<BR/>33.nonhuman/<BR/>34.animal/<BR/>35.animal experiment/<BR/>36.33 or 34 or 35<BR/>37.32 and 36<BR/>38.31 not 36<BR/>39.31 and 37<BR/>40.38 or 39<BR/>41.backache/<BR/>42.low back pain/<BR/>43.lumbago/<BR/>43.back pain.ti,ab.<BR/>44.backache.ti,ab.<BR/>45.Lumbago.ti,ab.<BR/>46.or/41-45<BR/>47.muscle relaxants/<BR/>48.benzodiazepines/<BR/>49.muscle relaxant$.ti,ab.<BR/>50.benzodiazepine$.ti,ab.<BR/>51.or/47-50<BR/>52.46 and 51<BR/>53.52 and 40</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>